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Breast cancer management continues to be a challenge due to the 
heterogeneity of the disease and the fact that individuals with the same stage 
and pathological diagnosis may respond differently to treatment as a result of 
differences in gene expression.  Several components of the Her-2/PI3K/Akt 
pathway were evaluated for their relevance as potential prognostic markers or 
indicators for treatment. A secondary objective was to evaluate the CISH 
technique for its suitability for analysis of Her-2 gene amplification on archived, 
Papanicolaou-stained fine needle aspiration (FNA) samples. 
 
Tissue blocks from a retrospective series of 93 primary breast carcinoma 
cases were selected, based on their Her-2 status.  Twenty six of these cases 
received trastuzumab treatment while 67 did not.  Expression of Her-2, ER, 
PI3K, PTEN, p-Akt, BCL2, NFκB, MDM2 and p53 were analysed and 
compared with various clinicopathological features. The CISH technique was 
evaluated for its suitability for analysis of Her-2 gene amplification on 
archived, Papanicolaou-stained FNA samples. 
 
Her-2(+) patients showed clear benefit from trastuzumab treatment although it 
was not significant.  Comparing Her-2 expression with downstream components 
in the PI3K/Akt pathway and clinicopathological parameters, significant 
associations were found between Her-2(+) and high NFκB expression 
(p=0.035), Her-2(+) and ductal carcinomas (p=0.006) and Her-2(+) and high 
tumour grade (p=0.004). There was no significant association between PI3K 
and PTEN expression.  A significant association was found between PI3K 
expression and lymphovascular invasion (p=0.012).  This study also found a 
strong association between both lymphovascular and lymph node involvement 
and a subgroup of breast cancers: Her-2(+)/ER(+)/PI3K(high expression), which 
was even stronger than the previously reported Her-2(+)/ER(+) subgroup.  High 
p-Akt expression was an indicator of good prognosis.  The absence of p-Akt 
expression was associated with a five fold increase in the risk of death 
compared to cases showing high p-Akt expression (HR 5.1; CI1.5-17.3). 
Significant associations were also found between high p-Akt and high MDM2 
expression (p=0.040) and between high p-Akt and high NFκB expression 
(p=0.014).  High MDM2 expression was associated with an absence of distant 
metastasis (p=0.017) and reduced risk for death.  Patients with tumours 
showing low MDM2 expression had a significant 3.2 fold increase in risk of 
death compared to those with MDM2 high category tumours (HR 3.2; CI1.1 – 
16.7).  A strong association was also found between high MDM2 expression 
and ductal carcinomas (p=0.051).  
 
This study confirmed the value of some markers already identified by other 
studies but also identified new markers as possible indicators of prognosis and 
treatment. These findings however need to be evaluated in a larger study. 
 
In addition, a 100% concordance was found between Her-2 CISH results on 
corresponding cytopathology and histopathology samples which serve as 
evidence that the Her-2 CISH technique can be successfully performed not only 
on paraffin embedded tissue sections but also on stained and archived FNA 
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Breast carcinoma is the most common malignancy in woman in many 
industrialized countries but its management continues to be challenging 
because of the heterogeneity of the disease (Jemal et al. 2005). It is widely 
acknowledged that individuals with the same stage and pathological diagnosis 
may respond differently to treatment as a result of differences in gene 
expression.  The gene expression profile predicts the tumour phenotype and the 
sensitivity to treatment (Pusztai 2008). Despite the substantial effort that has 
been invested in the identification and validation of additional prognostic 
markers aimed at improving risk stratification and treatment of breast cancer, 
very few molecular markers have proven reliable in the clinical setting.  
Clinically relevant molecular tests currently performed on breast carcinomas 
that can be used for early detection, prediction of prognosis, disease monitoring 
and gene-specific therapy, are limited. 
 
One of the molecular markers that is currently available and for which a 
targeted monoclonal antibody therapy is available, is Her-2.  Overexpression of 
Her-2 is usually associated with the amplification of the Her-2 gene and a poor 
prognosis (Owens et al. 2004).  
 
Trastuzumab, better known as Herceptin®, is a humanised targeted antibody 
against the extracellular domain (ECD) of the Her-2 protein.  The mechanisms 
of action of trastuzumab include internalization and degradation of the Her-2 
receptor resulting in reduced downstream signalling through the PI3K and 
MAPK pathways which in turn lead to the induction of the cyclin dependent 
kinase inhibitor, p27Kip1, responsible for promoting cell cycle arrest and 
apoptosis. 
 
Other mechanisms of action include the phosphorylation and activation of the 
Akt/PI3K-inhibiting molecule, PTEN, inhibition of PI3K downstream effectors 
such as Akt and mTOR, inhibition of Her-2 ECD proteolysis and reduced VEGF 
production (Sliwkowski et al. 1999; Cuello M et al. 2001; Lane et al. 2001; 
Molina et al. 2001; Yakes et al. 2002; Nagata et al. 2004; Owens et al. 2004).  




though.  According to a study by Liu et al. (2007), trastuzumab had little or no 
effect on the shedding of Her-2 ECD. 
 
Trastuzumab has been shown to reduce the risk of recurrence of Her-2 positive 
tumours by half and the mortality rate by one third in patients with early stage 
breast cancer (Romond et al. 2005).  Despite the clear benefit of trastuzumab 
treatment in terms of disease free survival (DFS) and overall survival (OS), 
about one third of patients with Her-2 overexpressing carcinomas exhibit 
primary resistance to this treatment and the majority of patients with metastatic 
breast cancer, who initially respond to trastuzumab, show disease progression 
within one year of commencement of treatment (Nahta and Esteva 2006). 
 
The reported cardiac failure in 28% of patients treated with trastuzumab and the 
cost of trastuzumab treatment (around R400 000,00 per annum), clearly 
indicate the need for improved knowledge of factors that would predict 
treatment response (Suter et al. 2004).  Further studies could ensure the 
selection of only patients that would benefit from this or any other treatment and 
enable oncologists to select the treatment best suited for each individual based 
on the genetic profile of their cancer.  Based on these facts, Her-2 status alone 
does not seem to be sufficient to justify trastuzumab treatment.  Recently, a 
number of biomarkers have been identified as potentially useful predictors of 
response to trastuzumab-based therapies.  These include components of the 
Her-2 downstream signalling pathway, such as PTEN whose activity contributes 
to the efficacy of trastuzumab, while PI3K co-amplification may render 
trastuzumab ineffective (Nagata et al. 2004). 
 
We have evaluated these as well as other components of the Her-2/PI3K/Akt 








































Figure 1:  The Her-2/PI3K/Akt signalling pathway  
Adapted from Hennessy et al. (2005) 
 
2.  Components of the Her-2/PI3K/Akt pathway 
 
2.1   HER-2 
2.1.1   Structure and function 
The Her-2 gene is a proto-oncogene located on the long arm of human 
chromosome 17(q11.2-q12). This gene encodes a 185kD transmembrane 
tyrosine kinase receptor protein (p185HER,Her-2/neu, erbB-2) which is one of 
four related cell surface receptors, Her-1(erbB-1,EGFR), Her-2 (erbB-2), Her-3 
(erbB-3) and Her-4 (erbB-4)(Rubin and Yarden 2001).  These receptors (with 
the exception of Her-2 which has a closed ligand binding site) have an 
extracellular domain that is cysteine rich and acts as a ligand/growth factor 
receptor binding site, a lipophilic transmembrane domain as well as an 
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Binding of an epidermal growth factor (EGF) to the epidermal growth factor 
receptor (EGFR) binding site or high receptor density (overexpression) leads to 
the formation of homo- or heterodimers with other members of the Her-family.  
Receptor dimerization leads to the activation of intrinsic PTK activity, as well as 
tyrosine autophosphorylation.  This in turn leads to the recruitment of a variety 
of signalling proteins, including the adaptor proteins, growth factor receptor-
bound protein-2 (GRB2), Src homology-2 (SH2) domain containing transforming 
protein (SHC), nck adaptor protein (Nck), phospholipase-C-gamma (PLC-γ), 
signal transducer and activator of transcription (STAT), amongst other proteins 
(Klapper et al. 2000; Kuhnen and Winter 2006; Smith et al. 2006).  Sequentially, 
these proteins are responsible for kinase-mediated activation of downstream 
signal transduction pathways such as the PI3K/Akt pathway, the mitogen-
activated protein kinase (MAPK) pathway, the Janus kinase/activator and signal 
transducer pathway (JAK) and the PLC-γ pathway (Ross et al. 2003).  The SH2 
domain of GRB2 can either bind directly to phosphotyrosines of the activated 
EGFR or it can bind EGFR indirectly through the adaptor protein SHC.  The 
SH3 domains of GRB2 are known to bind Son of Sevenless (SOS), which is an 
exchange factor for the GTPase, K-RAS, as well as c-Cbl, a regulator of EGFR 
endocytosis.  Binding of the GRB2-SOS complex to the activated EGFR leads 
to GTP loading of K-RAS and then to the activation of K-RAS effectors, such as 
C-RAF kinases and PI3K.  C-RAF in turn is responsible for the phosphorylation 
or activation of extracellular signal-related kinase (ERK) and MAPK/ERK kinase 
(MEK) (Figure 1) (Meng S et al. 2005; Immervoll et al. 2006). 
 
The Her-2 surface receptor has no ligand binding domain of its own and 
therefore cannot bind growth factors.  It does however, bind tightly to other 
ligand-bound EGFR family members to form heterodimers that stabilize ligand 
binding.  In fact, Her-2 is found to be the preferred dimer partner for other 
members of the HER family.  Heterodimers and especially those containing 
Her-2, result in stronger and prolonged signalling (Klapper et al. 2000).  The 
reason for this is the relatively slow rate of ligand dissociation from Her-2 
containing heterodimers as well as its slower rate of internalisation (Alroy and 
Yarden 1997).  This effect is enhanced when Her-2 is amplified or 
overexpressed and leads to enhanced responsiveness to growth factors and 
5 
 
ultimately malignant growth (Rubin and Yarden 2001).  The most potent 
heterodimer combination is Her2-Her3, which is also the combination most 
commonly found in malignancy (Alroy and Yarden 1997; Pinkas-Kramarski et al. 
1998).  In fact, Her-2 and Her-3 were described as obligate heterodimers due to 
their inability to signal as homodimers. This is attributed to their unique 
structural features.  Her-2 has a closed ligand-binding domain and Her-3 an 
inactive kinase domain and yet when combined, they form the most potent 
signalling unit when it comes to cell growth and development (Garrett et al. 
2003 ). 
 
The Her-2 pathway can also be activated via proteolytic cleavage of its 
extracellular domain (ECD) resulting in a 95 kDa NH2-terminally truncated 
membrane-bound fragment with kinase activity (Christianson et al. 1998). 
 
2.1.2   Interactions with other proteins  
A protein that was found to potentially play a role in Her-2 overexpression and 
tumourigenesis is Muc4, which is a heterodimeric transmembrane glycoprotein 
consisting of a mucin subunit (muc4α) and a transmembrane subunit (muc4β) 
(Sheng et al. 1990; Kozloski et al. 2010).  Muc4 is a cell surface mucin with a 
protective function, protecting the epithelium from injuries and infections by 
keeping it lubricated (Hattrup and Gendler 2008).  Abnormal expression of 
Muc4 has been reported in a number of malignancies where it is believed to 
play a role in cancer development by influencing cellular mechanisms that 
promote cancer development, such as cell adhesion, promotion of oncogenesis 
as well as cell signalling potential (Komatsu et al. 1997; Ponnusamy et al. 2008; 
Yonezawa et al. 2008; Kozloski et al. 2010).  Muc4 is found to increase 
phosphorylation of Her-2 and this ultimately results in the activation of the Akt 
pathway (Carraway et al. 1999). Muc4 was also found to be responsible for 
suppressing the internalization of Her2-Her3 and thus enhancing the surface 
concentration of Her2-Her3 heterodimers (Funes et al. 2006). 
 
2.1.3   Clinical implications 
Her-2 is overexpressed in about 20-30% of breast carcinomas and associated 
with high grade breast carcinomas, high incidence of recurrence, short 
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remission time, distant metastases and overall poor prognosis, especially in 
lymph node positive disease (Slamon et al. 1987; Slamon et al. 1989; Owens et 
al. 2004; Yaziji et al. 2004).  Her-2 overexpression is rare in benign breast 
disease and when present it is associated with an increased risk of subsequent 
invasive breast cancer (Klapper et al. 2000; Stark et al. 2000). 
 
In addition to predicting more aggressive tumour behaviour, Her-2 
overexpression may also be predictive of response to both hormonal- and 
chemotherapeutic agents.  Her-2 overexpression has been associated with 
resistance to tamoxifen treatment (Dowsett 2001; Konecny et al. 2003; 
Johnston 2006).  In fact, a few studies reported tamoxifen treatment to be 
beneficial in Her-2(-)/ER(+) tumours, but not in Her-2(+)/ER(+) tumours.  One 
study suggested that tamoxifen treatment may actually have a detrimental effect 
on Her-2(+) tumours (Borg et al. 1994; Lohrisch and Piccart 2001).  According 
to two preclinical studies, trastuzumab treatment is able to enhance the growth 
inhibitory activity of anti-oestrogens (including tamoxifen) in Her-2(+)/ER(+) 
breast tumours and may even reverse resistance of Her-2(+)/ER(+) tumours to 
anti-oestrogens (Witters et al. 1997; Kunisue et al. 2000).  One study reported 
an improved outcome when Her-2(+)/ER(+) breast cancers in postmenopausal 
patients were treated with cyclophosphamide, doxorubicin, and 5-fluorouracil 
(CAF)  regimen and tamoxifen (Albain et al. 2009).  Her-2(+) tumours show 
sensitivity to dose-intensive treatment with CAF but resistance to non-
anthracycline, non-taxane containing chemotherapeutic agents (Thor et al. 
1998; Ellis et al. 2001; Ménard et al. 2001).  Järvinen et al. (1999) suggested 
that the mechanism of anthracyclin sensitivity in Her-2(+) tumours may be 
related to the coexpression of Her-2 and TopIIα. They found TopIIα 
amplifications or deletions in more than 80% of Her-2(+) tumours while no 
TopIIα aberrations were found in Her-2(-) tumours. 
 
Her-2 status is mainly detected by the immunohistochemistry (IHC), but the 
methodological and specimen variability, the variety of antibodies available, the 
lack of antibody sensitivity, the various scoring systems and the fact that the 
score is not always very objective, raises questions about the reliability of this 
method (Mezzelani et al. 1999).  Fluorescent in-situ hybridization (FISH) 
7 
 
analysis on the other hand, is more objective, sensitive and reliable, but 
requires more sophisticated equipment and experience in cytogenetics (Slamon 
et al. 1987).  Additionally, it is also much more expensive than the IHC method.  
Chromogenic in-situ hybridization (CISH) could be a more economical 
alternative to FISH, as it is said to be as sensitive and reliable as FISH. The 
only downside is that it only allows for a single colour detection of one probe at 
a time and in the case of polysomy of chromosome 17, it does not allow for 
correction of Her-2 amplification (Vocaturo et al. 2006).  At the time of this 
study, only 2 CISH kits had FDA approval, namely Invitrogen’s “SPOT-light” kit 
for Her-2 testing and more recently the HER2 CISH pharmDx™ Kit from DAKO. 
 
Staining for Her-2 receptor overexpression by IHC and testing for Her-2/erb-B2 
oncogene amplification by FISH or CISH encompass the current standard for 
determining patient eligibility for trastuzumab-based therapy (Jemal et al. 2005).  
Currently, local medical aid schemes will only approve trastuzumab treatment 
for patients with cancers shown to overexpress Her-2 by FISH analysis and 
may not accept an IHC (3+) result.  A cost effective alternative would be to stain 
for Her-2 with IHC and then to confirm only the (2+) cases with CISH or FISH.   
 
One of the most important reasons for determining the Her-2 status of a patient 
is that the intensity of the IHC staining or level of amplification with FISH would, 
to an extent, predict the response to trastuzumab treatment (Burstein et al. 
2001; Slamon et al. 2001).  Vogel et al. (2002) reported a 35% response rate for 
carcinomas with a Her-2 IHC score of (3+), while the (2+) cases showed only 
negligible benefit from trastuzumab treatment.  Likewise, Burstein et al. (2001) 
reported a response rate of 34% in IHC (3+) carcinomas versus a 13% 
response rate in IHC (2+) carcinomas.  
 
Lane et al. (2000) reported that although treatment of Her-2 overexpressing 
cells with monoclonal antibodies against the extracellular domain of Her-2 
reduced phosphorylation and signalling of Her-2, it did not inhibit downstream 
signalling.   As a result of these findings, this group postulated that inhibiting 
Her-2 receptor activity in Her-2 overexpressing tumours with the use of targeted 




One possible downside of the existing Her-2 tests is that they only detect gene 
amplification or protein overexpression which does not necessarily reflect the 
functional activity of the receptor. Interestingly, in Her-2(+) invasive breast 
cancers, only 12% of Her-2 receptors appeared to be activated or 
phosphorylated while more that 58% were found to be phosphorylated in ductal 
carcinoma in situ (DiGiovanna et al. 2002).  In a study involving 800 cases of 
Her-2 overexpressing breast cancers, adverse prognosis was limited to the 
cases displaying phosphorylated Her-2, suggesting that phosphorylated Her-2 
may be a more powerful prognostic marker that Her-2 overexpression (Thor et 
al. 2000).   
 
Elevated levels of Her-2 ECD (p95) have been found in the sera of patients with 
breast, ovarian and prostatic cancer (Leitzel et al. 1992; Myers et al. 1996; 
Meden et al. 1997).  The level of p95 in the serum was found to correspond to 
the level of Her-2 expression and tumour load.  Furthermore, this is also used 
as a marker for metastatic disease and predictor of recurrence, survival and 
response to anti-oestrogen therapy. Serum p95 has been reported to neutralize 
the activity of anti-Her-2 antibodies like trastuzumab that has been designed 
against the p95 domain of the Her-2 molecule (Leitzel et al. 1995; Molina et al. 
1996; Brodowicz et al. 1997; Krainer et al. 1997).  In addition, Christianson et al. 
(1998) found a strong correlation between p95 expression and nodal positivity 
in breast carcinomas but no significant correlation between p185 expression 
and nodal status or any of the other prognostic factors.  In a study by Scaltriti et 
al. (2007), breast cancer cells were transfected with p95/Her-2 and Her-2 (full 
length) and subjected to treatment with trastuzumab and lapatinib, a Her-2 
tyrosine kinase inhibitor.  The cells transfected with p95/Her-2 were resistant to 
trastuzumab but responded well to lapatinib, indicating that breast cancers 
expressing p95/Her-2 require alternative or additional anti-Her-2 treatment to 
trastuzumab which is the current standard for Her-2-positive tumours.  Finn et 
al. (2009), however did not find p95/Her-2 status to be a predictor of lapatinib 
benefit in Her-2(+) patients, although it correlated well with patient outcome, 




Other potential mechanisms of trastuzumab resistance includes alternative or 
increased signalling through the PI3K/Akt pathway, downregulation of PTEN, 
decreased receptor-antibody interaction due to cell surface proteins such as 
Muc4.  Muc4 was found to prevent trastuzumab binding by masking the 
receptor or Her-2 related receptors and non-Her-2 receptors such as insulin-like 
growth factor 1 receptor (IGF1R).  IGF1R was found to be involved in crosstalk 
with Her-2 in trastuzumab resistant cells (Price-Schiavi et al. 2002; Nagata et al. 
2004; Diermeier et al. 2005; Nahta et al. 2005) 
 
Multiple studies have shown that Her-2 overexpression or amplification does 
play a substantial role in the prognosis of breast cancer and should be done on 
all breast cancers.  In fact, Her-2 amplification was found to be of greater 
prognostic value than any other prognostic indicator, hormonal-receptor status 
included (Slamon et al. 1987; Slamon 2004). 
 
2.2   PI3K 
2.2.1   Structure and function 
There are three families of phosphoinositide kinases; phosphoinositide 3-
kinases (PI3Ks), PtdIns 4-kinases (PtdIns4Ks) and PtdIns-P(PIP) kinases 
(PIP5Ks).  These phosphoinositide kinases are responsible for phosphorylating 
phosphoinositol (PtdIns), a phospholipid and phospholipase substrate that 
forms part of the cell membrane and consists of a head group and five free 
hydroxyl groups that can be phosphorylated. 
 
Phosphorylated derivatives of phosphoinositol are called phosphoinositides (or 
inositol phosphate second messengers) and are responsible for regulating 
proliferation, vesicle trafficking, glucose transport, organisation of the 
cytoskeleton, location and activity of intracellular proteins, platelet function as 
well as cell survival (Fruman et al. 1998). 
 
PI3K is a protein encoded by the gene, PIK3CA, which is a 34 kilobase gene 
situated on chromosome 3q26.3 and contains 20 exons.  Class IAPI3Ks are 
composed of heterodimers or subunits, a 110-120 kDa catalytic domain or 
kinase domain, p110, as well as an associated 61 kDa regulatory or adaptor 
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subunit, p85.  The catalytic domain consists of an N-terminal region which binds 
to the regulatory subunit, p85, a RAS protein (small GTP-binding protein) 
binding region as well as a phosphoinositide kinase (PIK) region (Fruman et al. 
1998).  The catalytic domain possesses intrinsic protein kinase activity apart 
from lipid kinase activity.  The protein kinase phosphorylates serine residues 
within the catalytic domain itself or within its associated regulatory subunit.  This 
phosphorylation of p85α by p110α at serine 608, results in downregulation of 
the lipid kinase activity of p110α (Carpenter et al. 1993; Dhand et al. 1994; 
Stoyanova et al. 1997; Vanhaesebroeck et al. 1997).  The regulatory subunit, 
p85, which usually associates with PI3K, lacks enzymatic activity but contains 
the following modular units: an N-terminal Src-homology 3 (SH3) domain, two or 
three proline-rich regions, a region similar to GTPase-activating proteins for Rho 
protein binding (Rho GAPs), as well as two Src-homology 2 (SH2) domains, 
one at the C-terminal (C-SH2) and one at the N-terminal (N-SH2) (Fruman et al. 
1998).  p85 is also responsible for regulating the activation and location of 
p110α within the cell.  At the cell membrane, the p85 subunit binds to the 
phosphorylated receptor tyrosine kinase (RTK) which leads to conformational 
changes in the p110 domain and in turn, results in kinase activation (Pommery 
and Henichart 2005).  Another way in which class IA PI3Ks are activated or 
regulated is by RAS, which binds to the RAS protein binding region of p110.  
RAS, in turn, is activated when the bound GDP is replaced by GTP during a 
process of transition mediated by enzymes known as guanosine nucleotide 
exchange factors (GEFs).  Reverse transition is modulated by GTPase-
activating proteins (GAPs) which are responsible for promoting hydrolysis of the 
bound GTP molecules at the end of the stimulation cycle (Riuz et al. 2007).  
The RAS-GTP complex then activates downstream targets such as p110 
(Rodriquez-Viciana et al. 1994).  It is found that most of the activators of p110 
via p85/pYMXM interaction, are also responsible for activating RAS (Druker et 
al. 1990; Ling et al. 1992).  RAS and most of the YMXM- containing proteins are 
associated with the cell membrane, therefore recruitment of p85/p110 
heterodimers not only enhances catalytic activity, but also moves the PI3K from 
the cytoplasm to the cell membrane where its substrates and activator RAS 
reside (Fruman et al. 1998).  Activated PI3K is responsible for the 
phosphorylation of membrane bound PIP2 (Phosphatidylinositol-3,4-
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bisphosphate)to generate PIP3 (Phosphatidylinositol-3,4,5-trisphosphate) 
(Pommery and Henichart 2005).  
 
2.2.2   Clinical implications 
Amplifications, deletions and somatic mutations of PIK3CA have been 
implicated in many cancer types, such as breast, colon, stomach, lung, liver and 
brain (Karakas et al. 2006).  Campbell et al. (2004) discovered the highest 
frequency (up to 40%) of PIK3CA missense mutations in breast cancers.  “Hot 
spots” for somatic mutations map to E542 and E545K in the helical (exon 9) and 
H1047R in the catalytic (exon 20) domain of p110α (Campbell et al. 2004).  
PIK3CA mutations lead to gain of function in PI3K signalling, which in turn leads 
to disturbances in control of cell growth and survival resulting in a competitive 
growth advantage, metastatic growth advantage and often therapy resistance.  
In fact, mutations in exon 20 are believed to inhibit the therapeutic response to 
EGFR-targeted therapies in patients with metastatic colorectal cancer (Kang et 
al. 2005; De Roock et al. 2010). 
 
Wang et al. (2011) found PIK3CA mutations to be more frequent in elderly 
patients.  Saal et al. (2005) reported a strong correlation between PIK3CA 
mutations, ER, PR and Her-2 expression and lymph node metastases.  In fact, 
in the subgroup ER(+)/Her-2(+) and lymph node positive breast cancers, 
PIK3CA mutations were present in 58% of cases.  A strong inverse relation to 
PTEN mutation was described where PTEN was functional or positive in 86% of 
cancers bearing PIK3CA mutations.   Mutations in both PIK3CA and PTEN 
were rare.  They could however not establish any significant relation between 
PI3K status and disease free survival or overall survival  (Saal et al. 2005).  
Jensen et al. (2011) found that patients with PIK3CA mutations or high PI3K 
pathway activation had a significantly worse overall survival despite adequate 
treatment.  They found no significant correlation between PTEN or pHer-2 and 
patient outcome (Jensen et al. 2011).  In an independent study, Aleskandarany 
et al. (2010) found PI3K expression to be associated with poor prognostic 
variables such as a higher grade and size, a higher proliferation factor, nodal 
involvement and vascular invasion in breast cancer.  Their findings concurred 
with other studies that found PI3K to be an independent indicator of overall 
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survival and disease free survival, except perhaps of tumour grade 
(Aleskandarany et al. 2010).  
 
Johnston (2006) reported an association between the activation of the PI3K/Akt 
pathway and resistance to tamoxifen or conventional cytotoxic drugs and also 
lack of response to Her-2 targeted therapy.  He also reported that in preclinical 
studies mTOR antagonists were able to restore sensitivity to endocrine therapy 
in breast cancer cells (Johnston 2006).  Campbell et al. (2001) demonstrated 
that the activated PI3K/Akt pathway interacts directly and indirectly with ER, 
protecting cancer cells from tamoxifen-induced apoptosis and activating ER in a 
hormone-independent fashion.  Clinical evidence suggests that PI3K and K-
RAS contribute to the modulation of ER while ER in turn, activates the PI3K/Akt 
pathway.  The activated PI3K/Akt pathway has been shown to confer anti-
oestrogen resistance while inhibition of this pathway reverses the resistance 
(Chandarlapaty et al. 2011).  Wang et al. (2011) suggested that PI3K activation 
may lead to resistance to trastuzumab as well as lapatinib (Wang et al. 2011). 
 
In support of these findings, studies in human cancer xenografts have shown 
that combinations of inhibitors, targeting Her-2 and PI3K, or Her-2 and AKT are 
superior to single-agent treatments (Chandarlapaty et al. 2011; Chakrabarty et 
al. 2011 ).    
 
Assessment of PI3K pathway activation may provide an additional method of 
identifying patients less likely to respond to Herceptin-based therapy (Berns et 
al. 2007). 
 
2.3   PTEN 
2.3.1   Structure and function 
PTEN (phosphatase and tensin homologue deleted on chromosome ten) is a 
tumour suppressor gene (10q23.3) that is mutated at high frequency in a large 
number of cancers.  PTEN plays a major role as regulator of signal transduction 
pathways that are involved in growth, adhesion, migration, invasion and 
apoptosis (Cully et al. 2006). PTEN has also been found to be of critical 




The protein encoded by the PTEN gene contains a catalytic or phosphatase 
domain at the N-terminal region which has both lipid phosphatase and protein 
tyrosine phosphatase activity.  In other words, PTEN is able to dephosphorylate 
both tyrosine and serine/threonine residues, although its tumour suppressor 
function is completely reliant on its lipid phosphatase activity (Myers et al. 
1997).  An enlarged active site allows for binding phosphatidylinositol (PI) 
substrates, while its actin-binding and SH2 domains are responsible for binding 
phosphotyrosine-containing proteins.  The N-terminal domain of PTEN displays 
a close similarity to the cytoskeletal protein tensin, which is responsible for 
maintaining the cellular structure and is also thought to play a role in signal 
transduction by binding to actin filaments at focal adhesions (Davis et al. 1991b; 
Li et al. 1997).  As part of its protein phosphatase activity, PTEN is able to 
dephosphorylate and thus down-regulate the actions of focal adhesion kinase 
(FAK) and adaptor proteins, SHC and IRS, leading to complex dissociation 
between adaptor proteins and GRB2/SOS which in turn results in inactivation of 
the RAS/MAPK pathway (Gu et al. 1998; Weng et al. 2001).  RAS is found to 
have the exact opposite effect to that of PTEN. While PTEN dephosphorylates 
PIP3 and SHC, leading to inactivation of the Akt and MAPK pathways, RAS is 
able to activate both the Akt and MAPK pathways by phosphorylating MEK via 
RAF and PIP3 via PI3K (Serrano et al. 1997).  Both the FAK-p130
Cas and SHC-
ERK/MAPK pathways are implicated in cell adhesion, migration and invasion 
(Gates et al. 1994; Cary et al. 1996; Tamura et al. 1998; Gu et al. 1999).  A C2 
domain in the C-terminal region binds phospholipids and is believed to be 
responsible for anchoring PTEN to the plasma membrane.  As the C2 domain is 
situated in close proximity to the catalytic domain on the PTEN protein, it is 
believed to position the catalytic domain in relation to its substrate, 
phosphatidylinositol, in the cell membrane (Lee et al. 1999; Yamada and Araki 
2001).  As part of its lipid phosphatase activity, PTEN dephosphorylates 
phosphoinositide substrates (at the D3 positions) and therefore negatively 
regulates the levels of second messengers, PIP3 and PIP2 to PIP2 and PIP 
respectively (Maehama  and Dixon 1998).  Activated PI3K is responsible for 
phosphorylating PIP2 and PIP to PIP3 and PIP2 respectively, which clearly 
illustrates the antagonistic functions of both PTEN and PI3K.  Accumulation of 
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PIP3 at the cell membrane results in recruitment of proteins containing a 
plekstrin homology domain from the cytoplasm to the cell membrane.  One such 
protein is Akt/protein kinase B (PKB).  Binding of Akt by PIP3 causes 
conformational changes in the Akt molecule, allowing phosphorylation at both 
Thr-308 and Ser-473 by phosphoinositide dependent kinase-1/protein kinase C-
related kinase-2 (PDK1/PRK2) complex, triggering the Akt pathway (Balendran 
A et al. 1999; Eugene S et al. 1999).  By dephosphorylating PIP3, PTEN acts as 
a tumour suppressor that negatively regulates Akt/PKB and therefore also the 
Akt/PI3K pathway.  In the absence of PTEN, PIP3 and PIP2 accumulate which 
has the same effect as activated PI3K, triggering downstream effectors such as 
Akt/PKB, PDK1, protein kinase C (PKC) and GEFs amongst others (Stocker et 
al. 2002).  Apart from negatively regulating Akt, PTEN also controls the 
transcription of the anti-apoptotic factor, NF-κB (Mayo et al. 2002b).  PTEN is 
also responsible for downregulating transcription of anti-apoptotic protein BCL2, 
while BCL2 in turn is known to inhibit PTEN-induced chemosensitivity (Zhang et 
al. 2001).  PTEN, when overexpressed, was found to play a role in recruiting 
p27Kip1 to the cyclin-E/CDK2 complex, resulting in decreased cyclin-E/CDK2 
activity which in turn leads to diminished pRb phosphorylation and cell cycle 
arrest at the S phase (Cheney et al. 1999).  PTEN is able to autoregulate its 
function and expression through stabilization of another tumour suppressor, 
p53.  PTEN and p53 are mutually dependent on each other; PTEN enhances 
the transactivation of p53, while p53 facilitates the transcription of PTEN (Shu et 
al. 1988; Stambolic et al. 2001; Mayo et al. 2002a; Sheng et al. 2002).  PTEN is 
also responsible for protecting p53 against proteasomal degradation mediated 
by MDM2 (Mayo et al. 2002b). 
 
2.3.2   Clinical implications 
Wang et al. (2011) reported PTEN loss in about one third of Her-2(+) breast 
cancer and did not find PIK3CA mutation and PTEN loss to be mutually 
exclusive as other studies have suggested (Saal et al. 2005; Wang et al. 2011).  
Perez-Tenorio et al. (2007) found PTEN loss in 37% of cases which were 
associated with PIK3CA mutations, ER(+), small tumour size, low Her-2 
expression and high Akt1 and cyclin D1 expressions.  Saal et al. (2005) 
observed PTEN loss with nodal metastases, increased PIP3 production and 
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subsequent activation of the Akt pathway, supporting findings that PTEN inhibits 
cell migration while PIP3 is responsible for regulating cell motility (Depowski et 
al. 2001; Huang et al. 2003; Raftopoulou et al. 2004). 
 
PTEN deletions or mutations have been found to generally occur late in tumour 
development, with a high frequency in high grade tumours while rarely present 
in low grade tumours (Rasheed et al. 1997).  PTEN activity has also been found 
to contribute to the efficacy of trastuzumab and radiation therapy while PTEN 
loss was associated with increased PI3K/Akt activity and resistance to 
trastuzumab-based therapy in Her-2 overexpressing breast tumours, suggesting 
that PTEN loss could serve as a predictor of trastuzumab resistance (Nagata et 
al. 2004; Hennessy et al. 2005).  Fabi et al. (2010) evaluated the protein 
expression of PI3K, p-Akt and PTEN in 73 metastatic breast cancer patients 
treated with trastuzumab and found that patients co-expressing PTEN and p-Akt 
had a significantly longer progression free survival (PFS) (p = 0.01) than those 
that were only PTEN positive (p = 0.06). They suggested that co-expression of 
PTEN and p-Akt may identify those patients more likely to benefit from 
trastuzumab-based therapy.  They found co-expression of PTEN and p-Akt in 
29 out of 73 Her-2(+) metastatic breast cancers (Fabi et al. 2010).  Similar 
findings were reported by Esteva et al. (2010) who observed that PTEN loss 
was associated with a shorter survival time and poor response to trastuzumab 
therapy. 
 
A study by Nagata et al. (2004) found that PI3K inhibitors were able to 
overcome trastuzumab resistance induced by PTEN loss, suggesting that 
therapies targeting PI3K could overcome this resistance. 
 
The EGFR-selective tyrosine kinase inhibitor, gefitinib (ZD1839, “Iressa”) was 
found to be effective against both EGFR, Her-2 and Her-3 overexpressing 
tumour cells by dephosphorylating these receptors and reducing PI3K and Akt 
activation as a result (Moasser et al. 2001).  It was shown that gefitinib 
resistance in EGFR overexpressing cells was the result of PTEN loss with 
subsequent hyperactivation of the Akt pathway.  Reconstitution of PTEN re-
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established EGFR driven Akt signalling and restored gefitinib sensitivity (She et 
al. 2003). 
 
2.4   Akt 
2.4.1   Structure and function 
The Akt protein family, also known as the Protein Kinase-B (PKB) or 
serine/threonine-specific protein kinase family, plays an important role in 
regulating cell survival, growth, proliferation, metabolism, angiogenesis and 
migration in response to insulin, growth factors or inflammatory agents (Franke 
et al. 1995; Datta et al. 1999).  Akt is the cellular homologue of v-Akt, a protein 
encoded by a gene in the acute transforming retrovirus, Akt8, that was isolated 
from a mouse T-cell lymphoma (Belacossa et al. 1991).  The three isoforms of 
Akt are Akt1/PKB-α, Akt2/PKB-β and Akt3/PKB-γ.  Akt1/PKB-α is involved in the 
cellular survival pathway, Akt2/PKB-β plays an important role in the insulin 
signalling pathway and Akt3/PKB-γ appears to be involved in growth and 
development of the brain (Yang et al. 2004).  Akt1 is encoded by the gene, Akt1 
(14q32.32-32.33). The three isoforms of this protein show an 80% sequence 
correlation and consist of three regions namely, the N-terminal region that 
contains a PH domain, a centre region also referred to as the catalytic or kinase 
region and a C-terminal region which is the regulatory domain and contains a 
hydrophobic (HF) motif (Kannan et al. 2007; Yang et al. 2002). The PH domain 
shows high affinity for PI3K products, PIP2 and PIP3, regulates intracellular 
trafficking of the protein and is responsible for translocating Akt/PKB from the 
cytosol to the cell membrane for activation/phosphorylation (Currie et al. 1999; 
Cantley 2002).  Association with PIP2 and PIP3 at the plasma membrane is 
believed to induce conformational changes in the Akt/PKB molecule, exposing 
two crucial amino acids, threonine (Thr308) within the activation loop of 
Akt/PKB and serine (Ser473) within the HF motif near the C-terminus of 
Akt/PKB (Stokoe et al. 1997; Milburn et al. 2003).   In order to activate the 
kinase activity of Akt, both Thr 308 and Ser473 residues needs to be 
phosphorylated (Alessi and Cohen 1998; Wang et al. 2003; Hennessy et al. 
2005).  The kinase responsible for the phosphorylation of Thr308, is 
phosphoinositide-dependent protein kinase-1 (PDK1) (Walker et al. 1998).   
PDK1 contains a PH domain in its C-terminal region and is located at the cell 
17 
 
membrane as a result of translocation in the same manner as its substrate, 
Akt/PKB (Alessi et al. 1997).  The HF motif on Akt/PKB contributes to the 
activating process by serving as a docking site for PDK1, allowing 
phosphorylation of Thr308 by PDK1 in the activation loop of the kinase domain 
(Balendran et al. 2000).  For many years the identity of the kinase responsible 
for phosphorylating  Akt/PKB on Ser473 has eluded scientists until 2005 when 
Sarbassov et al. (2005) demonstrated that it was in fact the mammalian target 
of rapamycin (mTOR)-rictor complex (mTOR2) that was responsible for 
phosphorylating Ser473 in the hydrophobic motif creating full activation of 
Akt1/PKB.  Other factors that are reported to also phosphorylate Akt are heat 
shock protein-90 (HSP90), cell division cycle-37 (CDC37) and mitogen-
activated protein kinase activated protein kinase-2 (MAPKAPK2) (Taniyama et 
al. 2004).  Integrins are known to also activate Akt via focal adhesion kinase 
(FAK), integrin-linked kinase (ILK) and paxillin (Pxn).   Akt can also be activated 
in response to cellular stress such as ultraviolet light, ischaemia, hypoxia, 
hypoglycaemia, heat shock and oxidative stress.  There are also a variety of 
genetic events capable of activating Akt such as activating point mutations or 
amplifications of Akt, PI3K, RAS family members or growth factor receptors and 
loss of PTEN expression or function (Li et al. 1997; Yuan and Cantley 2008).  
The negative regulators of Akt are PTEN, SH2-containing inositol phosphatase 
(SHIP), carboxyl-terminal modulator protein (CTMP) and PH domain leucine-
rich repeat phosphatases (PHLPP) (Basso et al. 2002; Fornaro et al. 2003; 
Pommery and Henichart 2005; Mendoza and Blenis 2007). 
 
Akt promotes cellular survival by phosphorylating and inactivating the function 
of several pro-apoptotic proteins which include several BCL2 homology domain 
3 (BH3)-only proteins.  These proteins include antagonists of cell death: BAD, 
caspase-9, forkhead-related family of mammalian transcription factor-1 
(FKHRL1) and glycogen synthase kinase 3 (GSK3) (Wang et al. 2002; Fornaro 
et al. 2003; Hennessy et al. 2005).  In order to induce apoptosis, BAD, in its 
unphosphorylated state, associates with Bcl-xL. Phosphorylation of BAD 
mediated by Akt creates a binding site for 14-3-3 proteins.  BAD dissociates 
from Bcl-xL and interacts with 14-3-3 proteins in order to prevent apoptosis (Zha 
et al. 1996; Datta et al. 2000).  Survival factors can suppress apoptosis by 
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inducing phosphorylation of FKHRL1 by Akt, resulting in association with 14-3-3 
proteins and subsequent cytoplasmic retention of FKHRL1.  Another substrate 
that is inactivated by Akt phosphorylation is GSK3, which is responsible for 
inactivating pro-survival BCL2 member, MCL-1 (Cross et al. 1995; Maurer et al. 
2006).  Phosphorylation of the protease, caspase-9, by Akt decreases its 
protease activity and therefore also apoptosis (Cardone et al. 1998).  Akt 
upregulates anti-apoptotic factors including c-AMP response element-binding 
protein (CREB), NF-κB, BCL2 and MDM2, leading to chromosome instability 
and cancer (Brunet et al. 1999; Carroll et al. 1999; Hennessy et al. 2005).  
 
MDM2, an E3 ubiquitin ligase, is responsible for p53 degradation once it has 
been activated by Akt and translocated into the nucleus (Mayo and Donner 
2001).  Akt can also activate NF-κB by phosphorylating IκB kinase (IKK), 
resulting in transcription of pro-survival genes (Wu et al. 1996; Sovak et al. 
1997).  Another substrate of Akt is the forkhead box O (FOXO) family of 
forkhead transcription factors which are activated under stress conditions when 
it accumulates in the nucleus where it plays a role in the expression of pro-
apoptotic genes.  
 
Phosphorylation by Akt creates a 14-3-3 binding site, resulting in FOXO 
inactivation by cytoplasmic sequestration (Accili and Arden 2004).  
Phosphorylation by Akt down-regulates the cell-cycle inhibitory effects of both 
p27Kip1  and p21WAF1 by nuclear export and cytoplasmic localization through 14-
3-3 binding (Zhou et al. 2001; Liang et al. 2002; Shin et al. 2002; Viglietto et al. 
2002).  Akt is able to inhibit the expression of p27Kip1 through phosphorylation 
and inhibition of the FOXO transcription factors (Medema et al. 2000).  Cell-
cycle regulators c-Myc and cyclin D1 and E, and transcription factors c-jun and 
β-catenin all play a role in G1-to-S-phase cell-cycle transition and are all 
targeted by GSK3 for proteasomal degradation.   Phosphorylation by Akt 
inhibits GSK3 function and enhances the stability of these proteins and their 
functions which amongst others also involve the WNT signalling pathway (Diehl 




One of the functions of Akt is promotion of cell growth which happens primarily 
through the activation of mTOR-raptor complex (mTORC1) and is regulated by 
both nutrients and growth factor signalling.  mTORC1 regulates translation 
initiation and plays a role in controlling cell growth.  The tuberous sclerosis 
complex 1 (TSC1) forms a complex with tuberous sclerosis complex 2 (TSC2), 
thereby acting as a stabilizer of TSC2 (Chong-Kopera et al. 2006).  By 
phosphorylating TSC2, Akt inactivates TSC2 and therefore indirectly activates 
mTORC1 resulting in cell growth (Gao and Pan 2001; Tapon et al. 2001; 
Manning et al. 2002).  By inactivating mTORC1, activated TSC2 and its 
activator, AMP-activated protein kinase (AMPK), protects cells from energy 
deprivation-induced apoptosis (Inoki et al. 2003).  mTORC1 not only promotes 
cell growth, but is also involved in regulation of cell proliferation and Akt also 
controls the translation of proteins essential for cell-cycle progression through 
phosphorylation of TSC2 and subsequent activation of mTORC1(Skeen et al. 
2006).  Akt regulates nutrient uptake and metabolism through downstream 
targets and stimulates glucose uptake in response to insulin.  The PI3K/Akt 
pathway is also critical in maintaining cellular metabolism in conditions of limited 
growth factors such as hypoxia and glucose deprivation found in solid tumours, 
by regulating the expression of glycolytic enzymes (Elstrom et al. 2004; 
Hammerman et al. 2004).  Akt is found to be involved in both normal and 
pathological angiogenesis stimulated by endothelial cells, cells producing 
angiogenic signals, such as tumour cells or in hypoxic conditions.  In endothelial 
cells, the PI3K/Akt pathway is activated by vascular endothelial growth factor 
(VEGF) upon which activated Akt mediates endothelial cell survival, growth and 
proliferation (Fujio and Walsh 1999).  One of the targets of phosphorylated Akt 
and more specific, Akt1, is endothelial nitric oxide synthase (eNOS) which upon 
activation by Akt produces nitric oxide (NO).  NO is a major role player in 
endothelial cell migration and angiogenesis by stimulating vasodilation and 
vascular remodelling (Dimmeler et al. 1999; Ackah et al. 2005).  Surprisingly, 
activated Akt1 but not Akt2 has been found to decrease mammary epithelial cell 
migration (Irie et al. 2005). 
 
Studies done on mouse tumour models have suggested that in epithelial cells, 
Akt1 inhibits metastases, while Akt2 promotes metastases but that the opposite 
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is true in fibroblasts, where Akt1 promotes metastases while Akt2 inhibits it 
(Arboleda et al. 2003; Hutchinson et al. 2004; Zhou et al. 2006). 
 
2.4.2   Clinical implications 
Sun et al. (2001) found activated Akt1 to be present in tumour cells of high 
grade tumours that were late stage and had a poor outcome while Perez-
Tenorio et al. (2002) linked Akt1 with poor response to endocrine therapy.  
Bacus et al. (2002) found Akt2 to be frequently associated with aggressive, Her-
(2+) breast tumours and metastases.  Stemke-Hale et al. (2008) reported the 
incidence of Akt1 mutation of only 1.4% in a study involving more than 400 
breast cancers. Akt2 and Akt3 mutations were not detected.  Perez-Tenorio et 
al. (2007) found no significant association between p-Akt expression, nodal 
status or PIK3CA mutation.  They did however observe elevated levels of p-Akt, 
total Akt and Cyclin D1 with mutated PIK3CA and/or Her-2 overexpression. 
 
Davies et al. (2009) measured the levels of p-Akt and PTEN in melanomas and 
found that almost all cases with elevated levels of p-Akt had low PTEN levels. 
Interestingly, they also found significantly higher p-Akt and lower PTEN levels in 
melanomas that metastasised to the brain compared to those that metastasized 
to the liver or lung (Davies et al. 2009).  Shah et al. (2005) found that when p-
Akt expression was located primarily in the nucleus, it was associated with 
nodal metastases and a poor prognosis in non-small cell lung cancers. 
 
High levels of p-Akt were found in immune-resistant tumours and associated 
with upregulation of anti-apoptotic molecules.  This finding suggests that the 
PI3K/Akt pathway may represent a mechanism for immune escape and has 
implications in immunotherapy and presents a challenge to develop 
immunotherapy against immune-resistant tumour cells (Noh et al. 2009). 
 
Recently the first human trial for MK-2206, a potent oral allosteric Akt inhibitor 
has been concluded.  The results were promising, particularly in tumours where 
Akt activation was the result of PTEN loss, but needs further evaluation in larger 




2.5   NF-κB 
2.5.1   Structure and function 
NF-κB is a nuclear transcription factor complex that controls the expression of a 
large number of genes responsible for controlling normal but crucial cellular and 
organisational processes, such as, inflammatory and immune responses, 
cellular proliferation and survival.   As a result, loss of NF-κB regulation has 
been implicated in a number of disease states, such as inflammatory, 
autoimmune diseases and cancer and neurodegenerative diseases, such as 
Parkinson and Alzheimer’s disease (Gilmore 1999; Mattson and Camandola 
2001; Soós et al. 2004; Collister and Albensi 2005).  The NF-κB protein, first 
discovered in the laboratory of the Nobel Prize winner David Baltimore in 1986, 
is encoded by the gene NF-κB (4q24).  The NF-κB protein forms part of a family 
of proteins that are structurally related through a conserved N-terminal DNA-
binding domain called the Rel homology (RH) domain (Sen and Baltimore 
1986).  The RH domain serves as a dimerization interface to other NF-κB 
transcription factors and also binds to the inhibitory protein, nuclear factor of 
kappa light polypeptide gene enhancer in B-cells inhibitor, IκB, as well as DNA.  
NF-κB proteins can be divided into two classes or sub-families.  The class I or 
‘NF-κB’ sub-family includes p105 and p100 and the class II or ‘Rel’ sub-family 
includes RelA, RelB, and c-Rel.  The class I proteins contain a large number of 
ankyrin repeats that masks the nuclear localization sequence (NLS) and 
renders the protein inactive.  The long C-terminal domain prevents nuclear 
localization and DNA-binding (Kieran et al. 1990; Davis et al. 1991a; Haskill et 
al. 1991; Rice et al. 1992; Grilli et al. 1993).  These large precursors, p105 (NF-
κB1) and p100 (NF-κB2) undergo phosphorylation followed by ubiquitination 
and proteasomal degradation of the C-terminus to form shorter, active DNA-
binding subunits, p50 and p52 respectively (Ghosh et al. 1990; Naumann and 
Scheidereit 1994; Palombella et al. 1994).  On their own these sub-units do not 
activate transcription, except when they form heterodimers with members of the 
class II sub-family.  In addition, the p50 and p52 homodimers can also form 
complexes with nuclear protein Bcl-3 and as such activate transcription (Bours 
et al. 1993).  In contrast, the class II proteins contain transcription activation 
domains in their C-terminus.   All NF-κB proteins can form either homodimers or 
heterodimers except for RelB, which can only form heterodimers.  The most 
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common heterodimer is p50-RelA, also commonly referred to as NF-κB and 
happens to be the major Rel/NF-κB complex in most cells (Grilli et al. 1993; 
Siebenlist et al. 1994). 
 
In an inactive state the Rel/NF-κB heterodimer is located in the cytoplasm 
sequestered by the inhibitory protein IκB that is responsible for masking the 
NLS of NF-κB proteins by means of their ankyrin repeat domains (Davis et al. 
1991a; Haskill et al. 1991; Henkel et al. 1992).  IκB proteins are also capable of 
removing the Rel/NF-κB complex from its DNA-binding locus (Davis et al. 
1991a; Ernst et al. 1995; Thompson et al. 1995; Beauparlant et al. 1996).  A 
number of studies have demonstrated that IκB molecules bind specific targets 
therefore different IκB molecules inhibit specific Rel/NF-κB dimers (Baeuerle 
and Baltimore 1989; Beg et al. 1992; Thompson et al. 1995).  
 
NF-κB is activated by 3 major pathways; the canonical or classical pathway, the 
non-canonical or alternative pathway and the casein kinase 2 (CK2) pathway.  
In the canonical pathway, activation of the Rel/NF-κB dimers occur when the 
enzyme IκB kinase (IKK) is activated mainly in response to bacterial and viral 
infections or pro-inflammatory cytokines (Baeuerle and Baltimore 1988; Rayet 
and Gélinas 1999).  IKK, also referred to as the IKK complex, contains two 
kinase subunits, IKKα and IKKβ, and an associated regulatory protein IKKγ also 
referred to as NEMO (Zabel U and Baeuerle PA 1990).  IKK, in turn 
phosphorylates the inhibitory protein, IκB and p105, which results in dissociation 
of IκB from the NF-κB complex, ubiquitination and finally proteasomal 
degradation of IκB and p105 resulting in the release of p50-, p65- and c-Rel-
containing dimers (Baeuerle and Baltimore 1988; Hayden and Ghosh 2004).  
Degradation of the Rel/NF-κB inhibitor, IκB, uncovers the NLS and gives rise to 
an active Rel/NF-κB heterodimer.  Activated Rel/NF-κB translocates into the 
nucleus where it binds to specific sequences of DNA called the response 
elements (RE).  This DNA/NF-κB complex then recruits other role players such 
as co-activators and RNA polymerase, which are responsible for transcribing 
downstream DNA into mRNA.  mRNA in turn, is translated into protein, which 
results in a change of biological function of proteins involved in immune and 
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inflammatory response, cell growth and proliferation to name a few (Baldwin 
1996).  
 
In the alternative pathway, IKK is activated mainly by cytokines such as B-cell 
activating factor (BAFF), CD40 and lymphotoxin β (LTβ) via NF-κB inducing 
kinase (NIK) (Coope et al. 2002; Dejardin et al. 2002; Kayagaki et al. 2002).  
IKK, in turn mediates selective phosphorylation and processing of p100 in the 
RelB/p100 complex to generate an active RelB/p52 complex through the 
process of ubiquitination and proteasomal degradation (Pomerantz and 
Baltimore 2002).  This active RelB/p52 complex is now able to enter the nucleus 
to facilitate transcription.  
 
The third pathway is IKK independent and activated in response to UV-C 
irradiation independent of DNA damage and is believed to activate CK2 via the 
p38 pathway.  CK2 is responsible for phosphorylating IκB directly (Kato et al. 
2003; Tergaonkar et al. 2003).  Activated NF-κB turns on the genes responsible 
for cell proliferation and protects the cell against processes that would induce 
apoptosis.   Activated NF-κB is responsible for the increased expression of pro-
inflammatory cytokines (IL1, IL2, IL6, TNF), chemokines (IL-8, MCP-1, GROα), 
growth factors (VEGF, GM-CSF, MMP2, MMP9), adhesion molecules (ICAM1, 
VCAM1, ELAM1) and anti-apoptotic proteins (c-IAP1, c-IAP2, c-FLIP,  XIAP, 
BCL2 family members) (Shishodia and Aggarwal 2004; Li et al. 2005).  The 
external apoptotic pathway starts at the cell membrane and involves membrane 
death receptors.  One such receptor is tumour necrosis factor-receptor1 (TNF–
R1), which transduces both death and survival signals via two complexes.  
Complex I is situated at the cell membrane and constitutes TNF-R1, tumour 
necrosis factor receptor 1-associated death domain (TRADD), receptor-
interacting protein (RIP), TNF receptor-associated factor 2 (TRAF2) and cellular 
inhibitor of apoptosis protein 1 (c-IAP1).  Complex I transduces survival signals 
and activates NF-κB. Complex II on the other hand is located in the cytosol, 
constitutes Fas-associated death domain (FADD) and procaspases 9 and 10 
and transduces apoptotic signals should NF-κB fail to upregulate anti-apoptotic 
Fas-associated death domain-like interleukin-1-ß-converting enzyme-inhibitory 
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protein (FLIPL) (Sheikh and Huang 2003).  As a result, defective NF-κB function 
would render cells vulnerable to apoptosis and result in cell death.  
 
Regulation of NF-κB transcription factors is of critical importance as 
deregulation has serious pathological implications.  Persistent inhibition leads to 
inappropriate immune cell development, delayed cell growth and infertility, while 
persistent activation by upstream kinases (including PI3K via Akt) or genes 
encoding NF-κB transcription factors or mutations inactivating IκB on the other 
hand, lead to cancer (Micheau and Tschopp 2003; Danial and Korsmeyer 2004; 
Gilmore 2006; Escárcega et al. 2007; Perkins 2007).  DNA binding by Rel/NF-
κB transcription factors is regulated at multiple levels which include: 
dimerization, inhibition by IκB, DNA binding, interaction with other transcriptional 
co-activators and also with the basal transcriptional mechanism (Brasier 2006).  
 
2.5.2   Clinical implications 
There is strong evidence to support the roles of Rel/NF-κB proteins and their 
IκB regulators in cell proliferation and oncogenesis (Rayet and Gélinas 1999).  
As a matter of fact, c-Rel, RelA, p100, p105, Bcl-3 and IκB have all been 
associated with oncogenesis as a result of gene amplification, overexpression, 
re-arrangement, translocation and mutation.  Constitutive activation of Rel/NF-
κB proteins were found in most cancer cell lines and in many tumour types 
(Shishodia and Aggarwal 2004).  Houldsworth et al. (1996) found genes 
encoding Rel/NF-κB proteins to be amplified or rearranged in up to 25% of 
certain human lymphoid tumours while Biswas et al. (2004) reported activated 
Rel/NF-κB to be present in 86% of ER- and Her2(+) breast carcinomas.  Some 
studies have shown p100 to be overexpressed in up to 75% of breast cancer 
biopsies examined.  In contrast to p100 rearrangements found in lymphomas, 
overexpression of p100 in breast cancer cells due to failure of cytokines to 
induce processing of p100, results in a high cytoplasmic concentration of 
precursor p100 as well as p52.  In this setting, p100 forms tertiary complexes 
with p50/RelB and p50/p65 heterodimers, leading to cytoplasmic sequestration 
and inhibition of NF-κB-related proteins which according to Dejardin et al. 
(1995) could play a role in oncogenesis.  Although NF-κB was initially linked to 
ER negative breast cancers, new evidence associates NF-κB with a subset of 
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ER(+) breast cancers that are at increased risk for relapse despite adequate 
hormonal treatment (Zhou et al. 2005). 
 
Chronic inflammation has long been associated with carcinogenesis and tumour 
progression.  The production of pro-inflammatory cytokines, chemokines, 
growth factors and anti-apoptotic proteins as a result of inflammation induced 
NF-κB activation were found to be involved in cancer progression and 
chemoresistance (Coussens and Werb 2002; Chen et al. 2007). 
 
Recently the drug Gallotannin (GT) has been found to be effective in inhibiting 
NF-κB signalling and tumour growth in colon cancer (Al-Halabi et al. 2011).  
Phytoestrogens, genistein and quercetin have also been shown to inhibit NF-κB 
signalling and induce apoptosis in Her-2(+) breast cancer cells (Seo et al. 
2011). 
 
2.6   p53 
2.6.1   Structure and function 
The p53 gene that is situated on the short arm of chromosome 17(17p13.1) was 
discovered in 1979.  As a sequence specific transcription factor, the p53 
molecule is composed of an N-terminal activation domain, a central DNA-
binding domain, an MDM2 binding site and a C-terminal tetramerization domain 
that also includes the nuclear export signal, followed by a regulatory domain 
that contains the DNA-damage recognition site and nuclear localization signals 
(Harris 1996; Somasundaram 2000).  
 
One of the most important functions of p53 is to guard the cell against malignant 
transformation.  p53 is activated by cellular stresses like DNA damage, 
oncogene activation, hypoxia and nutrient deprivation.  p53 regulates the target 
genes that induce cell cycle arrest, DNA repair, apoptosis, cellular senescence 
or changes in metabolism (Lee et al. 1995; Maya et al. 2001; Harris and Levine 
2005; Bensaad et al. 2006; Efeyan et al. 2006; Vousden and Lane 2007).  
Depending on the type or duration of stress, DNA damage or conditions of 
cellular growth, p53 would selectively activate a subset of target genes in order 
to achieve growth arrest, apoptosis, DNA repair or a change in differentiation 
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(Hupp et al. 1992; el-Deiry 1998).  p53 regulates G1-S checkpoint in response 
to minimal DNA damage or other minor stress factors like heat shock, hyperoxia 
or hypoxia.  Under these conditions, p53 would target p21WAF-1 or 14-3-3 to 
induce G1 arrest to allow repair of damaged DNA (Kastan et al. 1991; Kuerbitz 
et al. 1992; McKay et al. 1999).  Under conditions of extreme stress or severe 
DNA damage, p53 activates pro-apoptotic genes, such as, BAX, PIDD, Noxa or 
Puma (Miyashita and Reed 1995; Owen-Schaub et al. 1995; Polyak et al. 
1997). 
 
p53 regulates the expression of target genes by binding to the regulatory region 
of the target DNA (Ryan et al. 1993; Kaufmann 1995; Teyssier et al. 1999).  p53 
is able to regulate target genes due to its ability to selectively associate with 
different transcription factors, each with its own unique regulatory function.   The 
association and regulatory function of p53 is determined by post translational 
modifications that are able to change the conformation of the p53 molecule and 
as a result its association with transcription factors and regulatory proteins 
(Adler et al. 1997; Sionov and Haupt 1999; Ashcroft et al. 2000).  The p53 
molecule has more than 18 phosphorylation sites that can be modified in 
response to stress or DNA damage and determines the function of the 
molecule.  Phosphorylation of p53 was found to change during the course of a 
normal cell cycle and corresponds with its ability to associate with its regulatory 
proteins p300, MDM2 and JNK (Fuchs et al. 1998; Buschmann et al. 2000).  
Phosphorylation of p53 is regulated by phosphatases (Li et al. 2000). 
 
p53 is kept at low levels in normal, unstressed cells to safeguard the cell 
against disruption of the cell cycle and untimely cell death.  This is attained 
through the fact that p53 has a relatively short half-life and a mechanism by 
which unphosphorylated p53 is continuously being ubiquitinated largely by 
MDM2 ubiquitin ligase, a major negative regulator of p53 and degraded by the 
26S proteasome.  MDM2 inhibits p53 by binding its transactivation sites and by 
targeting p53 for proteolytic degradation.  MDM2 is one of the transcriptional 
targets of p53.  Since MDM2 is responsible for inhibiting p53 activity, this gives 
rise to a negative feedback loop (Ghosh and Bose 2005; Francoz et al. 2006).  
p53 positively regulates MDM2 levels while MDM2 negatively regulates p53 
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levels and activity. MDM2 is able to form a complex with both mutant and wild-
type p53 (Barak et al. 1993; Wu et al. 1993; Freedman et al. 1999).  MDM2 
functions as an E3 ubiquitin ligase and degrades p53 by targeting it for 
ubiquitination.  This is achieved by three mechanisms.  Firstly, MDM2 
recognizes, binds and blocks the N-terminal transactivation domain of p53, 
inhibiting its function as a transcription factor.   Secondly, by binding lysine 
residues in the p53 C-terminus, MDM2 mediates a covalent attachment of 
ubiquitin to p53 and labels p53 for proteasomal degradation.  Ubiquitinated p53 
is then degraded by the 26S proteasome.  Lastly, MDM2 exports p53 from the 
nucleus to the cytoplasm which is essential for p53 degradation. In the absence 
of MDM2-mediated degradation, p53 is activated (Barak et al. 1993; Wu et al. 
1993; Kubbutat et al. 1997; Ghosh and Bose 2005; Francoz et al. 2006).  
 
2.6.2   p53 activation following DNA damage 
In the event of DNA damage, either by UV or ionising radiation or a chemical 
agent, multiple molecular pathways are able to activate p53, resulting in both an 
increase in the levels of p53 protein and its binding affinity for specific DNA 
sequences (Maltzman and Czyzyk 1984; Liu et al. 1996b).  Following genotoxic 
stress, p53 is phosphorylated by different upstream mediators at various sites 
resulting in both an increased half life and transactivation activity (Meek 1994).  
Transcriptional activation of p53 results in both G1 and G2 arrest.  Some of the 
upstream mediators that play a role in the activation and stabilization of p53 in 
response to DNA damage include ataxia-telangiectasia mutated (ATM), kinase 
families such as MAP kinases, cyclin dependent kinases (CDKs) and DNA 
dependent kinase (DNA-DK) as well as tumour suppressor proteins p19ARF and 
p16INK4a  (Bischoff et al. 1990; Marshall 1994; Zhang et al. 1998).  ATM is a DNA 
damage checkpoint gene and its product is one of the major regulators of p53 in 
response to ionizing-radiation induced damage.  ATM kinase phosphorylates 
p53 on serine 15 and dephosphorylates p53 on serine 376 in order to facilitate 
specific binding of 14-3-3proteins to p53 and to increase sequence specific 
DNA binding by p53 (Matsushime et al. 1992; Waterman et al. 1998).  ATM 
kinase phosphorylates and activates checkpoint kinase 2 (Chk2) and nuclear 
tyrosine kinase c-Abl, in response to DNA damage (Baskaran et al. 1997).  
Activated Chk2 not only regulates cell cycle arrest at G2 but is also able to 
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phosphorylate p53 at serine 20, which is known to interfere with MDM2 binding, 
preventing ubiquitination in response to DNA damage resulting in an increase in 
p53 stability.  Activated c-Abl binds p53 and enhances its sequence specific 
transactivation ability (Goga et al. 1995; Hirao et al. 2000).  Recent studies have 
shown that tumour suppressor p14ARFis able to stabilize p53 by binding and 
promoting MDM2 for degradation.  The ARF-INK4 gene locus encodes two 
unrelated tumour suppressor proteins; p16INK4a and p19ARF.  p16INK4a  binds and 
inhibits CDK4 and CDK6, while p19ARF  binds and promotes the rapid 
degradation of MDM2, while modifying, stabilizing and increasing p53 levels at 
the same time.  Ubiquitination of p53 is suppressed and p53 accumulates in the 
nucleus where it is stabilized and activated (Stott et al. 1998; Zhang et al. 
1998). 
 
Acetylation by p300/CBP-associated factor (PCAF) is another modification of 
p53 that inhibits ubiquitination by MDM2 and aids in stabilizing p53.  Acetylation 
of p53 also aids in p53 DNA binding and stimulates p53-mediated 
transactivation of downstream targets through recruitment of co-activators 
(Dornan et al. 2003; Cesková et al. 2006). 
 
c-Myc is a transcription factor responsible for increasing both the transcription 
and stabilization of p53, while c-Myc transcription in turn, is downregulated 
following p53 activation as part of a negative regulatory feedback loop 
(Hermeking and Eick 1994).  
 
2.6.3   Cell cycle arrest and DNA repair 
The first step in the process of DNA repair is to arrest the cell cycle to prevent 
proliferation of cells containing damaged DNA which would otherwise pose a 
threat of tumour development.   The cell is arrested at checkpoints in the G1/S 
and G2/M phases of the cell cycle.  CDK1 is a major regulator of cell cycle 
progression and requires phosphorylation at T161 and association with cyclin B 
in order to be activated.  In contrast, phosphorylation of CDK1 at Y15 and T14 
during G2 phase results in deactivation of CDK1, which is directly inhibited by 
three transcriptional targets of p53 that are p21WAF1, Gadd45 and 14-3-3.  p53 
mediated transcriptional induction of p21WAF1 plays a major role in mediating the 
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G1 arrest.  p21WAF1 binds to and inhibits cyclin B/CDK1 complexes by 
sequestering them in the nucleus.  The resulting accumulation of pRb binds 
members of the E2F transcription family in order to constrain them.  This 
process brings about G1 arrest.  Phosphorylation of pRb by CDK4 or CDK6 in 
mid or late G1 phase has the effect of dissociating pRb from E2F.  Free E2F is 
now able to activate target genes needed for the cell to enter into S phase.  The 
next step involves the biochemical processes involved in DNA repair.  Both 
Gadd45 and 14-3-3 play a mediating role in G2 arrest.  14-3-3 is responsible for 
sequestering cyclin B/CDK1 in the cytoplasm while Gadd45 prevents binding of 
cyclin B and CDK1 through direct interaction with CDK1.  p53 is also 
responsible for the transcriptional repression of cyclin B. Gadd45 and p21WAF1 
are believed to play a role in DNA repair through their interaction with 
proliferating cell nuclear antigen (PCNA) (Serrano et al. 1993; Dyson 1998; 
Chan et al. 1999; Moore et al. 1999; Taylor and Stark 2001). 
 
Once repair is completed successfully, the cellular functions can progress to cell 
division.  
 
Should repair not be possible as a result of excessive damage, the p53-
mediated apoptotic pathway comes into play (Ma et al. 2005).  
 
Figure 2:  Cell cycle regulation by p53 
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2.6.4   Apoptosis 
p53 upregulates the synthesis of the pro-apoptotic protein BAX, while it 
downregulates the synthesis of the anti-apoptotic protein, BCL2 (Figure 3).  
BAX together with other pro-apoptotic proteins aids in the release of 
cytochrome C proteins from the mitochondria.  Cytochrome C is an apoptogenic 
factor, which when released into the cytosol, binds apoptotic protease activating 
factor-1 (Apaf-1).  Apaf-1binds and hydrolyses dATP to ATP.  Together, the 
hydrolysed dATP, Cytochrome C and Apaf-1 forms the Apaf-1/cytochrome C 
complex.  This apoptosome complex in turn cleaves and activates procaspase-
9 to yield active caspase-9 which in turn cleaves bound procaspase-3 to 
produce the active effector molecule caspase-3. Executioner caspase-3 cleaves 
key cellular proteins and dismantles the cell resulting in apoptosis.  Caspases 
are cysteine proteases that act in a proteolytic cascade to dismantle and 
remove dying cells and can be divided into upstream caspases (caspases 2, 8, 
9, 10 and 12) and downstream or effector caspases (caspases 3, 6 and 7). 
Upstream procaspases are activated by dimerization while downstream 
procaspases are activated by the proteolytic action of activated upstream 
caspases (Liu et al. 1996a; Zamzami et al. 1998; Fesik and Shi 2001; Boatright 
et al. 2003; Czerski and Nuñez 2004; Renatus et al. 2001).  Caspase-3 is also 
responsible for cleaving and downregulating anti-apoptotic BCL2 while p21WAF1, 
which is upregulated by p53, is in turn responsible for downregulating caspase-
3.   BCL2 protein suppresses the pro-apoptotic activity of BAX.  BCL2 also 
prevents the binding of Apaf-1 to procaspase-9.  The level of activation is 
dependent on the competition between the pro- and anti-apoptotic agents 
involved in the apoptotic pathway (Fussenegger et al. 2000; Hengartner 2000; 
Bose and Ghosh 2007). 
 
There is some evidence that p21WAF1 has a dual role in the p53-MDM2 network.  
p21WAF1 assists in the arrest of the cell cycle when it is activated by p53, but 
also has a second function of protecting the cell against apoptosis.  MDM2 is 
found to be a negative regulator of p21WAF1 independent of p53.  MDM2 
promotes p21WAF1 degradation by facilitating the binding of a proteasomal 




Figure 3:  The p53-mediated apoptotic pathway 
Adapted from Bose and Ghosh (2007) 
 
Downregulation of p21WAF1 activity results in enhanced p14ARF expression.  The 
p14ARF protein in turn sequesters MDM2 in the nucleolus, which results in a 
decrease in p53 degradation and therefore increased levels of p53 (Javelaue 
and Besancon 2002; Vassilev et al. 2004). 
 
2.6.5   Interactions with other proteins / cellular components 
As mentioned before, PTEN and p53 are mutually dependant on each other.  
p53 facilitates the transcription of PTEN, while PTEN enhances transactivation 
of p53 and for this reason loss of p53 expression would result in a decrease in 
PTEN expression (Wang et al. 2005). PTEN also protects p53 from survival 
signals by opposing PI3K/Akt signalling that promotes translocation of MDM2 
from the cytoplasm to the nucleus where it negatively regulates p53 (Mayo and 
Donner 2001).  PTEN restricts MDM2 to the cytoplasm by inhibiting nuclear 
entry of MDM2.  In the cytoplasm, MDM2 is degraded while cellular content and 
transactivation of p53 is increased.   By protecting p53, PTEN aids in the 
process of sensitization of tumour cells to chemotherapeutic agents that rely on 

























p53 and NF-κB are regarded as functional antagonists as they are responding 
to different types of stress in entirely antagonistic ways.  While p53 responds to 
intrinsic stress, like DNA damage by initiating cell cycle arrest or cell death and 
oxidative phosphorylation, NF-κB responds to extrinsic stress, like inflammation 
or cytokine activation and initiates cell division and aerobic glycolysis.  It is clear 
that these two transcription factors cannot function in the same cell at the same 
time.  Regulatory proteins in the activation pathway of both these transcription 
factors are responsible for ensuring that when the one is activated, the other is 
inactivated (Ak and Levine 2010).   
 
2.6.6   Clinical implications 
Mutations in the p53 gene have been found in more than half of human cancers 
and more than 30% of breast cancers. Over one thousand p53 mutation types 
have been identified.  The majority of the mutations occur in the core domain 
which also contains the sequence-specific DNA binding function, resulting in 
loss of its transcriptional activities and hence causes the loss of tumour 
suppressor activity (Hollstein et al. 1991; Cho et al. 1994).  In cancer cells 
harbouring a mutant p53 gene, the p53 protein is unable to control cellular 
proliferation, resulting in inefficient DNA repair and genetically unstable cells 
(Levine 1997).  Some mutations render p53 transcriptionally active against a 
different target gene, resulting in gain of function phenotypes (Blandino et al. 
1999; Deppert et al. 2000).  Mutant p53 expression was found to be elevated 
due to the fact that p53 was stabilized as a result of the inability of mutant p53 
to induce expression of its major negative regulator, MDM2 (Lane 1994). 
 
Overall phosphorylation of p53 (mutant as well as wild type) was found to be 
substantially increased in cancer, irrespective of the type and was believed to 
be due to the failure of one or more phosphatases (Minamoto et al. 2001). 
Extensive phosphorylation is expected to cause conformational change in the 
p53 molecule and alter its association with target molecules. This theory 
provides a possible mechanism by which p53 activities are altered in cancers 




Normal p53 protein is usually undetectable by IHC techniques due to its short 
half-life, while mutant p53 proteins accumulate in the nucleus of tumour cells 
due to an increased half-life and structural changes.  It is noteworthy that IHC 
techniques may in some instances give false positive results when wild-type 
p53 is stabilized due to cellular stress while false negative results have been 
seen in some cancers harbouring nonsense mutations or deletions (Schmitt et 
al. 1998; Geisler et al. 2001). 
 
p53 mutations and/or overexpression in  breast carcinoma has been associated 
with shorter disease free survival and overall survival, low ER content and high 
proliferation rate.  Exceptionally high p53 expression was found in ER-/PR- 
medullary and high grade ductal carcinomas of the breast (Borg et al. 1995).  
Cancers with mutations located in regions encoding parts of the protein involved 
in zinc-binding were associated with significantly shorter disease free survival 
and overall survival compared to mutations involving other domains (Borg A et 
al. 1995; Borresen AL 1995).  Patients with tumours overexpressing both Her-2 
and p53 were found to have a significantly shorter disease free and overall 
survival than when they were overexpressed individually (Yamashita et al. 
2004).  
 
p53 mutations have been associated with a good as well as poor treatment 
response depending on the type and mode of action of a particular treatment 
regimen.  The fact that wild-type p53 is able to repair UV-type DNA damage is 
proving useful  clinically in that some types of cancer carrying mutant p53 genes 
may be more sensitive to adjuvant radiotherapy and certain chemotherapeutic 
drugs than those with wild-type p53 function.   As p53 mutation is associated 
with high grade malignancies and metastases, preferential killing of these cells 
carrying mutated p53 would be of great benefit to cancer treatment (Sidransky 
et al. 1992; Peyrat et al. 1995; Stal 1995).  Cytotoxic drugs like 5-fluorouracil 
and doxorubicin rely on functioning p53 to execute their cytotoxic effects.   
Breast cancers expressing high levels of wild type p53 showed an increased 
level of apoptosis and tumour regression after treatment with doxorubicin and 
radiotherapy, while p53 deficient cancers continued to grow and showed little 
evidence of apoptosis (Lowe et al. 1994).  p53 mutations  especially those 
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involving loop domains L2 and L3 were associated with resistance to 
doxorubicin treatment and relapse as a result of defective apoptosis due to 
inactive p53.  p53 mutations were also associated with Her-2 expression, a high 
histological tumour grade and lack of bcl-2 expression.  All of these parameters 
were also associated with chemoresistance, especially when present 
simultaneously (Geisler et al. 2001).  
 
p53 mutations were also found to be present at an increased frequency in triple 
negative breast cancers and was shown to be a strong negative prognostic 
indicator for disease free survival and overall survival in this group of cancers, 
especially when treated with adjuvant anthracycline-based chemotherapy 
(Cheang et al. 2008; Chae et al. 2009).  Non-inflammatory breast cancers and 
particularly the basal or triple negative type breast cancers with p53 mutations 
showed increased sensitivity to high dose epirubicin-cyclophosphamide 
treatment, while those with wild type p53 showed complete resistance 
(Bertheau et al. 2002; Bertheau et al. 2007). 
 
Bergh et al. (1995) found the mutational status of p53 of little value in predicting 
treatment response to radiotherapy and tamoxifen treatment in node positive 
breast cancers.  Geisler et al. (2001) found no statistically significant relation 
between p53 immunostaining and treatment response despite its association 
with p53 mutation status.  
No association was found between p53 status and the clinical efficacy of 
trastuzumab (Köstler et al. 2005).  Varna et al. (2011) found that p53 status 
could be useful in selecting the best cancer treatment because of its strong 
impact on the prognosis of breast cancer, provided that p53 status is 
determined by DNA sequencing and not IHC.  IHC was found to be unreliable in 
determining p53 status.  Soussi (2007) found that the prognostic significance of 
p53 is in fact dependent on the specific p53 mutation present and explains why 







2.7   MDM2 
2.7.1   Structure and function 
MDM2, encoded by the MDM2 gene (12q14.3-q15), consists of 491 amino 
acids and has a molecular weight of 56kDa.  The MDM2 molecule contains 
several structural domains including a N-terminal domain essential for p53 
binding, a nuclear localization signal (NLS) and nuclear export signal (NES) 
essential for nuclear-cytoplasmic trafficking of MDM2, a central acidic region, a 
zinc finger (Zn) and RING finger motif as well as a nucleolar localization signal 
(NoLS) (Ganguli and Wasylyk 2003).  The acidic region facilitates interaction 
between the ribosomal protein, L5 and associated 5S ribosomal RNA (rRNA) 
(Marechal et al. 1994).  The function of the zinc finger domain is still poorly 
understood.  The RING domain located near the C-terminal contains two 
additional zinc fingers in a ring formation enabling the molecule to bind to 
specific RNA structures.  The RING domain contains a nucleotide binding motif, 
a nucleolar localization sequence and has E3 ubiquitin ligase activity that may 
contribute to p53 regulation.  The MDM2 molecule also contains residues that 
when phosphorylated, play a role in MDM2 regulation (Marechal et al. 1994).  
Although the key target of MDM2 is probably p53, it also interacts with other 
tumour suppressor proteins, such as, pRb, p73 and p14ARF / p19ARF (Xiao et al. 
1995; Kamijo et al. 1998; Pomerantz et al. 1998; Zhang et al. 1998; Dobbelstein 
et al. 1999).  As discussed earlier in section 2.6.1, MDM2 is an important 
negative regulator of p53 in normal, unstressed cells.  MDM2 inhibits p53 by 
binding its transactivation sites and by targeting p53 for proteolytic degradation 
(Leng et al. 1995; Haupt et al. 1997; Kubbutat et al. 1997).  Three domains of 
the MDM2 molecule are involved in the ubiquitination process: the p53 
interaction domain, the RING finger domain responsible for mono-ubiquitination 
and the p300 interaction domain for poly-ubiquitination (Fang et al. 2000; 
Grossman et al. 2003).  MDM2 was found to differentially catalyze mono-
ubiquitination and poly-ubiquitination of p53 in a dosage-dependent manner 
which implies that low levels of MDM2 would induce mono-ubiquitination and 
nuclear export of p53, while high levels of MDM2 would result in poly-
ubiquitination and nuclear degradation of p53.  The assumption was made that 
these two mechanisms come into play under different physiological conditions.  
For example, in normal unstressed cells where the MDM2 levels are kept low, 
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p53 is regulated by MDM2-mediated mono-ubiquitination and p53 cytoplasmic 
translocation.  MDM2-mediated poly-ubiquitination and nuclear degradation of 
p53 on the other hand would be the most likely mechanism exploited when 
MDM2 is overexpressed in malignancy or during late stage DNA damage 
response (Freedman et al. 1999; Boyd et al. 2000; Shirangi et al. 2002; Li et al. 
2004a; Stommel and Wahl 2004). 
 
MDM2 not only promotes the proteolytic degradation of p53 but is also 
responsible for its own proteolytic degradation as well as that of other proteins 
(Honda and Yasuda 2000).  MDM2 is regulated by phosphorylation of residues 
in its acidic domain which could change its function, stabilize p53 and negatively 
regulate p53-MDM2 interaction.  As discussed earlier in section 2.6.2, p19ARF 
directly interact with MDM2 to sequester MDM2 in the nucleolus, neutralising its 
inhibitory effect on p53 (Pomerantz et al. 1998; Stott et al. 1998). 
 
MDM2 serves as a substrate for Akt binding.   Akt-mediated phosphorylation of 
MDM2 enhances MDM2-mediated ubiquitination and degradation of p53. 
Through this mechanism Akt indirectly reduces the levels of p53 and promotes 
cellular survival, proliferation and tumourigenesis.  Ogawara et al. (2002) 
reported that Akt-mediated phosphorylation of MDM2 did not affect the 
subcellular location of MDM2.  Overexpression of MDM2 can result in excessive 
inactivation of p53, diminishing its tumour suppressor function.  MDM2 also 
affects the cell cycle, apoptosis and tumourigenesis through interactions with 
other proteins, including RAS, pRb and ribosomal protein L5 (Freedman et al. 
1999).  
There is some evidence to suggest that overexpression of MDM2 may also play 
a p53-independent role in G1 cell cycle arrest by regulating DNA replication 
provided that there is additional genetic damage (Lundgren et al. 1997; Jones et 
al. 1998 ).  MDM2 overexpression may be the result of one of three 
mechanisms namely gene amplification, increased transcription or enhanced 
translation (Oliner et al. 1992; Watanabe et al. 1994; Bueso-Ramos et al. 1996; 





2.7.2   Clinical implications 
The most common mutations are found in the zinc finger domain of MDM2. It 
disrupts the negative regulation of MDM2 by Rb protein L11, which no longer 
recognizes the binding site and in doing so, creates a potential mechanism for 
oncogenic activation (Lindström et al. 2007). 
 
Increased levels of MDM2 have been found in a wide variety of tumours 
including certain carcinomas, sarcomas, melanomas and some haematological 
malignancies.  MDM2 was found amplified in breast cancers at a frequency 
ranging between 4% and 14% (Marchetti et al. 1995; McCann et al. 1995; 
Momand et al. 1998; Turbin et al. 2006). 
 
Momand et al. (1998) found that p53 mutations and MDM2 amplifications do not 
generally occur within the same tumour, while Cordon-Cardo et al. (1994) found 
a significant correlation between the overexpression of both p53 and MDM2 in 
the same tumour and a poor survival rate (P<0.05) but found no correlation 
between MDM2 on its own and clinical outcome.  A study by Al-Kuraya et al. 
(2004) based on more than 2000 cases, found no correlation between MDM2 
amplification and disease free survival.  Turbin et al. (2006) however, in a study 
based on the same number of cases, found a strong negative correlation 
between MDM2 IHC expression and disease free survival, independent of other 
pathological or clinical factors.  The intensity of IHC staining had little or no 
effect on the clinical outcome (Turbin et al. 2006).  McCann et al. (1995) found 
no correlation between p53 and MDM2 expression. 
 
According to Sheikh et al. (1993) ER(+) cells express higher levels of MDM2 
compared to ER- cells.  They suggested that oestrogen may play an important 
role in growth stimulation of breast carcinoma by modulating the expression of 
MDM2, which in turn may inactivate the function of p53.  
 
2.8   BCL2 
2.8.1   Structure and function 
The BCL2 gene has been mapped to 18q21.3.  The name is derived from a 




inappropriately expressed as a result of the chromosomal translocation 
[t(14,18)] and associated with a poor outcome (Tsujimoto et al. 1984). The 
BCL2 protein forms part of the BCL2 family of apoptosis regulating proteins, 
which includes both anti-apoptotic and pro-apoptotic proteins.  The anti-
apoptotic proteins include BCL2 proper, Bcl-x-protein long isoforms (Bcl-XL), 
myeloid cell leukaemia sequence-1 (Mcl-1), CED-9, A1/Bfl-1 and BHRF-1.  
The pro-apoptotic members are divided into multidomain pro-apoptotics that 
include proteins like BCL2-associated X protein(BAX) and BCL2-agonist/killer 
(BAK) while the BCL2-homology domain 3 (BH3)-only pro-apoptotics include 
proteins like BCL2-agonist of cell death (BAD), BH3-interacting domain death 
agonist (BID), BCL2-interacting mediator of cell death (BIM) and BCL2-
interacting killer (Bik).  Members of the BCL2 family have one or more of four 
characteristic BCL2 homology (BH) domains in common.  The domains are 
BH1, BH2, BH3 and BH4, which are crucial to the function of these members 
(Fesik and Shi 2001; Petros et al. 2004).  BH1 and BH2 play a role in the 
function of the anion channel that regulates the release of cytochrome C from 
the mitochondria.  BH3 is essential for heterodimerization between members 
and the minimum domain requirement for the pro-apoptotic function BH4 
allows for dimerization with pro-apoptotic proteins (Kluck et al. 1997; Yang et 
al. 1997; Kelekar and Thompson 1998). 
 
Members of the BCL2 family share a general structure that consists of a 
hydrophobic helix, surrounded by amphiphatic helices, which play a central 
role in the intrinsic pathway of apoptosis.  The anti-apoptotic members of the 
BCL2 family form an integral part of the outer mitochondrial membrane 
protein and regulate the mitochondrial membrane permeabilization (MMP). 
MMP plays a pivotal role in the process of apoptosis and is controlled by 
activation or inactivation of an inner mitochondrial permeability transition 
pore, which regulates matrix Ca2+, pH and voltage.   At least two possible 
mechanisms have been described.  The first mechanism involves a 
permeability transition pore complex (PTPC) formed by cyclophilin-D, 
peripheral-type benzodiazepine (PBR), adenine nucleotide transporter (ANT) 
and the voltage-dependent anion channel (VDAC).   This complex then 
associates either with pro-apoptotic BCL2 proteins like BAX, BAK1 and BIM, 
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which accelerate the opening of the channel or with one of the anti-apoptotic 
proteins like BCL-XL, which causes closure (Shimizu et al. 1999; Vyssokikh 
and Brdiczka 2003).  The second mechanism involves the pro-apoptotic 
proteins and their translocation from the cytosol to the mitochondria where it 
forms protein pores by oligomerization and association with other proteins or 
by antagonizing the anti-apoptotic proteins by binding via their BH3 domains.   
Pro-apoptotic members like BAX, BID and BIM are inactive and must 
translocate from the cytosol to the mitochondria in order to induce apoptosis.  
Pro-apoptotic members of the BCL2 family proteins induce the release of 
cytochrome C from within the mitochondria into the cytosol, while the anti-
apoptotic members inhibit the release of cytochrome C.  Apoptosis is 
determined by the ratio of pro-apoptotic to anti-apoptotic proteins (Krajewski 
et al. 1995; Ogura et al. 1999 ). 
The mitochondrial pathway of apoptosis is activated by various types of intra- 
and extra-cellular stress, including DNA damage, growth factor withdrawal, 
oxidative stress, stresses in the endoplasmic reticulum, death receptor 
stimulation, anticancer drugs and irradiation (Ron 2002; Green and Kroemer 
2004).  Stress, like Gamma- and UV radiation, cytotoxic drugs and removal 
of cytokines induce apoptosis by a mechanism that alters the MMP with 
subsequent cytochrome C release. Intracellular stress like oncogenes, DNA 
damage, hypoxia and deprivation of survival factors, activate p53 (Marshall 
1994; Baskaran et al. 1997; Zhang et al. 1998). 
Growth factors influence apoptosis via the PI3K/Akt pathway.  Growth factors 
bind growth factor receptors and activate PI3K which in turn activates Akt. 
Activated Akt is a negative regulator of BAD, a pro-apoptotic member of the 
BCL2 family involved in mitochondrial apoptosis (Thompson et al. 1995). 
p53 is responsible for transcriptional activation of the BAX, Noxa, p53-
upregulated modulator of apoptosis (PUMA) and BID while repressing the 
anti-apoptotic proteins.  Other transcriptional targets of p53 involved in the 
apoptotic pathway include Apaf-1 and PTEN (Oda et al. 2000; Thornborrow 
et al. 2002; Yu et al. 2003).   
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2.8.2   Clinical implications 
As anti-apoptotic proteins, BCL2 and Bcl-XL are able to inhibit the mitochondrial 
apoptotic pathway by preventing the release of cytochrome C from the 
mitochondrion and the subsequent activation of caspases-9 and -3.  As a result 
both BCL2 and Bcl-XL are able to inhibit drug and radiation induced apoptosis 
and therefore reduce the effectiveness of chemotherapeutic agents and even 
more so when they are over-expressed (Huang 2000; Kim et al. 2002). 
 
In a study by Silvestrini et al. (1994), BCL2 expression was associated with 
small, slow growing, ER- and p53- tumours.  The predictive value of BCL2 was 
found to be dependent on p53 expression.  Lee et al. (1997) found a strong 
relation between hormonal status, histologic tumour and nuclear grade and 
BCL2 expression.   Although they found an association between BCL2 status 
and survival, BCL2 was not a reliable indicator for overall survival.  Charpin et 
al. (1998) found BCL2 expression only of limited prognostic value.  They 
reported an association between BCL2 expression and a longer disease free 
survival but not with overall survival.  Callagy et al. (2006) evaluated 930 breast 
tumours and found BCL2 to be an independent predictor of prognosis 
particularly in the first 5 years after diagnosis and a useful addition to the 
Nottingham prognostic index (NPI).  In a study involving more than 11 000 
early-stage breast cancer cases, Dawson et al. (2010) found BCL2 to be an 
independent indicator of favourable prognosis for all types of early breast 
cancer irrespective of ER or Her-2 status or type of adjuvant therapy received.  
Similarly, Treré et al. (2007) found BCL2 to be an independent predictor of 
clinical outcome, irrespective of nodal status. They associated BCL2(-) 
carcinomas with a 5x higher risk for relapse and 7x higher risk for death, 
compared with BCL2(+) carcinomas.  Geisler et al. (2001) found Her-2 
(+)/BCL2(-) cancers with a high histological grade to be resistant to doxorubicin. 
 
2.9   Oestrogen Receptor 
2.9.1   Structure and function 
Oestrogen receptors (ER) are DNA-binding transcription factors that regulate 
gene expression and are activated by the hormone 17β-oestradiol to mediate 
the effects of oestrogen on tissue growth, development and maintenance.  Two 
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different subtypes of oestrogen receptors, encoded by different genes, have 
been identified.  ERα (ESR1) is encoded by a gene located on chromosome 6 
(6q25.1) while ERβ (ESR2) is encoded by a gene located on chromosome14 
(14q) (Moggs and Orphanides 2001; Levin 2005; Dahlman-Wright et al. 2006). 
The two subtypes show significant sequence homology and exhibit functional 
domains characteristic of the nuclear receptor super family.  Both are composed 
of five domains (A-F), which include the A/B domain on the N-terminal which is 
an agonist-independent transcriptional activation function (AF-1) domain.  The 
C-domain is a conserved DNA-binding domain that binds oestrogen response 
elements in DNA.  The D-domain is a hinge region that connects the C and E 
domains. The E-domain is a dimerization region.  The function of the F-domain 
on the C-terminal is unclear. (Moggs and Orphanides 2001; Nilsson et al. 2001) 
 
Although both ERα and ERβ are widely expressed in different tissue types, 
notable differences are found in their expression patterns.  ERα is expressed in 
the endometrium, breast cancer cells, ovarian stromal cells and the 
hypothalamus, while ERβ is expressed in the prostate, brain, bone, kidney, 
intestinal mucosa, lungs, heart and endothelial cells.  These two subtypes are 
co-expressed in many cell types and may form homo- (αα or ββ) or 
heterodimers (αβ) (Li et al. 2004b). In their inactive state, both receptors are 
found in the cytosol, although a small amount of the ERs have also been found 
within the nucleus and cell membrane (Htun et al. 1999).  Oestrogen is a 
steroidal hormone and can pass through the phospholipid of the cell membrane, 
therefore ERs do not need to be membrane-bound in order to bind with 
oestrogen.  Oestrogen binding to the receptor triggers a number of events 
starting off with receptor phosphorylation, dimerization and migration of the 
receptor from the cytosol into the nucleus and subsequent binding of the 
receptor dimer to the promoter region of target genes, also referred to as 
hormone response elements.  This DNA/receptor complex then recruits other 
proteins that are responsible for the transcription of downstream DNA into 
mRNA and finally protein that is able to change cellular function.  This pathway 
is known as the genomic pathway and is also influenced by several co-
repressors such as nuclear hormone receptor co-repressor (NCoR) and 
silencing mediator or retinoic acid and thyroid hormone receptors (SMRT) and 
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co-activators such as amplified in breast cancer 1 (AIB1) or steroid receptor co-
activator 1 (SRC1) (Shou et al. 2004). 
 
2.9.2   Clinical implications 
More than half of breast cancers are found to be ER(+).  Unfortunately only 
about half of these ER(+) breast cancers show sensitivity to hormonal treatment 
(e.g. tamoxifen) and a significant number of these cancers ultimately develop 
secondary resistance to hormonal treatment, leading to tumour progression, 
metastasis and death (Osborne 1998; Schiff et al. 2004).  Richard et al. (1987) 
reported a worse relapse-free survival and overall survival in ER(-) patients 
compared to ER(+) patients.  They also found a significantly worse relapse-free 
and overall survival in ER(-)/EGFR(+) patients compared to ER(-)/EGFR(-) 
patients.  They also reported a significant association between tumour size and 
differentiation.  Onitilo et al. (2009) found tumours of the subtype 
ER(+)/PR(+)/Her2(-) to benefit from chemotherapy while supporting the findings 
of other studies which have shown the ER(-)/PR(-)/Her2(-) (triple negative) 
subtype to be associated with large tumours, a high incidence of nodal positivity 
and the worst overall and disease-free survival for the first four years. After four 
years the mortality rate declines rapidly to be on par with other cancers. 
 
One proposed mechanism for developing inherent resistance is the co-
amplification of both human epithelial growth factors, especially Her-2 and co-
activator AIB1 in ER(+) breast cancers (Osborne et al. 2003).  In fact, tamoxifen 
is found to play the role of an oestrogen agonist rather than antagonist in breast 
carcinomas that express high levels of both Her-2 and AIB1, resulting in 
stimulation rather than suppression of tumour growth (Shou et al. 2004).  
Another mechanism by which oestrogen can promote growth is the fact that ER 
located in or near the cell membrane has the ability to activate EGFR as well as 
Her-2.  This pathway is referred to as the non-genomic pathway.  This receptor 
cross-talk happens in both directions and therefore ER and AIB1 in turn can 
also be phosphorylated by EGFR or HER-2 (Razandi et al. 2003).  This non-
genomic pathway is believed to be the reason for tamoxifen monotherapy 
failure and the introduction of gefitinib as an EGFR/Her-2 pathway inhibitor in 
order to close the so-called “loophole” and restore tamoxifen’s antagonistic 
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effect on ER(+) tumours.  Shou et al. (2004) found oestrogen withdrawal in 
ER(+) tumour to be a valid alternative to a combination of tamoxifen and 
gefitinib treatment.  This approach would unfortunately only be beneficial to a 
small fraction of ER(+) patients as less than 10% of ER(+) cancers express high 
levels of Her-2, suggesting the existence of another mechanism through which 
the majority of ER(+) cancers escape endocrine therapy. 
 
2.10   Aims 
 To determine the expression and prognostic value of selected markers 
in the Her-2/PI3K/Akt pathway 
 
 To evaluate the chromogenic in-situ hybridization (CISH) technique for its 
suitability for analysis of Her-2 gene amplification on archived, 















































MATERIALS AND METHODS 
   
3.1   Ethical Approval 
Ethical approval has been obtained from the Human Research Ethics 
Committee at the University of Cape Town. (HREC reference number 
082/2009) 
 
3.2   Sample selection 
We have selected a retrospective series of primary breast carcinoma cases 
based on their Her-2 immunohistochemical results.  Twenty seven cases 
were Her-2 negative, 7 had a score of (1+), 17 had a score of (2+), while 42 
had a score of (3+). 
 
A total of 93 cases were selected for this study (referred to as cohort A).  
Sixty seven cases were from the archives of the NHLS Division of Anatomical 
Pathology at Groote Schuur hospital (cohort B), but since trastuzumab was 
not offered at state facilities at the time of the study, a second cohort of 26 
cases from the private sector that received trastuzumab treatment was 
included (cohort C).  These tissue blocks were obtained from two 
independent private pathology laboratories in Cape Town.  
 
A limiting factor in case selection and follow up period has been the fact that 
routine Her-2 testing on all invasive breast cancer cases was only introduced 
late in 2006.  For this reason, only patients who had a mastectomy after the 
introduction of routine Her-2 testing, unless they had Her-2 testing done on 
request, were included in the study.  The outcome was based on the patient 
status on 1 July 2011.  All cases were reviewed and appropriate tissue 
blocks selected for study. 
 
3.3   Data Collection 
The histology and cytology reports were obtained from the NHLS Division of 




Clinical information was obtained with the help of clinical collaborators at the 
oncology unit at Groote Schuur hospital and private practice oncology units. 
Patients that were lost to follow up or died of unrelated causes were excluded 
from the study. 
 
The following clinical and pathological information was recorded: 
 Clinical stage of tumour at time of mastectomy 
 Histopathological grade  
 Tumour type  
 Age of patient at time of mastectomy 
 Date of onset of treatment 
 Lymph node status  
 Lymphovascular invasion  
 Her-2 IHC and ISH results 
 Oestrogen receptor (ER) status*  
 Treatment / therapy received  
 Follow up of patient – minimum of 4 years: 
- Alive and disease free 
- Alive with disease 
- Dead 
- Disease free survival (DFS) 
- Overall survival (OS) 
 
* The progesterone receptor (PR) status was not consistently tested for in the 
treatment work-up during this particular period.  In view of this inconsistency, 
the PR results were not recorded in this study. 
 
3.4   Immunohistochemistry (IHC) 
IHC was performed on formalin-fixed, paraffin-embedded tissue sections. 
 
3.4.1   Buffers and reagents used 
3.4.1.1   Phosphate buffered saline (PBS) pH7.6 
Used for diluting antibodies (without Tween 20) and rinsing (with Tween 20) 
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NaH2PO4 (2H20) 0.78g 
Na2HPO4  6.4g 
NaCL   42.5g 
Dissolve the above in 5L distilled water.  
Adjust to pH7.6 using HCL or NaOH. 
Add 2.5ml Tween 20 for PBS with Tween when used for rinsing. 
 
3.4.1.2   Tris-HCl buffered saline (TBS) pH7.6 
Used for diluting antibodies and rinsing 
(HOCH2)3CNH2  3g   (TRIS hydroxymethylaminomethane) 
NaCl    40.5g 
1M HCl   19ml 
Distilled water to 5L  
 
3.4.1.3   0.1M Citrate buffer pH6.0 
Used for antigen retrieval 
Citric acid  10.5g 
Dissolve in 4.0L of distilled water. 
Adjust to pH6.0 with NaOH 
Make up to 5L with distilled water. 
 
3.4.1.4   1mM EDTA pH8.0 
Used for antigen retrieval 
EDTA   1.86g 
Dissolve in 4.9L distilled water. 
Adjust to pH8.0 with 1M NaOH. 
Make up to 5L with distilled water. 
 
3.4.1.5   1% Copper sulphate 
Used to enhance DAB staining/colour 
CUSO4   10g 





3.4.1.6   Scotts tap water 
Used for “blueing” after counterstaining with haematoxylin 
Na2CO3  3.5g 
MgSO4.7H2O 20g 
Dissolve in 1L tap water. 
 
3.4.2   Controls 
A  Study cohorts  
Within the total population (93 cases – cohort A), we had a cohort that 
received trastuzumab treatment (26 cases – cohort C), while remaining 
cohort did not receive trastuzumab treatment (67 cases – cohort B) and was 
used as a control group. 
 
B  Test controls  
Appropriate positive tissue controls were included in each test run*.  
For negative controls (IHC), the primary antibody was substituted by PBS 
buffer. 
 
*Please refer to Table 1 for specific positive tissue controls that were used 
for each antibody. 
 
3.4.3   Method for IHC  
 Cut sections 4µm thick 
 Float sections onto APES coated slides and blot 
 Heat-fix the sections onto the slides by leaving slide on a hot plate 
(~60ºC) for at least 10 min. 
 De-wax in xylene and hydrate slides in graded alcohols down to water 
 Rinse slides in running tap water 
 Perform the appropriate antigen retrieval by heat induced epitope 
retrieval using Citrate buffer at pH6.0 for 2min or EDTA buffer at pH8.0 
for 90 sec, depending on specific antibody requirements (See Table1).  
 Remove slides from pressure cooker and immerse in running tap 
water to cool down. 
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 Block for endogenous peroxidase activity by treating slides with 1% 
H2O2 in distilled water for 5-10 min (to block non-specific staining) 
 Rinse in running tap water 
 Block for non-specific binding by treating slides with normal goat 
serum (1:20) for 5-10 min (DAKO)  
 Drain the normal serum from the slides 
 Apply appropriately diluted primary antibody for required / optimised 
incubation time.  See Table 1 for specific antibody dilutions and 
incubation times.  Dilution of antibody p-Akt was done using TBS. 
 Rinse thoroughly with PBS  
 Apply Envision reagent (secondary antibody) for 25-30 min (DAKO) 
(NB. use the appropriate Envision reagent for each antibody i.e. goat 
anti-mouse OR goat anti-rabbit) 
 Rinse in running tap water 
 Apply the chromogenic substrate (1ml buffer + 1 drop 3,3’-
diaminobenzidine-tetrahydrochloride (DAB) for 3-5 min (DAKO) 
 Rinse in running tap water 
 Immerse slides in 1% copper sulphate for 3-5 min (enhances the DAB   
staining) 
 Rinse in running tap water 
 Counter stain in haematoxylin 
 Rinse in running tap water 
  “Blue” the slides in Scott’s tap water  
 Rinse in running tap water 
 Dehydrate in graded alcohols, rinse in xylene and mount with DPX or 
Entellan mounting medium. 
 
The buffer used (either EDTA or Citrate) for antigen retrieval was determined 
by the suggested pH requirement specified in the datasheet provided by the 
supplier of the antibody. 
 
Primary antibodies and normal goat sera were diluted in PBS without Tween 
unless otherwise indicated.  
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All rinse steps are performed with PBS with Tween unless otherwise 
indicated. 
 
In the case of antibody p-Akt, PBS was substituted with TBS in all rinsing and 
dilution steps. 
 
To prevent further dilution of the reagents, excess fluid was mopped up 
around sections before reagents were applied.  
 
Staining was performed in a humidity chamber. 
 








Table 1:  Summary of antibodies, antigen retrieval, clones, dilutions, controls and incubation times 
 












Cat # A0485 
DAKO Goat Anti-Mouse 
EDTA buffer    
pH8.0   90 sec  
Breast carcinoma 1: 250 30 min PBS 
PI3K 3E7 Abnova Goat Anti-Mouse 
Citrate buffer    
pH6.0   2min 






Citrate buffer    
pH6.0   2min 





EDTA buffer    
pH8.0   90 sec 
Skin 1:50 14 hours TBS 
NF-κB 
Polyclonal 




EDTA buffer    
pH8.0  90 sec 





Citrate buffer    
pH6.0  2min 
Leiomyosarcoma  1:100 60 min PBS 
Bcl-2 124 DAKO Goat Anti-Mouse 
EDTA buffer    
pH8.0   90 sec 
Tonsil 1:50 40 min PBS 
p53 DO-7 DAKO Goat Anti-Mouse 
d EDTA buffer   
pH8.0   90 sec 
Colonic 
adenocarcinoma 
1:100 40 min PBS 
Information obtained from package inserts provided by suppliers and further optimization done by researcher
51 
 
3.4.4   Evaluation of slides 
Evaluation of the IHC results was done simultaneously by two investigators. 
 
Table 2:  Scoring of Her-2 results 
Staining pattern Score Assessment 
No staining or membrane staining in less than 10% or tumour cells. 0 negative 
Faint/barely perceptible membrane staining in more than 10% of 
tumour cells. The cells exhibit incomplete membrane staining. 
1+ negative 
Weak to moderate staining of entire membrane in more than 10% of 
tumour cells. 
2+ equivocal 
Strong staining of entire membrane in more than 10% of tumour cells. 3+ positive 
 
Table 3:  ER scoring 
Based on the Allred scoring system (Allred et al. 2004) 
Proportion 
0 1 2 3 4 5 
0% <1% 1%-10% 11%-33% 34%-66% >66% 
Intensity 
0 1 2 3 
No staining Weak staining Moderate Strong 
 
The sum of the proportion and intensity scores was regarded as the total ER 
score out of a possible score of 8.  According to recommended clinical 
practice, scores from 0 to 2 were regarded as ER negative and scores from 3 
to 8 as ER positive (Lester et al. 2012). 
 
Table 4:  Evaluation of all other IHC results 
% of cells stained score 
<5% 0 
5% - 50% low 






3.5   Chromogenic in-situ hibridization (CISH) 
CISH was performed on 10 histopathological and corresponding cytological 
samples.  The cytological samples were archived, Papanicolaou-stained, 
FNA slides taken prior to the mastectomy and the histopathological samples, 
formalin-fixed, paraffin-embedded tissue sections taken from the mastectomy 
specimen. 
 
3.5.1   Probe   
The Her-2 CISH probe (SPOT-Light® HER2 CISH kit from Invitrogen)           
(FDA approved). 
 
3.5.2   Sample pre-treatment for CISH  
Information obtained from the SPOT-Light® HER2 CISH kit package insert 
(Intended for use on formalin-fixed, paraffin-embedded tissue) 
 
3.5.3   Preparation of archived cytology slides for CISH: 
 Immerse slides in xylene until coverslip and mounting medium is 
removed.   
 De-stain in 2% acid alcohol until completely de-stained 
 Soak in 100% ethanol for 5min 
 Wash thoroughly in dH2O 
 
3.5.4   Histopathological sample pre-treatment  
 Cut formalin-fixed, paraffin-embedded tissue into 4μm thick sections 
and float onto Histo-bond or APES treated slides 
 Air dry slides or dry at 37°C, and then bake 2hours at 60°C 
 
3.5.5   Deparaffinization 
 Immerse in xylene until wax is removed 
 Soak in 100% ethanol for 5min 





Method for CISH for both histopathological and cytological specimens  
 
3.5.6   Heat pre-treatment 
 Place slides in slide rack. (Including supplied test control slide) 
 Heat the Heat Pre-treatment solution in a beaker on a hotplate until 
temperature reaches ≥98°C. Cover beaker to prevent evaporation. 
 Place slides in boiling solution and boil for 15 min.  Ensure that the 
temperature remains between 98°C and 100°C.  
 Transfer slides immediately to dH2O at room temperature 
 Wash in dH2O 
 
3.5.7   Enzyme digestion  
 Remove enzyme pre-treatment solution (pepsin) from the fridge and 
allow to reach room temperature 
 Add enough enzyme pre-treatment solution to cover the tissue 
sections and incubate for 5 min at room temperature 
 Wash in dH2O 
 
3.5.8   Dehydration in graded ethanol series  
 Dehydrate in graded alcohols 
 Allow slides to air dry 
 
3.5.9   Denaturation and hybridization 
 Add 15µl of probe to the centre of a 22 x 22 mm coverslip 
 Place coverslip, probe side down, on the appropriate area of the tissue 
sample on the slide 
 Seal the edges of the coverslip with rubber cement in order to prevent 
evaporation 
 Allow rubber cement to dry (10 min) 
 Place slides in preheated hybridizer with humidity strips and set 
program to:  
A: Denature at 95°C for 5 min and  
B: Incubate overnight (±14 hrs) at 37°C 
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3.5.10   Stringent wash (Day 2) 
 Prepare two Coplin jars containing saline sodium citrate (SSC) buffer, 
one at room temperature and the other heated to 70°C 
 Peel off rubber cement from slides 
 To remove coverslip without tearing tissue, pre-soak slides in SSC at 
room temperature for 2-3 min, until the coverslip slides off easily  
 Rinse in SSC at room temperature 
 Immerse slide in Coplin jar containing SSC at 70°C for 5 min 
 Wash in dH2O 
 
3.5.11   Immunodetection 
 Immerse slides in 30% H2O2 in 100% methanol (1:9) (10 min) 
 Wash in PBS/Tween 20 (0.01%) 
 Add CAS-Block™ - 2-3 drops per slide and incubate  (10 min) 
 Blot off reagent with tissue paper (do not rinse) 
 Add mouse anti-digoxigenin antibody – 2-3 drops per slide and 
incubate    
(30 min) 
 Wash in PBS/Tween 20 (0.01%) 
 Add goat anti-mouse HRP polymer conjugate – 2-3 drops per slide 
and incubate (30 min) 
 Wash in PBS/Tween 20 (0.01%) 
 Prepare DAB substrate-chromogen solution: add one drop of each of 
the 3 solutions to 1ml of dH2O 
 Add DAB – 2-3 drops per slide and incubate (30 min)  
 Place slides in slide rack 
 Wash in running tap water 
 
3.5.12   Counterstaining and mounting 
 Counterstain tissue sections with haematoxylin (5 secs)  
 Evaluate intensity of counterstain and stain for further (3-5secs) if 
needed 
 Wash in running tap water 
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 Dehydration in graded ethanol series, immerse in xylene  
 Coverslip using DPX or Entellan 
 
2.5.13   Slide evaluation  
Slides were evaluated simultaneously by two investigators using an Olympus 
BX43 light microscope. 
 
An individual Her-2 gene appears as a small round single dot. 
Non-amplification according to the Invitrogen Spot-light® HER2 CISH kit 
package insert is defined as: 
 1-5 single dots in the majority (>50%) of carcinoma cells 
 
Amplification according to the Invitrogen Spot-light® HER2 CISH kit package 
insert is defined as: 
 >5 dots in the majority of carcinoma cells 
 Large clusters in the majority of carcinoma cells 
 A mixture of multiple dots and large clusters in the majority of 
carcinoma cells 
 A mixture of multiple dots and small clusters in the majority of 
carcinoma cells 
 Small clusters in the majority of carcinoma cells 
 
Unclear cases of amplification or non-amplification according to the 
Invitrogen Spot-light® HER2 CISH kit package insert is defined as: 
 Specimens that exhibit 4-6 dots in the majority of carcinoma cells 
 If the average number of dots is between 4 and 6 after 30 carcinoma 
cells have been counted, an additional 30 cells should be counted for 
a total of 60 cells. 
 
3.6   Her-2 IHC and Her-2 CISH on corresponding histopathology and 
cytopathology specimens 
The IHC stained slides for Her-2, a test that is routinely performed on all 
breast carcinomas, were re-evaluated simultaneously by two observers. We 
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have selected 10 cases which had both tissue blocks and archived FNA 
slides available, for testing.  We performed Her-2 CISH analysis on the 
histopathology sample cut from a paraffin embedded tissue block taken from 
the mastectomy specimen, as well as corresponding cytology sample.   The 
cytopathology sample was obtained by de-staining one archived, diagnostic 
FNA slide that was taken shortly before the mastectomy was performed. 
 
We used the ISH results to re-classify all equivocal IHC Her-2 (2+) cases.  
 
3.7   Determining the apoptotic index 
The apoptotic index was calculated as the average of the apoptotic cell count 
in 50 consecutive high power fields (40X objective) in haematoxylin and 
eosin-stained tumour sections of all cases, using a normal light microscope 
(Olympus BX43).  Areas of necrosis were avoided and multiple apoptotic 
bodies in one small area that could have originated from one cell were 
counted as one.  
 
3.8   Statistical analysis 
The Shapiro Wilk test was used to test whether continuous variables were 
normally distributed.  A value of >0.05 is regarded as normal distribution. 
 
The association between clinicopathological variables and protein expression 
was analyzed using analysis of variance (ANOVA) for continuous variables 
and the chi-square or Fishers’ exact test for categorical variables.  The 
Fisher’s exact test was used if the expected cell frequency in any of the 
contingency tables was <5. The level of significance was set at p <0.05 for all 
analyses.   
 
Survival curves according to key variables was plotted using Kaplan Meier 
graphs and the Log Rank test for equality of survivor functions were used to 
assess statistical significance.  
 
The Cox-proportional hazards model was used to estimate the hazard ratios 
(HR) and the 95% CI for overall and disease free survival between the 
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various subgroups based on their difference in protein expression, adjusting 
for age.  A multivariate Cox regression was attempted adjusting for stage, 
grade and age as variables but the estimates changed dramatically from the 
age adjusted estimates and the model was deemed unstable. 
 
Hazard ratio (HR) describes the relative risk based on the comparison of 
event rates or hazard rates between two groups over a given time period. 
The hazard rate is the ratio of the number of events within a group to the total 
number in the group over a given time period. HR = 1.0 indicates equal risk 
rates. HR >1.0 indicates increased risk and HR<1.0 decreased risk. 
 
Confidence intervals (CI or 95% CI) is the range of HR’s likely to contain the 
mean HR or in other words the mean HR has a 95% chance of being 
contained in the CI interval. If the CI contains 1.0, the HR is not considered 
statistically significant and equal risk / chance apply.  If the CI is greater and 
excluding 1.0, it indicates increased risk while a CI less and excluding 1.0 
would indicate decreased risk. For each variable, the first category was used 
as reference group. 
 
Both overall and disease free survival was measured from date of first 
treatment to the date of related death or first relapse. Patients who died of 
unrelated causes where excluded from this analysis. 
 
STATA version 12.1 (StataCorp LP, 4905 Lakeway Drive, College Station, 
TX77845, USA) statistical software was used for all analysis with the 

































4.1   Age distribution 
The study included 93 invasive breast carcinomas from patients with ages 
ranging from 22 to 78 years.  Age distribution was found to be normal 
according to the Shapiro Wilk test for normality (p=0.9).  The mean age was 
53.5 years and the standard deviation (SD) 10.76.  The highest frequency of 





Figure 4:  Histogram showing the age distribution of patients 
 
4.2   Racial profile 
The racial profile of the patients from Groote Schuur hospital was largely 
Coloured (42/67, 62.7%), followed by African patients (10/67, 14.9%) and 
White patients (3/67, 4.5%).  The race was not stated in 12 (17.9%) cases. 
The patients from the second cohort obtained from the private laboratories 
were predominantly White (20/26, 76.9%), followed by Coloured patients 
(3/26, 11.5%).  The race was not stated in 3 (11.5%) cases.   
 
 



















4.3   Clinicopathological characteristics 
Clinicopathological characteristics such as carcinoma classification, stage, 
grade, lymphovascular invasion, presence of distant metastasis, presence of 
nodal metastasis, treatment offered and patient outcome are listed in Table 
5. 
 
4.4   Treatment 
All patients had surgical resection.  None of these patients received 
treatment before surgical resection.  Patients who had received trastuzumab 
were from the private sector.  Two patients were treated with a single 
treatment option.  The majority of patients received a combination of 3 or 
more of the treatment options, depending on hormonal status, tumour stage 

























Table 5:  Clinicopathological characteristics 
Characteristics n=93 % 
   
Carcinoma classification:   
   Ductal  85 91.4% 
   Lobular 8 8.6% 
Stage:   
   I 14 15.1% 
   II 48 51.6% 
   III 30 32.3% 
   IV 1 1.1% 
Grade:   
   1 14 15.1% 
   2 36 38.7% 
   3 43 46.2% 
Lymphovascular  invasion:   
   Y 70 75.3% 
   N 23 24.7% 
Lymph node metastasis:   
Y 59 63.4% 
N 34 36.6% 
Distant metastases:    
   Y 28 30.1% 
   N 65 69.9% 
Treatment:   
   Surgery - Mastectomy 81 87.1% 
   Surgery – Wide local excision 12 12.9% 
   Hormonal Therapy 61 65.6% 
   Chemotherapy 71 73.3% 
   Radiotherapy 58 62.3% 
   Trastuzumab 26 28.0% 
Outcome:   
   Disease free 59 63.4% 
   Alive with disease 14 15.1% 
   Dead 20 21.5% 
   




Table 6:  Treatment combinations    
Chemotherapy only 4 
Chemotherapy + hormone therapy 6 
Chemotherapy + hormone therapy + trastuzumab 6 
Chemotherapy + hormone therapy + radiotherapy 20 
Chemotherapy + hormone therapy + radiotherapy + trastuzumab 10 
Chemotherapy + radiotherapy 15 
Chemotherapy + radiotherapy + trastuzumab 6 
Chemotherapy + trastuzumab 4 
Hormone therapy + radiotherapy 6 
Hormone therapy only 13 
Radiotherapy only 1 
Surgery only 2 
 
4.5   Immunohistochemistry results 
 
4.5.1   Her-2  
Twenty seven (29.0%) cases were Her-2 negative, 7 (7.5%) had a score of 
(1+) (considered negative), 17 (18.3%) had a score of (2+) (considered 
equivocal), while 42 (45.2%) had a score of (3+) (considered positive).  Three 
Her-2 (2+) results were reclassified as Her-2 negative, while 14 were re-
classified as Her-2 positive according to ISH results. 
 
A statistically significant association was found between Her-2 results and 
NFκB expression (p=0.035).  NFκB expression was high in 63.2% (55/87) of 
Her-2(+) cases compared to 36.8% (32/87) in Her-2(-) cases whereas NFκB 
expression was low in 16.7% (1/6) of Her-2(+) cases and 83.3% (5/6) Her-2 





Figure 5:  Representative IHC staining of Her-2 with score  (A) Pos control. 
Infiltrating duct carcinoma Her-2 (3+) (400x)  (B) Infiltrating duct carcinoma 
Her-2 (1+) (400x)  (C) Infiltrating breast carcinoma Her-2 (2+) (400x)           
(D) Infiltrating duct carcinoma Her-2 (3+) (400x) 
 
4.5.2   ER 
The distribution of ER expression (proportion + intensity) were as follows: 44 
cases were negative, 2 cases had a score of 2, 1 case had a score of 3, 3 
cases had a score of 4, 11 cases had a score of 5, 5 cases had a scored 6, 
10 cases had a score of 7 and 27 cases had a score of 8.  Forty six were 
regarded as ER(+) and 47 as ER(-).  
 
A statistically significant association was found between ER status and BCL2 
expression (p=0.022).  BCL2 expression was high in 63% (30/47) ER(+) 
cases and in only 36.2% (17/47) ER(-) cases, while BCL2 expression was 








Figure 6:  Representative IHC staining of ER with intensity score   (A) 
Positive control ER (3+) (400x) (B) Infiltrating duct carcinoma ER (1+) (400x) 
(C) Infiltrating duct carcinoma ER (2+) (400x) (D) Infiltrating duct carcinoma 
ER (3+)  
 
4.5.3   PI3K 
Seventy nine (84.9%) cases showed high PI3K expression, 13 (14.0%) low 
and 1 (1.1%) was found to be negative for PI3K expression. 
 
We found no significant association between PI3K and any of the other 







Figure 7:  Representative IHC staining for PI3K   (A) Positive control. 
Adrenal gland (400x)  (B) Infiltrating breast carcinoma showing negative PI3K 
expression  (400x)  (C) Infiltrating breast carcinoma showing low PI3K 
expression  (D) Infiltrating breast carcinoma showing high PI3K expression 
(400x) 
 
4.5.4   PTEN 
PTEN showed high expression in 55 (59.1%) of cases, low expression in 27 
(29.0%) cases and was negative in 11 (11.8%) cases. 
 
An association was found between PTEN and p-Akt expression (p=0.053) 
and between PTEN and Her-2 expression (p=0.065) although these were not 
statistically significant. 
 
p-Akt expression was high in 67.8% (40/59) of cases that showed high PTEN 
expression, 23.7% (14/59) of cases that showed low PTEN expression and 









Her-2 was negative in 54.1% (20/37) of cases that showed high PTEN 
expression, 24.3% (9/37) of cases that showed low PTEN expression and in 




Figure 8:  Representative IHC staining for PTEN   (A) Positive and negative 
control.  Endometrium showing non-expressing neoplastic glands and normal 
stroma showing high PTEN expression (400x)  (B) Infiltrating duct carcinoma 
showing negative PTEN expression (400x)  (C) Infiltrating duct carcinoma 
showing low PTEN expression (400x)  (D) Infiltrating duct carcinoma showing 
high PTEN expression (400x) 
 
4.5.5   p-Akt 
p-Akt showed high expression in 59 (63%) of cases, low expression in 26 
(28%) cases and was negative in 8 (9%) cases. 
 
Significant associations were found between both p-Akt and NFκB 
expression (p=0.014) and p-Akt and MDM2 expression (p=0.040).  High 






Akt expression, compared to 26.4% (23/87) in cases that showed low p-Akt 
expression and in 6.9% (6/87) of cases that were negative for p-Akt 
expression.  High MDM2 expression was present in 70.3% (52/74) of cases 
that were showing high p-Akt expression, while it was present in 26.4% 
(16/74) of cases showing low p-Akt expression and in only 12.2% (6/74) of p-
Akt negative cases (Appendix 5). 
 
 
Figure 9:  Representative IHC staining for p-Akt  (A) Positive control. Skin 
(400x)  (B) Infiltrating duct carcinoma showing negative p-Akt expression 
(400x)  (C) Infiltrating duct carcinoma showing low p-Akt expression  













4.5.6   MDM2 
High expression of MDM2 was found in 74 (80%) cases, low expression in 14 
(15%) cases and was negative in 5 (5%) cases. 
 
 
Figure 10:  Representative IHC staining for MDM2  (A) Positive control. 
Leiomyosarcoma (400x)  (B) Infiltrating duct carcinoma showing negative 
MDM2 expression (400x)  (C) Infiltrating duct carcinoma showing low MDM2 








4.5.7   NFκB 
Cytoplasmic expression of NFκB was present in all cases. High cytoplasmic 





Figure 11:  Representative IHC staining for NFκB   (A) Positive control. 
Prostate (400x)  (B) Infiltrating breast carcinoma showing low NFκB 
expression (100x)  (C) Infiltrating breast carcinoma showing low NFκB 








4.5.8   BCL2 
High BCL2 expression was seen in 47 (50%) cases, low expression in 20 




Figure 12:  Representative IHC staining for BCL2   (A) Positive control. 
Tonsil (100x)  (B) Infiltrating breast carcinoma showing negative BCL2 
expression (400x)  (C) Infiltrating breast carcinoma showing low BCL2 
expression (400x) (D) Infiltrating breast carcinoma showing high BCL2 
expression (400x) 
 
4.5.9   p53 
High expression of p53 was found in 21 (23%) cases. The same number 
showed low expression while 51 (55%) cases showed no p53 expression. 
 
No statistically significant association was found between p53 and any of the 
other protein markers.  There was however a slight association between p53 





(4/37) of cases showing high p53 expression, compared to 21.6% (8/37) of 
cases showing low p53 expression and 67.6% (25/37) of cases where p53 
expression was negative (Appendix 9). 
 
 
Figure 13:  Representative IHC staining for p53  (A) Positive control. Colonic 
Adenocarcinoma (400x)  (B) Infiltrating duct carcinoma showing negative p53 
expression (400x)  (C) Infiltrating duct carcinoma showing low p53 
expression (400x)  (D) Infiltrating duct carcinoma showing high p53 
expression (400x) 
 
4.6   Association between clinicopathological variables and protein 
expression 
 
4.6.1   Age 
A statistically significant association was found between age and Her-2 
expression (p=0.044).  The mean age for Her-2 (+) expression was 51.6 
years (SD 8.6) compared to a slightly older 56.2 years (SD 11.7) for Her-2  (-) 
expression.  No statistically significant association was found between age 









4.6.2   Tumour type 
A statistically significant association was found between tumour type and 
Her-2 expression (p=0.006).  Of the 56 cases that were Her-2 (+), 98.2% 
(55/56) were ductal carcinomas compared to 1.8% (1/56) lobular carcinomas. 
 
A strong association was also present between tumour type and MDM2 
expression (p=0.051) and a slight association between tumour type and ER 
expression (p=0.059).  Of the 74 cases that showed high MDM2 expression, 
91.9% (68/74) were ductal carcinomas and 8.1% (6/74) were lobular 
carcinomas.   
 
Of the 46 cases that were ER(-), 97.8% (45/46) were ductal carcinomas and 
2.2% (1/47) were lobular carcinomas.  In contrast, 85.1% (40/47) of the 
ER(+) cases were ductal carcinomas and 6.7% (7/47) were lobular 
carcinomas  (Appendix 11). 
 
4.6.3   Tumour grade 
Significant associations were found between tumour grade and p53 (p = 
0.013), Her-2 (p = 0.004) and NFκB (p = 0.051) expressions (Appendix 12). 
 
p53 showed a significant increase in expression with higher tumour grades (p 
= 0.013).  High p53 expression was seen in 23.8% of grade 2 tumours and 
76.2% of grade 3 tumours.  High p53 expression was absent in grade 1 
tumours.  
 
Positive Her-2 expression was associated with high grade tumours and 
varied from 5.4% in grade 1 tumours, 39.3% grade 2 tumours to 55.4% in 
grade 3 tumours (p=0.004).  Conversely, Her-2 expression was negative in 
11 out of 14 (78.65%) grade 1 tumours. 
 
Similarly, high NFκB expression was associated with high grade tumours and 
increased from 12.6% in grade 1 tumours to 39.1% in grade 2 tumours and 




4.6.4   Lymphovascular invasion 
Significant associations were evident between lymphovascular invasion and 
both PI3K (p=0.010) and ER expression (p<0.001).  High PI3K was seen in 
79.7% (63/79) of cases that showed lymphovascular invasion compared to 
20.3% (16/79) in cases that were negative for lymphovascular invasion. 
 
ER was positive in 95.7% (45/47) of cases that showed lymphovascular 
invasion compared to only 4.3% (2/47) expression when lymphovascular 
invasion was absent (Appendix 13). 
 
4.6.5   Lymph node metastasis 
There was a significant association between ER expression and nodal 
involvement (p=0.002).  ER expression was positive in 78.7% (37/47) of 
cases that showed lymph node involvement, compared to 21.3% (10.47) 
expression in those cases that were negative for nodal involvement   
(Appendix 14). 
 
4.6.6   Distant metastasis 
There was a statistically significant association between MDM2 and distant 
metastasis (p=0.017).  High MDM2 expression was seen in 75.7% (56/74) of 
cases without distant metastases and in 24.3% (18/74) of cases with distant 
metastasis while MDM2 was negative in 20.0% (1/5) of cases that showed no 
distant metastasis and in 80.0% (4/5) of cases showed distant metastasis.  
There was no association between the presence of distant metastases and 
any of the other markers (Appendix 15). 
 
4.6.7   Apoptotic index 
There was a statistically significant association between the apoptotic index 








4.7   Survival analyses  
 
4.7.1 Survival analysis according to trastuzumab treatment 
The survival graph (Figure 14) shows a survival advantage for cohort C, 
however this was not statistically significant (p=0.267).  The median OS for 
cohort C was 80 months.  Due to the relatively short follow up period and low 
number of regressions, the median OS for cohort B could not be determined.  
The 5 year OS for cohort B was 75%, in contrast to 90% for cohort C.  The 
risk of death for cohort C was 2.5 fold less than that of cohort B (HR 0.4; CI 
0.1 – 1.5) but this was not significant according to the age adjusted Cox 




Figure 14:  The Kaplan-Meier graph comparing overall survival between 
patients in cohort B and cohort C 
 
According to the log rank test there was no statistically significant difference 
in DFS between cohort B and cohort C (p = 0.429).  The Kaplan-Meier graph 
shows a DFS advantage for cohort C but due to the low number of 
regressions the median DFS could not be calculated for either of these two 
groups.  The 5 year DFS for cohort B was 70%, in contrast to 80% for cohort 
C (Figure 15).  The risk for recurrence for cohort C was 1.7 times less than 









Figure 15:  The Kaplan-Meier graph comparing disease free survival 
between patients in cohort B and cohort C 
 
4.7.2   Survival analysis according to Her-2 expression  
According to the log rank test, there was no statistically significant 
association between Her-2 expression and OS in cohort A.  The median OS 
for Her-2 positive tumours was 80 months.  The 5 year OS for Her-2 positive 
tumours was 79% while that of the Her-2 negative tumours was 75% (Figure 
16).   
 
 




The 5 year OS for the Her-2(+) cases in cohort B was 69%, while the OS for 






group was 1.2 times higher than the risk in the Her-2(-) group (HR 1.2; CI 0.4 
– 3.4) (Appendix 21).  
 
The 5 year OS for cohort C was 91% (Appendix 19). 
 
 
Figure 17:  The Kaplan-Meier graph for OS for cohort B according to Her-2 
expression 
 
According to the log rank test there was no significant association between 
DFS and Her-2 expression (p = 0.473) in cohort A. The 5 year DFS for the 
Her-2 positive group was 77%, while that for the Her-2 negative group was 
65% (Appendix 17).  The risk for recurrence in the Her-2 positive group was 
1.4 times lower than in the Her-2 negative group (HR 0.7; CI 0.3 – 1.8) 
(Appendix 22). 
 
There was also no significant association between DFS and Her-2 
expression in cohort B (p = 0.709).  After 5 years, 74% of the Her-2 positive 
group and 65% of the Her-2 negative group remained disease free 
(Appendix 18).   
 
The 5 year DFS for cohort C was 80% (Appendix 19). 
 
4.7.3   Survival analysis according to PI3K expression 
According to the Kaplan-Meier graph for OS (cohort A) (Figure 18), patients 
with tumours that showed no PI3K expression had the best OS, followed by 
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those with low PI3K expressing tumours.  Patients with high PI3K expressing 
tumours had a median OS of 80 months.  The 5 year OS was 75% for 
patients with tumours showing high PI3K expression, 92% for low PI3K 
expression and 100% for negative PI3K expression (Appendix 17).  The risk 
for death in the PI3K low category was 3.3 fold less when compared to the 
PI3K high category (HR0.3; CI 0.0 – 2.3).  No deaths were recorded in the 
PI3K negative category (Appendix 20).  
 
The median DFS of patients according to PI3K expression could not be 
calculated due to few recorded deaths.  After 5 years 68% of PI3K high 
category, 85% of PI3K low category and 100% of PI3K negative category 
patients were disease free (Appendix 17).  The risk of recurrence for the 
PI3K negative category was half that of the PI3K high category (HR 0.5; CI 
0.1 – 2.2) (Appendix 22). 
 
 
Figure 18:  The Kaplan-Meier graph for overall survival for cohort A 
according to PI3K expression 
 
4.7.4   Survival according to PTEN expression 
In cohort A, the median OS for the PTEN high category was 80 months.  The 
5 year OS for the PTEN high category was 80%, PTEN low category 73% 
and PTEN negative category 91%.  The age adjusted Cox regression 
analysis shows that cases that showed low PTEN expression had a 1.9 fold 
increased risk of death compared to cases that showed high PTEN 
77 
 
expression (HR 1.9; CI 0.7 – 5.2) but this was not statistically significant 
(Appendix 20).  No deaths were observed in the PTEN low category. 
 
In cohort C, there was a significant association between PTEN expression 
and OS (p=0.015).  The median OS for the group that showed no PTEN 
expression was 20 months, while the median OS for the group that showed 
high PTEN was 80 months (Figure 19).  The 5 year OS for the PTEN high 
category was 89% and the OS for the PTEN low category was 100%. The 
OS for the PTEN negative category was 0%, however this category only 
contained 1 subject (Appendix 19).   According to the age adjusted Cox 
regression analysis (data not shown), the risk of death for the PTEN low 
category was 2 times that of the PTEN high category (HR 2.0; CI 0.1 – 34.7).  
Due to the limitations of small sample size of cohort C and low number of 










Figure 19:  The Kaplan-Meier graph for overall survival in cohort C according 
to PTEN expression  
 
According to the log rank test, there was no significant difference in DFS in 
cohort A according to the levels of PTEN expression (p = 0.367).  After 5 
years 70% of patients in the PTEN high category, 64% in the PTEN low 
category and 90% in the PTEN negative category were disease free 




There was no significant difference in DFS according to categories of PTEN 
expression in the cohort B (p = 0.0955).  The 5 year DFS for the PTEN high 
category was 68%, PTEN low category was 56% and the PTEN negative 
category was 100% (Appendix 18).   
 
In cohort C, patients with cancers that were PTEN expression negative had a 
median DFS of approximately 19 months.   After 5 years 80% of the PTEN 
high category and 100% of the PTEN low category were disease free 
(Appendix 19).  The finding of 0% for the PTEN negative category was 
disregarded due to the presence of only a single case in this category. 
 
4.7.5   Survival analysis according to p-Akt expression 
In cohort A, there was a statistically significant association between p-Akt 
expression and OS (p = 0.046).  The median OS for the cohort that did not 
express Akt was 46 months compared to 80 months for the group that 
showed high p-Akt expression.  The 5 year OS for the p-Akt high category 
was 83%, the OS for the p-Akt low category was 73% and the OS for the p-
Akt negative category was 46% (Figure 20).  The p-Akt low category had a 
2.1 fold increased risk of death compared to the p-Akt high category (HR 2.1; 
CI 0.8 – 5.9), while the p-Akt negative category had a significant 5.1 fold 
increased risk for death compared to the p-Akt high category (HR 5.1; CI 1.5 







Figure 20:  The Kaplan-Meier graph for overall survival for cohort A 
according to p-Akt expression 
 
4.7.6   Survival analysis according to NFκB expression 
Patients with high NFκB expressing cancers showed a median OS of 80 
months compared to those patients with low NFκB expressing cancers which 
had a median OS of 48 months (cohort A).  These results were not 
statistically significant (p=0.169).  The risk of death for the group showing low 
NFκB expression was 3.6 times that of the group showing high NFκB 
expression (HR 3.6; CI 1.0 – 13.1) (Appendix 20). 
 
4.7.7   Survival analysis according to MDM2 expression 
In cohort A, patients with cancers that showed high MDM2 expression had a 
median survival of approximately 80 months.  The limited number of deaths 
recorded in patients with cancers showing low or negative MDM2 expression 
prevented the determination of median survival in this group.  The 5 year OS 
for the MDM2 negative category was 60%, for the low category 65%, and for 
the high category 80% (Appendix 17).  
 
In cohort B, the 5 year OS for the MDM2 high category was 79%, for the low 
category 58% and for the negative category 60% (Appendix 18).  The risk of 
death in the MDM2 low category was 3.2 fold higher than the risk in the 
MDM2 high category (HR 3.2; CI 1.1 – 9.7), while the risk of death in the 
MDM2 negative category was 2.6 fold higher than the MDM2 high category 
(HR 2.6; CI 0.6 – 12.2) (Appendix 21). 
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No significant association was established between MDM2 expression and 
DFS using the log rank analysis (p = 0.0871).  The median DFS for cases 
showing no MDM2 expression was 34 months.   After 5 years 75% of MDM2 
high category, 80% of MDM2 low category and 0% of MDM2 negative 
category remained disease free (Figure 21).  The risk for recurrence in the 
MDM2 negative category showed a 3.5 fold increase compared to the MDM2 
high category (HR 3.5; CI 1.01 – 12.1) and was significant (Appendix 22). 
 
 
Figure 21:  The Kaplan-Meier graph for DFS for cohort A according to MDM2 
expression 
 
4.7.8   Survival analysis according to BCL2 expression 
There was no statistically significant association between BCL2 expression 
and OS (p = 0.831) in cohort A.  The median OS for the group that showed 
high BCL2 expression was 80 months.  The 5 year OS for BCL2 high 
category was 80%, the OS for both BCL2 low and negative categories were 
75% (Appendix 17).  There was no significant association between BCL2 
expression and DFS (p = 0.952).  
 
4.7.9   Survival analysis according to p53 expression 
There was a significant association between p53 expression and OS 
(p=0.029) in cohort A (Figure 22).  The median OS for patients with p53 
negative cancers was 80 months.  The low number of deaths recorded in the 
p53 low and high categories prevented the calculation of median OS in these 
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groups.  The 5 year OS for the p53 high category was 67%, for the p53 low 
category 89% and for the p53 negative category 81% (Figure 23).  Patients 
with tumours expressing high levels p53 had a 5.5 fold increase in the risk of 
death compared to those with tumours expressing low levels of p53 and this 
was significant (HR 0.18; CI 0.0 – 0.9).  Patients with tumours negative for 
p53 expression had a 2.5 fold reduced risk for death, compared to those with 
tumours expressing high p53 levels (HR 0.4; CI 0.2 – 1.0) (Appendix 22). 
 
 
Figure 22:  The Kaplan-Meier graph for overall survival according to p53 
expression for cohort A 
 
In cohort B, there was a statistically significant association between p53 
expression and OS (p=0.001).  The median OS for patients with tumours 
expressing high levels of p53 was 42 months (Figure 23).  The 5 year OS for 
the p53 high category was 40%, the low category was 85% and the negative 
category was 83% (Appendix 18).  According to the age adjusted Cox 
regression analysis (Appendix 21), patients with tumours expressing high 
levels of p53, had a 5 fold increased risk of death compared to those with 
tumours showing low (HR 0.2; CI 0.0 – 0.9) or negative (HR 0.2; CI 0.1 – 0.7) 




Figure 23:  The Kaplan-Meier graph for overall survival according to p53 
expression for cohort B 
 
In cohort C, the median OS for the p53 negative category was 80 months. 
The 5 year OS for both the p53 low and high categories were 100%, while 
the OS for the p53 negative category was 78% (Appendix 19).   
  
As a result of too few regressions in cohort A, the median DFS could not be 
determined in any of the categories of p53 expression (Figure 24).  After 5 
years 55% of the p53 high category, 79% of the p53 low category and 75% of 
the p53 negative category remained disease free (Appendix 17).  The risk 
for recurrence in the p53 high category was 2.5 times more when compared 
to the p53 low category (HR 0.4; CI 0.1 – 1.4) and double that of the p53 
negative category (HR 0.5; CI 0.2 – 1.3) (Appendix 22). 
 
In cohort B, the 5 year DFS for the p53 high category was 0%, for p53 low 
category 75%, and for the p53 negative category 77% (Appendix 18). The 
risk for recurrence in the p53 high category was 3.3 fold higher compared to 
the p53 low (HR 0.3; CI 0.1 – 1.1) and negative (HR 0.3; CI 0.1 – 0.8) 





Figure 24:  The Kaplan-Meier graph for disease free survival for cohort A 
according to p53 expression 
 
 
In cohort C, the 5 year DFS for the p53 low and high categories were 100%, 
while that of the p53 negative category was 63% (Appendix 19).  The Cox 
regression analysis for this cohort was deemed unstable due to the small 
sample size and too few recurrences. 
 
4.7.10  Survival analysis according to the apoptotic index 
The median OS for the apoptotic category (5 <7) in cohort A was 80 months.  
The 5 year OS for the (<3) category was 77%, for category (3 <5) 72%, for 































Figure 25:  The Kaplan-Meier graph for overall survival for cohort A 
according to the apoptotic index 
 
 
The overall survival according to the apoptotic index for cohort B did not 
reach significance in any of the 4 categories.  The 5 year OS for the category 
(<3) was 75%, for category (3 <5) 65%, for category (5 <7) 80% and for 
category (≥7) 72% (Appendix 18). 
 
The median OS for cohort C according to the apoptotic index was 80 months.  
The 5 year OS for the category (<3) was 85%, for category (3 <5) 90%, for 
category (5 <7)100%, and for category (≥7) 80%.  This was not statistically 
significant (Appendix 19). 
 
The median DFS for cohort C could not be established for any of the 
apoptotic categories.  The 5 year DFS for apoptotic category (<3) was 85%, 
for category (3 <5) 67%, for category (5 <7) 64% and for category (≥7) 69% 





Figure 26:  The Kaplan-Meier graph for DFS for cohort A according to the 
apoptotic index 
 
A median DFS was not reached in any of the categories of apoptosis.  The 5 
year DFS for apoptotic category (<3) was 80%, for category (3 <5) 63%, for 
category (5 <7) 65% and for category (≥7) 62% (Appendix 18).   
 
In cohort C, the median DFS for apoptotic category (5 <7) was around 41 
months.  The 5 year DFS for apoptotic category (3 <5) was 75% and 0% for 
both categories (5 <7) and (≥7).  No cases were recorded for the category 
(<3) (Appendix 19).  
 
4.7.11   Survival analysis according to age group 
Overall survival for cohort A showed a significant association with age 
(p=0.028).  The median OS for patients in the 45 to 65 year category was 80 
months.  The 5 year OS for the <45 year group was 65%, for the 45 to 65 
year group 76%, and for the ≥65 year group 100% (Figure 27).  When an 
age adjusted Cox regression analysis was performed (Appendix 20), 
patients in the 45 to 65 year category had half the risk of death compared to 
the <45 year group (HR 0.5; CI 0.2 – 1.3).  No deaths were recorded in the 




Figure 27:  The Kaplan-Meier graph for overall survival for cohort A 
according to age category* 
 
*agecat 1 : <45 years (n=20), agecat 2 : 45 to 65 years (n=59) and agecat 3 : 
≥65 years (n=14). 
 
Log Rank test: (2 degrees of freedom), Chi2 = 7.16, Pr>Chi2 = 0.028, N=93 
 
The Kaplan-Meier graph for OS according to age category for the cohort of 
patients who did not receive trastuzumab treatment (Figure 28) shows that 
the overall survival in the age group ≥65 years was better than any other 
group.   Again the <45 year age group showed the worst overall survival of 
the three groups.  The 5 year OS for the <45 year age group was 57%, for 
the 45 to 65 year old group 74% and for the ≥65 year group 100%.  After 5 
years 75% of the <45 year age group, 65% of the 45 to 65 year old group 
and 88% of the ≥65 year group were disease free (Appendix 18). 
 
The 5 year OS in cohort C for the age category <45 was 75%, for age 
category 45 to 65 years 92% and for ≥65 year age group 100%.  The 5 year 
OS in cohort B for the <45 year age group was 57%, for the 45 to 65 year 





Figure 28:  The Kaplan-Meier graph for overall survival according to age 
category for cohort B  
 
In cohort B, the 5 year DFS for the age group <45 was 75%, for the age 
group 45 to 65 years 65% and for the ≥65 age group 88%.  Due to the low 
number of recurrences in cohort C, a median DFS could not be determined in 
any of the age categories.  After 5 years 85% the of the <45 year age group 
was disease free, while no subject was disease free in either the 45 to 65 
year old group or the ≥65 year age group (Appendix 19).   
 
4.8   Comparing Her-2 evaluation by IHC and CISH on corresponding 
histopathological and cytopathological specimens  
 
We performed Her-2 CISH analysis on the histology as well as the 
corresponding FNA (cytology) sample.  An IHC score of <2 was regarded as 
negative, a score of 2 was equivocal and a score of 3 was positive.  CISH on 
the other hand needs a score of >5 to be considered positive for 
amplification.  Comparing Her-2 CISH results performed on cytopathological 
and histopathological specimens, there was a 100% correlation between Her-
2 CISH done on a de-stained, archived FNA (cytopathological) samples and 
the corresponding histopathological samples cut from paraffin embedded 
tissue blocks.  In addition, there was a 100% correlation between the positive 
and negative IHC and CISH results. Out of the 6 Her-2 (2+) IHC scores, we 
found the Her-2 CISH to be amplified in 1 case and not amplified in 5 cases 




Table 7:   Comparison between Her-2 IHC and Her-2 CISH on corresponding 
histopathological and cytopathological specimens 
 
Case no. Her-2 IHC Her-2 CISH on Histo Her-2 CISH on Cyto 
54 2 6.2 >10 
56 3 10 >10 
60 0 1.6 1.6 
65 2 2.1 3.6 
73 2 3.8 3.9 
79 2 2.3 2.7 
83 3 7.5 10 
87 3 6.2 7 
103 2 2.1 3.9 








Figure 29:  Her-2 CISH control results  (A) Pos control (cell line) 5-10 copies 
(original magnification 400x)  (B) Pos control 5-10 copies (±900x)  (C) Pos 
control (cell line) 10+ copies (original magnification 400x)  (D) Pos control 
10+ copies (±900x)  (E) Positive control histology 10+ copies (original 











Figure 30:  Her-2 CISH results  (A) 5-10 copies histology (original 
magnification 200x) (case 87)  (B) 5-10 copies histology (±900x) (case 87)  
(C) 3-5 copies cytology (original magnification 200x) (case 103)  (D) 3-5 

















Figure 31:  Her-2 CISH results  (A) 5-10 copies histology (original 
magnification 200x) (case 83)  (B) 5-10 copies histology (±900x) (case 83)  
(C) 10+ copies cytology (original magnification 200x) (case 83)  (D) 10+ 

















Figure 32:  Her-2 CISH results  (A) 3-5 copies histology (original 
magnification 200x) (case 73)  (B) 3-5 copies histology (±900x) (case 73)   
(C) 3-5 copies cytology (original magnification 200x) (case 73)  (D) 3-5 













































5.1   Introduction 
Breast cancer is a multifaceted disease with almost unique protein signature, 
prognosis and treatment response for each patient even for the same tumour 
type and grade. These findings underline the importance of being able to 
tailor cancer treatment based on the genetic profile for each individual. This 
approach ensures that every patient gets the treatment that would benefit her 
most, while at the same time minimizing the side effects of the treatment. 
 
Our results reveal some statistically significant associations between 
clinicopathological features, treatment response and protein expression. 
Some of the proteins tested show promise as markers for prognostic profiling 
and clinical management.  
 
5.2   Trastuzumab benefit 
In order to assess the benefit derived from trastuzumab treatment, we 
compared the OS and DFS in cohort C which was given trastuzumab 
treatment to cohort B that was not given trastuzumab treatment.  Although 
none of the results were statistically significant, it showed that trastuzumab 
did in fact lower the risk for both death and recurrence in cohort C and 
improved both the 5 year DFS and OS.  
 
5.3   Her-2 
Her-2 was positive in 60.8% of the breast cancers in our study.  However this 
most likely is an overestimation of the frequency of Her-2 positivity in our 
population as our cases were selected based on their Her-2 status in order to 
have representation of both Her-2 positive and negative cancers.  Slamon et 
al. (1987) reported Her-2 overexpression in 20 – 30% of breast cancers. 
 
In an attempt to try and understand what effect Her-2 signalling has on 
downstream components of the PI3K/Akt pathway, we compared  the 
expression of Her-2 to that of other components in the pathway.  There was 
no significant association between Her-2 expression and PI3K (p=0. 730), p-
94 
 
Akt (p=0.803), MDM2 (p=0.197), BCL2 (p=0.109) or ER (p=0.581) 
expression.  The lack of an association between Her-2 and PI3K expression 
suggests that Her-2 may not be responsible for the increase in PI3K 
expression.  The increase in PI3K expression may be due to the loss of 
PTEN function or due to an activating mutation within the PIK3CA gene itself.  
Since there was no association between PTEN and PI3K (p=0.812), the likely 
reason for PI3K activation is an activating mutation in the PIK3CA gene.   We 
found no association between Her-2 and p-Akt expression which is in 
contrast to the findings of Park and Kim (2007) who found significant 
associations between both nuclear and cytoplasmic p-Akt expression and 
Her-2 overexpression in a study involving 127 breast cancer cases.  Similarly 
Wu et al. (2008) reported a statistically significant association between p-Akt 
and Her-2 expression in a study involving 141 breast cancer samples.  
Vestey et al. (2005) on the other hand in a study involving 97 breast cancer 
cases, found no association between p-Akt and Her-2 expression (p=0.545).  
In the analysis it became evident that different immunohistochemical scoring 
methods were employed in the various studies, which may explain the 
discrepant findings.  What the abovementioned studies did have in common 
was the fact that they have used both the staining intensity and proportion in 
scoring p-Akt expression, while our study used proportion of staining only 
due to the subjectivity of intensity assessment and the variation in staining 
batches.   Another factor that may have influenced the results was the 
number of categories and how the scores were re-categorized.  There was 
however a significant and direct association between Her-2 and NFκB 
expression (p=0.035).  NFκB expression was predominantly high in Her-2 
positive cases and predominantly negative in Her-2 negative cases.  
Similarly, Shapochka et al. (2013) reported a significant association between 
Her-2 and NFκB expression.  The positive association between Her-2 and 
NFκB expression and the absence of any significant association between 
Her-2 and PI3K or p-Akt, suggests that Her-2, in the majority of cases, may 
be a factor responsible for the activation of NFκB.  This finding confirms the 
findings of Merkhofer et al. (2010) who showed that Her-2 activates NFκB 




A slight association was present between Her-2 and p53 (p=0.0566).  
Yamashita et al. (2004) found that patients with tumours that were positive 
for both Her-2 and p53 expression, had a significantly decreased DFS when 
compared to patients with a larger tumour size and positive lymph node 
status.  It was also reported that patients with both Her-2 and p53 positive 
tumours showed benefit when treated with high dose FAC (fluorouracil, 
doxorubicin, cyclophosphamide) (Thor et al. 1992).   
 
There was a slight association between Her-2 and PTEN expression 
(p=0.065) where PTEN negative expression was predominantly observed in 
Her-2(-) cases and PTEN low and high expression in Her-2(+) cases.  The 
influence of PTEN expression on the prognosis of Her-2 positive breast 
cancer patients treated with trastuzumab or radiation is somewhat 
controversial.  A few studies have suggested that PTEN contributes towards 
the efficacy of trastuzumab and radiation therapy and that PTEN loss is 
associated with resistance to trastuzumab treatment (Nagata et al. 2004; 
Hennessy et al. 2005; Esteva et al. 2010).  Yet another study concluded that 
PTEN status had no effect on trastuzumab benefit in Her-2 positive patients 
(Perez et al. 2013). 
 
A statistically significant association was found between Her-2 expression 
and tumour type (p = 0.006).  Of the 56 Her-2 positive cases the majority 
were ductal carcinomas (55) and only one case was a lobular carcinoma.  
Our observations are supported by the findings of both Porter et al. (1991) 
and Hoff et al. (2002), who found Her-2 expression to be diminished or 
absent in classic invasive lobular carcinoma.  Hoff et al. (2002) reported 
statistically significant associations between Her-2 gene amplification and 
tumour type (p<0.005).  They found absence of Her-2 amplification in 99% of 
invasive lobular carcinomas and low grade ductal carcinomas and suggested 
that should the Her-2 gene be amplified in any of the two abovementioned 
conditions, those cases be re-evaluated to exclude a misclassification.  
Similar results were reported by Porter et al. (1991) who found a single case 
of Her-2 amplification amongst 62 cases of lobular carcinoma.  Upon review 
it was found that it might not have been a true amplification.  A larger study 
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by Ariga et al. (2005) involving 390 invasive ductal carcinomas and 128 
invasive lobular carcinomas, reported Her-2 amplification in 17% of ductal 
carcinomas and 6% of lobular carcinomas.  Their finding of 6% of lobular 
carcinomas showing Her-2 amplification was higher than our findings as well 
as the findings of Hoff et al. (2002) and Porter et al. (1991).  
 
There was a statistically significant association between Her-2 expression 
and tumour grade (p=0.004).  Her-2 expression was found to be mostly 
negative in the lower grade tumours but showed a significant increase with 
increasing tumour grades.  Her-2 expression increased from 5.4% in grade 1 
tumours to 39.3% in grade 2 tumours and 55.4% in grade 3 tumours.  Similar 
findings were reported by Hoff et al. (2002) who found statistically significant 
associations between Her-2 gene amplification and tumour grade.  Ariga et 
al. (2005) have also reported statistically significant associations between 
Her-2 amplification and tumour grade.  Hoff et al. (2002) found no Her-2 
amplification in 72 out of 73 (99%) low grade ductal carcinomas, confirming a 
significant association between tumour grade and Her-2 status.  Although we 
found no Her-2 expression in 11 of the 14 (78.6%) grade1 carcinomas, we 
found Her-2 negative expression more or less evenly distributed between the 
different tumour grades.  It was suggested that the reason for the strong 
association between Her-2 expression and tumour grade may in part be due 
to the fact that both the rate of internalization and ligand dissociation from 
Her-2-containing dimers are very slow, with longer and more intense 
signalling as a result (Alroy and Yarden 1997; Klapper et al. 2000).  The 
effect is more pronounced when Her-2 is overexpressed and leads to 
enhanced growth responsiveness and ultimately, malignant growth (Rubin 
and Yarden 2001).   
 
We did not find any association between Her-2 expression and 
lymphovascular invasion, lymph node involvement or distant metastasis.  
Widodo et al. (2013) showed significant associations between 
lymphovascular invasion and p53 expression and between lymphovascular 
invasion and proliferation rate, but also did not find any association between 




According to the age adjusted Cox regression analysis, Her-2(+) expression 
was associated with an increased risk of death, when compared to Her-2(-) 
expression (HR1.2; CI 0.4 – 3.4) in cohort B.  The 5 year OS for the Her-2(+) 
cases in cohort B was 69%, compared to 91% in cohort C.  The 5 year OS 
for the Her-2(-) cases in cohort B was 78%.  Although these results were not 
statistically significant, it shows that trastuzumab treatment is effective in 
reducing the risk of death in Her-2(+) tumours.   
 
This study was not able to test the effectiveness of trastuzumab treatment on 
Her-2(-) tumours but results of a recent retrospective study at the University 
of Michigan showed that patients with Her-2(-) breast cancer that were 
incorrectly categorized as Her-2(+) and were treated with trastuzumab 
benefitted just as much as women who were actually Her-2(+).  They found 
Her-2 selectively expressed in cancer stem cells but because of the small 
numbers it did not reach the Her-2(+) threshold.  These tumour stem cells, 
although present in small numbers stimulate tumour growth and spread and 
are resistant to current chemo- and radiation treatments.  Researchers also 
found that primary Her-2(-) tumours showed higher Her-2 expression in bone 
metastases compared to the primary tumour.  Trastuzumab was able to 
selectively target these metastatic cells leading to survival benefit (Boltz 
2013). 
 
5.4   PI3K 
PI3K showed high expression in 85.4% of our total study population, low 
expression in 12.7% and was negative in 1.8% of cases.  PIK3CA mutations 
or PI3K pathway activation has been associated with a poor OS irrespective 
of treatment (Jensen et al. 2011).  PI3K pathway activation has also been 
associated with resistance to tamoxifen and conventional chemotherapeutic 
drugs and lack of response to anti-Her-2 drugs.  In an attempt to try and 
understand the role of PI3K in the Her-2/PI3K/Akt pathway we compared 
PI3K expression to other components in the pathway but did not find any 
association between PI3K expression and any of the other components in the 




The relationship between PI3K and PTEN is somewhat controversial and 
many different findings have been reported.  In this study, PI3K was positive 
in 79 cases (85%) of which PTEN was positive in 47 (59.5%), showed low 
expression in 22 (27.8%) and negative in 10 (12.7%) cases.  No case was 
found to be negative for both PTEN and PI3K expression.  Saal et al. (2005) 
found an inverse relationship between PI3K mutations and PTEN loss, where 
PTEN was positive or functional in 86% of cancers bearing PIK3CA 
mutations.  Our findings were not as striking as the findings of Saal et al. 
(2005) although we looked at PI3K immunoexpression and not mutations as 
they did.  Wang et al. (2011), on the other hand, did not find PIK3CA 
mutations and PTEN loss to be mutually exclusive as 3 out of 4 patients with 
PI3K mutations were also found to have no PTEN expression. 
 
No significant association between PI3K and tumour type was observed.  A 
significant association was present between PI3K expression and 
lymphovascular invasion (p = 0.012) and a slight association between PI3K 
expression and lymph node involvement (p=0.062).  Of the cases with high 
PI3K expression, 82.9% had lymphovascular invasion and 17.1% did not 
have lymphovascular invasion.  It could be argued that the PI3K/Akt pathway 
would most likely be activated in high grade tumours and that 
lymphovascular invasion would be more frequent in these tumours, but no 
association was found between PI3K and tumour grade.  There is no 
literature on the association between lymphovascular invasion and PI3K 
expression, although Saal et al. (2005) described a strong relationship 
between PIK3CA mutations, Her-2 expression and ER/PR status in lymph 
node positive breast cancers.  They found PIK3CA mutations in 58% of Her-
2(+)/ER(+) breast cancers.  We found a stronger association between PI3K 
expression and Her-2(+)/ER(+) cancers.  PI3K was overexpressed in 25 of 
the 27 (92.6%) Her-2(+)/ER(+) cases in this study.  Lymphovascular invasion 
was present in 23 of these 25 (92.0%) Her-2(+)/ER(+)/PI3K high expression 
cases.  The lymphovascular status was not available in the remaining 2 
cases.  Lymph node involvement was present in 18 (72.0%) of these Her-
2(+)/ER(+)/PI3K high expression cases.  Our findings not only confirms a 
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strong association between PI3K expression and the Her-2(+)/ER(+) subtype 
but also shows a strong association between a subtype Her-2(+)/ER(+)/PI3K 
high expression cancers and both lymphovascular and lymph node 
involvement. 
 
5.5   PTEN 
We found PTEN loss in only 11.8% of breast cancer cases in our study.  
Pérez-Tenorio et al. (2007) found PTEN loss in 37% of breast cancer cases, 
while Panigrahi et al. (2004) reported PTEN loss in 8% of their study 
population.  Other studies have also reported a lack of consistency in PTEN 
expression and suggested that it may be due to the use of different 
antibodies, tissue processing methods, scoring methods and cut-off criteria.  
Loss of PTEN expression reported in Her-2 positive cancers ranged between 
15% and 65% (Nagata et al. 2004; Esteva et al. 2010; Jensen et al. 2011).  
We observed loss of PTEN expression in 5.3% of Her-2(+) cancers which is 
lower than the reported findings and suggests that loss of PTEN function in 
our cohort population played a smaller role in tumour development than 
reported by other studies. 
 
According to our findings high PI3K expression was found in 90.9% of PTEN 
negative tumours.  Barbareschi et al. (2012) on the other hand reported 
PTEN loss and PIK3CA mutations to be present in the same cancer in 13% 
of their cases. 
 
No association was found between PTEN and Her-2 expression (p=0.065) 
and only a slight association between PTEN and p-Akt expression 
(p=0.0534).  Contrary to findings by Stemke-Hale et al. (2008) who found p-
Akt to be present in higher levels in PTEN low than PTEN high cancers, we 
found high expression of p-Akt in 67.8% of cases that showed high PTEN 
expression and only in 8.5% of cases that were negative for PTEN 
expression.  These results are surprising since Akt is supposedly activated 
by loss of PTEN and/or PI3K activation.  A study by Panigrahi et al. (2004) 
assessing the role of PTEN in signalling pathways also reported findings of a 
positive correlation rather than an inverse relationship between PTEN and 
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Akt.  They suggested that ER, rather than PTEN, is the most common 
regulator of Akt.  When comparing ER(+) expression with p-Akt expression, 
high p-Akt expression was present in (31/47) 66.0% of ER(+) cases, low 
expression in (12/47) 25.5% and no expression in (4/47) 8.5%, similar to the 
findings of Panigrahi et al. (2004).  Esteva et al. (2010) found no correlation 
between PTEN loss/PI3K mutations and p-Akt in a study involving 137 Her-2 
overexpressing breast cancer cases.  Interestingly, Fabi et al. (2010) found 
co-expression of PTEN and p-Akt to be associated with a lower risk for 
progression and an enhanced treatment response when treated with 
trastuzumab.  
 
No association was found between PTEN and PI3K, MDM2, BCL2, NFκB or 
p53 expression. Nor was there any significant association between tumour 
grade and PTEN expression (p=0.592).  By contrast, Rasheed et al. (1997) 
found PTEN expression to be associated with high grade tumours while 
PTEN was rarely present in low grade tumours.  The distribution of PTEN 
expression was found to be similar across all tumour grades.  
 
Loss of PTEN expression correlated with an increased risk of death in our 
total study population.  Low PTEN expression was associated with a 1.6 fold 
increased risk of death compared to high PTEN expression.  The number of 
PTEN negative cases and recorded deaths were unfortunately too small to 
produce a reliable result.  A statistically significant association was present 
between PTEN expression and OS in cohort C, which is consistent with 
previous studies that found PTEN activity to contribute to the efficacy of 
trastuzumab (Nagata et al. 2004; Hennessy et al. 2005; Esteva et al. 2010).   
 
High PTEN expression was associated with a decreased risk for progression 
in cohort C.  Our findings support the findings of those studies who found 
PTEN to be a valuable prognostic marker and powerful predictor of 
trastuzumab resistance (Nagata et al. 2004; Esteva et al. 2010).   A recent 
study looking at activating mutations in PIK3CA as well as Her-2 and PTEN 
status in patients with Her-2 amplified breast cancer that had recurrent 
disease after adjuvant trastuzumab treatment or showed disease progression 
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while on trastuzumab treatment, found PTEN to be absent or significantly 
diminished in 59% of cases and activating mutations in the PIK3CA gene in 
29% of cases.  Her-2 expression was lost in less than 5% of cases 
(Chandarlapaty et al. 2011).  Nagata et al. (2004) found that PI3K inhibitors 
were able to overcome trastuzumab resistance caused by PTEN-loss and 
subsequent PI3K/Akt pathway activation.  
 
5.6   p-Akt 
Since Akt seems to be a key player in the PI3K/Akt pathway, we compared p-
Akt expression with the expression of both upstream and downstream 
components in this pathway.  Phosphorylated Akt (p-Akt) was found to be 
overexpressed in (59/93) 63.4% of breast cancers in our study.   
 
No association was found between p-Akt and Her-2 or ER expression.  Our 
findings differ from that of Park and Kim (2007) who reported a significant 
association between p-Akt and Her-2 overexpression.  They also reported a 
significant association between nuclear p-Akt expression and ER expression.  
Stemke-Hale et al. (2008) found Akt mutations to be restricted to ER positive 
cases and found no Akt mutations in Her-2 positive breast cancer.  
Admittedly, they looked at Akt mutations and not protein expression.   
 
There was no significant association between p-Akt and PI3K expression and 
only a slight association between p-Akt and PTEN expression.  Fabi et al. 
(2010) reported significant associations between both p-Akt and PI3K and 
between p-Akt and PTEN expression.  Other studies found PTEN expression 
to be lower when the levels of p-Akt were increased and the PI3K/Akt 
pathway activated (Kang et al. 2005; Stemke-Hale et al. 2008).  Since there 
was no association between Her-2 and p-Akt expression or PI3K and p-Akt 
expression, it is possible that p-Akt was activated by an activating mutation 
within the Akt gene or by a mechanism other than the Her-2 pathway.  Akt  
mutations appear to be rare having been found in only 1.4% of cases in a 
large breast cancer study (Stemke-Hale et al. 2008).  A further possibility 
perhaps could be that PTEN, in an attempt to overcome or compensate for 
PI3K activity, was up-regulated by a negative control mechanism in response 
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to the increase in PIP3 concentration, which is the product of PI3K activity.  
PTEN response was not effective enough to completely block PI3K 
signalling. 
 
We did find significant associations between p-Akt and NFκB expression 
(p=0.014) and between p-Akt and MDM2 expression (p=0.040).  Similarly, 
deGraffenreid et al. (2004) reported a positive association between p-Akt and 
NFκB expression.  They suggested that NFκB may be the reason for 
tamoxifen resistance in p-Akt positive breast cancers due to its role in 
resistance to apoptosis and induction of angiogenesis and invasion.  They 
have suggested that inhibition of NFκB may be an effective strategy in 
reversing tamoxifen resistance in these cases.  A study by Schmitz et al. 
(2006) involving 121 breast cancer cases reported a significant association 
between p-Akt and its downstream effector, MDM2 as well.  Breast cancers 
expressing both p-Akt and MDM2 had a significantly worse prognosis 
compared to cancers expressing p-Akt alone.  The prognosis was even 
worse when p53 in addition, was negative. 
 
We found no association between p-Akt and BCL2 or p53 expression, nor did 
we find any significant association between p-Akt expression and tumour 
type, lymphovascular invasion, lymph node involvement, distant metastasis 
or the apoptotic index.  There was however a slight association between p-
Akt expression and tumour grade (p=0.066). 
 
Patients with tumours showing low p-Akt expression had a 2.1 fold increased 
risk of death compared to those that showed high p-Akt expression (HR 2.1; 
CI 0.8 – 5.9), while the group that showed no p-Akt expression had a 
significant 5.1 fold increased risk of death compared to those showing high p-
Akt expression (HR 5.1; CI 1.5 – 17.3).  These results shows p-Akt 
expression to be an independent prognostic factor but were unexpected as p-
Akt is supposedly associated with high grade tumours, treatment resistance 
and poor outcome (Sun et al. 2001; Cicenas et al. 2005; Schmitz et al. 2006).  
Looking at the findings of more recent studies it appears that the earlier 
perceptions of the role of p-Akt in survival has somewhat changed as 
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reflected in recent findings.  According to Yang et al. (2010), p-Akt 
significantly improves DFS in node positive breast cancers treated with 
paclitaxel.  Aleskandarany et al. (2011), on the other hand did not find p-Akt 
to be a prognostic marker but a study by Fohlin et al. (2013) found Akt2 
expression to be associated with a good long term prognosis in ER(+) breast 
cancer.  We found p-Akt to be a prognostic indicator irrespective of ER 
status.  p-Akt expression is associated with a better outcome. 
 
5.7   BCL2 
In our study population, BCL2 was positive in 50.5% of cases which is 
somewhat lower than the findings of Dawson et al. (2010), who reported 
positive BCL2 expression of 73% of breast cancers.  They found ER(+) 
expression in 86% and Her-2(+) expression in 8% of these cases, while we 
found ER(+) expression in 63.8% and Her-2(+) expression in 55.3% of BCL2 
positive cases.  We saw a significant association between BCL2 and ER 
expression (p=0.022) but did not find any significant association between any 
of the other upstream components and BCL2.  Our findings are supported by 
the findings of Silvestrini et al. (1994) who reported an association between 
BCL2 expression and low grade, slowly proliferating, ER(+) tumours. 
 
Since there was no significant association between BCL2 and p-Akt, it is 
possible that BCL2may be activated in a p-Akt independent manner, 
including an activating mutation within the BCL2 gene or another 
independent mechanism. 
 
In addition, we found no significant association between BCL2 expression 
and any of the clinicopathological variables.  We did not find a significant 
association between OS or DFS and BCL2 expression.  Dawson et al. (2010) 
found BCL2 to be a favourable, independent, prognostic marker in early 
stage breast cancer.  They have also reported a strong association between 
the intensity of BCL2 IHC staining and OS.  Women, whose cancers showed 
the most intense BCL2 staining, had the best OS.  We have opted not to use 
staining intensity but rather extent of staining to score protein expression 
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because staining intensity is subjective and is influenced by many factors 
such as tissue fixation, detection method and batch variation. 
 
 
5.8   MDM2 
MDM2 showed high expression in 79.6% of cases, low expression in 15.1% 
and no expression in 5.4% of cases.  We saw a significant association 
between MDM2 and p-Akt expression (p=0.040) but there was no association 
between MDM2 and any of the other upstream components.  These results 
confirms the role of Akt in MDM2 activation and are consistent with those 
previous studies that found associations between Akt and MDM2 activation 
and is in keeping with the Akt signalling hypothesis (Wang et al. 2011). 
 
There was no association between MDM2 and p53 expression.  MDM2 
showed high expression in 78.4% of cases in which p53 was negative and is 
in keeping with normal p53 expression and negative control exerted by 
MDM2.  In addition, MDM2 showed high expression in 71.4% of cases in 
which p53 was highly expressed.  This may be explained by the presence of 
dysfunctional MDM2 molecules that are unable to bind and label p53 for 
degradation or alternatively, p53 has undergone post-translational 
modification and has been stabilized as a result of oncogenic stress, leading 
to an increase in its half life and making it resistant to MDM2-mediated 
ubiquitination and degradation as MDM2 is unable to ubiquitinate p53 in its 
phosphorylated state (Meek 1994; Goga et al. 1995; Hirao et al. 2000; Ghosh 
and Bose 2005; Francoz et al. 2006). 
 
There was also a slight association between MDM2 expression and tumour 
type (p=0.051).  MDM2 expression was associated with ductal rather than 
lobular carcinomas. 
 
A statistically significant association was found between MDM2 expression 
and absence of distant metastasis (p=0.017).  The highest expression of 
MDM2 was found in cases that showed no distant metastasis.  This may be 
an indication of a protective role for MDM2 against distant metastasis and is 
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also in keeping with the findings of Hori et al. (2002) who associated MDM2 
expression with favourable prognostic indicators.  The role for MDM2 as 
prognostic indicator is controversial as it has been associated with both 
favourable and poor prognoses (Onel and Cordon-Cardo 2004). 
 
A positive association was present between MDM2 expression and OS.  
According to the age adjusted Cox regression analysis, low MDM2 
expression was associated with a 2.4 fold increase in risk of dying compared 
to high MDM2 expression, while no MDM2 expression, was associated with a 
2.8 fold increased risk of dying compared to high MDM2 expression.  Cases 
that showed high MDM2 expression showed a noticeable survival advantage 
to those cases that showed only low or no MDM2 expression.  These findings 
are in contrast with the findings from other studies which found MDM2 
expression to be associated with a poor clinical outcome (Jiang et al. 1997; 
Wang et al. 2005; Schmitz et al. 2006; Turbin et al. 2006).  A few studies 
have reported a positive relationship between MDM2 expression and clinical 
outcome in both breast cancers and melanomas (Hori et al. 2002; Polsky et 
al. 2002).  Polskyet al. (2002) found MDM2 to be an independent predictor of 
survival in primary malignant melanoma and reported statistically significant 
associations between MDM2 overexpression and both DFS and.  In support 
of our findings, a study by Hori et al. (2002) reported a positive association 
between MDM2 overexpression and favourable prognostic parameters such 
as low grade tumours and the absence of lymph node involvement. 
 
5.9   NFκB 
NFκB expression was found to be linked to high grade carcinomas, with high 
NFκB expression present in 12.6% of grade 1 tumours, 39.1% in grade 2 
tumours and 48.3% in grade 3 tumours (p = 0.051).  Our findings are 
supported by the findings of Ozbek et al. (2012) who reported an association 
between NFκB expression and tumour grade in renal cell carcinomas.  
Tannahill et al. (2009) on the other hand, did not find any association 
between cytoplasmic or nuclear NFκB expression (both total and 
phosphorylated) and tumour grade.  We found strong cytoplasmic staining for 
NFκB but very little evidence of nuclear staining in our study.  Where nuclear 
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staining was observed, it was present in less than 3% of the tumour cells.  
The antibody datasheet provided by the manufacturer, indicated that 
cytoplasmic staining should be expected.  We contacted the manufacturer 
and they indicated that the data sheet should in fact state that both nuclear 
and cytoplasmic NFκB staining is expected.  We subsequently found a paper 
by Miyamoto et al. (1994), with very similar findings.  They metabolically 
labelled mature B cells and fragmented them into nuclear and cytoplasmic 
pools before immuno-precipitating it with antibodies specific for NFκB and 
IκB.  They detected around 10% of the total NFκB protein in the nucleus of 
unstimulated, mature B cells, while the rest of the NFκB proteins (around 
90%) was found sequestered by IκB’s in the cytoplasm.  It was the findings of 
Cogswell et al. (2000) however that provided an explanation for our findings.  
They demonstrated the presence of p52, p50 and c-Rel subunits in the 
nucleus of almost all breast tumour cases, while the p65 subunit, which 
happens to be the subunit our NFκB antibody was directed against, was 
virtually undetected.  Their findings explain why we could not demonstrate 
significant nuclear staining for NFκB which in our case was directed 
specifically at the p65 subunit of the classic p50/p65, NFκB heterodimer.  
They suggested that a mechanism other than the typical mechanism of NFκB 
activation may be involved.  They also demonstrated the presence of p65 in 
the nucleus of cell lines but found that it differs from p65 expression in breast 
tumours.  They suggested that difference in p65 behaviour may be due to the 
extracellular environment which is the culture medium in cell lines or even the 
number of genetic replications of the immortal cell line (Cogswell et al. 2000).  
This fact would, to an extent, explain the discrepancy in the findings between 
different studies.  If the extracellular environment did in fact have an influence 
on p65 activation, one could postulate that p65 is activated directly or 
indirectly by an extracellular stimulus that is also present in the culture 
medium.  The reason for the increase in cytoplasmic NFκB expression with 
increase in tumour grade remains unclear.  We found no significant 
association between NFκB expression and lymphovascular invasion. 
 
We found statistically significant associations between NFκB and Her-2 




5.10   p53 
A statistically significant association was found between p53 expression and 
tumour grade (p = 0.013).  High p53 expression increased from 0% in grade1 
tumours to 13.9% in grade 2 tumours and 37.2% in grade 3 tumours.  This 
confirms the findings of other studies who reported significant associations 
between p53 expression and tumour grade (Ostrowski et al. 1991; Sirvent et 
al. 1995).  Since wild type p53 is usually not detected by 
immunohistochemistry at normal levels of expression due to its short half life 
and negative regulation by MDM2, an increase in p53 expression towards the 
higher tumour grades suggests an increase in the frequency of p53 
mutations or alternatively, an increase in p53 activity due to wild type p53 
being stabilized as a result of an increase in oncogenic stress signals.  
Similarly, in a large study, Olivier et al. (2006) found p53 mutations to be 
more frequent in aggressive phenotypes such as high grade, large size, 
lymph node positive and low hormone content cancers.  These results 
confirm our findings. 
 
A slight association was present between p53 and Her-2 expression 
(p=0.057).  Camerini et al. (2011) found no association between p53 and 
Her-2 expression but reported an association between p53 and tumour 
stage.  
 
Overexpression of nuclear p53 has been associated with a poor prognosis.  
Sirvent et al. (2001) reported a statistically significant association between 
p53 expression and shorter DFS and OS.  Similarly, we found a statistically 
significant association between p53 expression and OS (p = 0.029).  Patients 
with tumours expressing low levels p53 had a 5.5 fold reduction in risk for 
dying compared to those with tumours expressing high levels of p53.  
Patients with tumours negative for p53 expression had a 2.5 fold reduced risk 
of dying, compared to those with tumours expressing high p53 levels (HR 
0.4; CI 0.2 – 1.0).  These findings confirm the findings of Sirvent et al. (2001) 




5.11   Oestrogen receptor (ER) 
A statistically significant association was evident between ER and BCL2 
expression (p=0.022) and ER expression and lymphovascular invasion (p< 
0.001).  ER expression was negative in all cases without lymphovascular 
invasion and positive in 64.3% of cases with lymphovascular invasion. 
 
In addition, a statistically significant association was found between ER 
expression and lymph node involvement (p=0.002).  These findings are in 
contrast to those of Sofi et al. (2012) who did not find any correlation 
between ER/PR expression and lymph node involvement in breast 
carcinomas. 
 
ER expression was more frequent in lobular compared to ductal carcinomas.   
 
5.12   Age 
A statistically significant association was present between patient age and 
Her-2 expression (p=0,044).  This is consistent with the findings of at least 
one other study linking Her-2(+) tumours with a younger age and a possible 
contributing factor to the more aggressive tumour behaviour and prognosis in 
the younger population (Anders et al. 2011). 
 
There was no other association found between age and protein expression.  
 
p53, although not statistically significant, showed a decrease in expression 
with increase in age, a finding that is supported by the findings of another 
study (Stark et al. 2003).  To try and find an explanation for this observation, 
we looked at the various reasons for p53 immunoexpression.  p53 
expression could be linked to gain of function mutations in the p53 gene 
which could be further enhanced by the inability of mutant p53 to induce 
translation of MDM2, the  negative regulator of p53.  Another possible reason 
for the accumulation of p53 could be that wild-type p53 is activated 
(phosphorylated) and stabilized under conditions of stress which include 
oncogenic stress.  The half life of p53 is increased under these conditions of 
stress.  Negative regulation by MDM2 is inhibited due to the fact that MDM2 
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is degraded under these conditions.  In addition, MDM2 is only able to 
degrade unphosphorylated p53, which further enhances the level of wild type 
p53 (Meek 1994; Stott et al. 1998; Zhang et al. 1998).  Since it is impossible 
to distinguish between mutated and wild type p53 looking at protein 
expression, it is possible that some of the p53 expression observed was 
actually wild-type p53 and not the product of mutated p53.  It has been 
shown that the efficiency of the immune system as well as DNA repair 
diminish with age (Vyjayanti and Rao 2006; Woodland and Blackman 2006; 
Yamada et al. 2006).  One could postulate that the accumulation of DNA 
mutations over a life time in the p53 gene itself or the proteins involved in its 
activation in response to cellular stress or DNA damage, results in a decline 
in p53 activity and/or efficiency with increasing age and could possibly be a 
reason why most cancers arise in the last quarter of life and why we see 
diminished p53 expression with age.  Feng et al. (2007) tested this theory in 
a mouse model where mice were irradiated with gamma rays at ages of 6 
months, 20 months, 24 months and 28 months.  Both the levels of p53 
response to radiation as well as the level of p53 phosphorylation were lower 
in the older mice.  They also found lower levels of p53 mediated apoptosis in 
the spleens of older mice compared to the younger mice.  The decline in p53 
activity correlated progressively with an increase in age.  They also found a 
decline in total RNA as well as protein levels of ATM kinase in older mice.  
ATM kinase is responsible for stabilization and activation of p53 following 
DNA damage or cellular stress and could be a possible mechanism by which 
p53 activity is diminished in old age.  This decline in activation was only seen 
in the p53 pathway.  Activation of the Akt and mTOR pathways did not show 
a decline with an increase in age (Feng Z et al. 2007).  
 
Olivier et al. (2006) in a comprehensive study reported a significant 
association between p53 mutations and age with a noticeable decline in 
mutations in the cancers of women older than 60 years of age (Olivier M et 
al. 2006).  Although this could be a reason for the decrease in p53 
expression in older patients and confirms an association between p53 
mutation and expression, the reason for the decline in p53 mutations with 
increasing age is not clear. 
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A strong association was found between age and overall survival (OS) 
across all three cohorts, which was statistically significant in cohort A, but not 
in the two treatment dependent cohorts due to the limitation of sample size.  
In all three cohorts, the <45 year group had the worst median overall survival 
followed by the 45 <65 year group.  The ≥65 year age group showed the best 
median OS across all cohorts.   
 
These findings suggest an association between age and survival and also 
prove age to be a strong prognostic indicator in the premenopausal 
population.  This however is not a new finding but confirms that although the 
incidence of cancer is lower in the premenopausal population, carcinomas in 
this population tend to be more aggressive possibly as a result of oestrogen 
stimulation.  In keeping with this fact our study found that postmenopausal 
women and in particular those who had an oophorectomy, also had the best 
overall and disease free survival rates in the group that received trastuzumab 
therapy.  Looking at these findings, the use of anti-oestrogens or oestrogen-
deprivation therapy to either block the effect of oestrogen on these cancers 
or diminish the level of circulating oestrogen, seems like an effective 
treatment option.  Unfortunately, as mentioned before, Her-2 overexpression 
has been associated with resistance to anti-oestrogens, and in particular to 
tamoxifen, one of the most popular anti-oestrogens (Dowsett 2001; Lipton et 
al. 2002; Johnston 2006).  More than one study has suggested that anti-
oestrogen therapy may actually have a detrimental effect on Her-2(+) 
cancers (Borg A et al. 1994; Lohrisch and Piccart 2001).  Results of a few in 
vitro studies have shown that trastuzumab may actually be able to enhance 
the growth inhibitory effect of anti-oestrogens and may even reverse the 
resistance of Her-2(+) cancers to anti-oestrogens like tamoxifen and 
suggested that the combination of trastuzumab and an anti-oestrogen may 
actually be a powerful treatment approach (Witters et al. 1997; Kunisue et al. 
2000; Argiris et al. 2004).  The unfortunate reality is that unless trastuzumab 
becomes more affordable, only a few of Her-2(+) patients will be able to 
afford this benefit.  One can only hope that with the original patent for 
trastuzumab expiring in 2014, similar drugs will become more affordable and 
available to patients with breast cancer and not just a privileged few. 
111 
 
5.13   Her-2 ICH and CISH on matched cytopathology and 
histopathology samples 
We assessed the newly available brightfield chromogenic in-situ hybridization 
(CISH) method for effectiveness and suitability as a testing method for Her-2 
status on both formalin fixed paraffin embedded tissue and archived, Pap-
stained, FNA samples.  There was 80% concordance between Her-2 IHC 
and Her-2 CISH results.  Inaccuracy with both IHC and ISH remains a major 
issue worldwide.  The accuracy of Her-2 testing is crucial as a false positive 
result will lead to unnecessary and wasteful expenditure.  A false negative 
result would deprive a patient of trastuzumab therapy.  In an attempt to 
improve the accuracy of Her-2 testing in routine practice, the American 
Society of Clinical Oncology together with the College of American 
Pathologists (2007) published guidelines for Her-2 testing and analysis.  
They however could not clearly demonstrate the superiority of either the IHC 
or ISH method for Her-2 testing, but found the IHC method to be more 
dependent on pre-analytical variables than the ISH method, while the IHC 
method proved more reliable in fresh frozen tissue than the ISH method 
(Wolff AC et al. 2007).  They identified a list of variables as possible sources 
of Her-2 testing variation. 
 
There was 100% concordance of Her-2 CISH results on corresponding 
cytopathology and histopathology samples.  These findings serve as 
evidence that Her-2 CISH can be performed not only on paraffin embedded 
tissue but also on stained and archived FNA samples that have been de-
stained for CISH.  The advantage of being able to use stained FNA samples 
over unstained FNA samples is that it allows you to assess the material 
beforehand to make sure that you do in fact have adequate material and 
mark areas of interest before de-staining it.  We have also noticed a slightly 
higher score in the cytology samples which we have attributed to the 
possibility of antigen masking in formalin fixed paraffin embedded tissues.  
The fact that some nuclei are sliced when tissue is sectioned as part of the 
histology preparation may also explain the slightly lower average score.  We 
also observed that in cases where the nuclear detail on the FNA sample was 
partly obscured mainly due to drying artefact, the gene amplification could 
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still be assessed but it was more difficult to identify nuclear borders.  Liquid 
based cytology preparations should be an ideal method for CISH analysis as 
the material is normally very well preserved and concentrated in a small area 
on the slide.  The smaller area allows the use of a smaller amount of probe 
which makes it more cost effective.  The advantages of this method are that 
there is no need for a special dark room or fluorescent microscope and the 
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In spite of the limitations of this study on breast cancer, there are interesting 
conclusions with potential clinical significance. 
 
Her-2(+) immunoexpression was associated with ductal carcinomas and high 
tumour grade.  
 
High PI3K expression was associated with lymphovascular invasion and lymph 
node metastasis.  
 
This study also found a strong association between a specific subgroup of 
breast cancer [Her-2(+)/ER(+)/PI3K (high expression)] and both lymphovascular 
involvement and lymph node metastasis.   
 
High p-Akt expression was an indicator for good prognosis.  The absence of p-
Akt expression was associated with five fold increase in the risk of death 
compared to cases showing high p-Akt expression.   
 
High MDM2 expression was associated with an absence of distant metastasis 
and reduced risk of death (3.2 fold decrease in risk of death compared to low 
MDM2 expression).   
 
One of the shortcomings of this project was the small sample size, especially 
the cohort that received trastuzumab treatment, which in some instances 
proved too small to produce a reliable or significant result.  
 
Since this study focused on the immunohistochemical detection of proteins, it 
would be important to confirm and correlate these results with molecular 
genetic analyses. 
 
In addition, the chromogenic in-situ hybridization (CISH) technique for 
determining Her-2 amplification can be done successfully on archived, Pap-




Based on these findings we propose that liquid based cytological 
preparations would be ideal for CISH analysis as the material is normally 
very well preserved and concentrated in a small area on the slide.  The 
smaller area allows the use of a small amount of probe which makes it more 
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Appendix 1:  Correlation or Her-2 results with protein expression 
Variable N Her-2 pos Her-2 neg p-value 
     
PI3K high 79 48 (60.8%) 31 (39.2%) 0.730 
PI3K low 13 7 (53.8%) 6 (46.2%)  
PI3K neg 1 1 (100%) 0 (0%)  
     
PTEN high 55 35 (63.6%) 20 (36.4%) 0.065 
PTEN low 27 18 (66.7%) 9 (33.3%)  
PTEN neg 11 3 (27.3%) 8 (72.7%)  
     
p-Akt high 59 37 (62.7%) 22 (37.3%) 0.803 
p-Akt low 26 14 (53.8%) 12 (46.2%)  
p-Akt neg 8 5 (62.5%) 3 (37.5%)  
     
NFκB high 87 55 (63.2%) 32 (36.8%) 0.035 
NFκB low 6 1 (16.7%) 5 (83.3%)  
     
MDM2 high 74 46 (62.2%) 28 (37.8%) 0.197 
MDM2 low 14 9 (64.3%) 5 (35.7%)  
MDM2 neg 5 1 (20%) 4 (80%)  
     
BCL2 high 47 26 (55.3%) 21 (44.7%) 0.109 
BCL2 low 20 10 (50%) 10 (50%)  
BCL2 neg 26 20 (76.9%) 6 (23.1%)  
     
p53 high 21 17 (81%) 4 (9%) 0.057 
p53 low 21 13 (61.9%) 8 (38.1%)  
p53 neg 51 26 (51%) 25 (49%)  
     
ER pos 47 27 (57.4%) 20 (42.6%) 0.581 
ER neg 46 29 (63.0%) 17 (37.0%)  













Appendix 2:  Correlation of ER status with protein expression 
Variable N ER pos ER neg p-value 
     
PI3K high 79 43 (54.4%) 36 (45.6%) 0.105 
PI3K low 13 4 (52.0%) 9 (69.2%)  
PI3K neg 1 0 (0%) 1 (100%)  
     
PTEN high 55 31 (56.4%) 24 (43.6%) 0.370 
PTEN low 27 12 (44.4%) 15 (55.6%)  
PTEN neg 11 4 (36.4%) 7 (63.6%)  
     
p-Akt high 59 31 (52.5%) 28 (47.5%) 0.898 
p-Akt low 26 12 (46.2%) 14 (53.8%)  
p-Akt neg 8 4 (50.0%) 4 (50.0%)  
     
NFκB high 87 45 (51.7%) 42 (48.3%) 0.435 
NFκB low 6 2 (33.3%) 4 (66.7%)  
      
MDM2 high 74 37 (50.0%) 37 (50.0%) 0.384 
MDM2 low 14 6 (42.9%) 8 (57.1%)  
MDM2 neg 5 4 (80.0%) 1 (20.0%)  
     
BCL2 high 47 30 (63.8%) 17 (36.2%) 0.022 
BCL2 low 20 9 (45.0%) 11 (55%)  
BCL2 neg 26 8 (30.8%) 18 (69.2%)  
     
p53 high 21 9 (42.9%) 12 (57.1%) 0.367 
p53 low 21 9 (42.9%) 12 (57.1%)  
p53 neg 51 29 (56.9%) 22 (43.1%)  
     
Her-2 pos* 56 27 (48.2%) 29 (51.8%) 0.581 
Her-2 neg* 37 20 (54.1%) 17 (45.9%)  
Analysis was done using Fishers exact test and/or Chi square test as appropriate 













Appendix 3:  Correlation of PI3K results with protein expression 
Variable N PI3K high PI3K low PI3K neg p-value 
      
PTEN high 55 47 (85.4%) 7 (12.7%) 1 (1.8%) 0.812 
PTEN low 27 22 (81.5%) 5 (18.5%) 0 (0%)  
PTEN neg 11 10 (90.9%) 1 (9.1%) 0 (0%)  
      
p-Akt high 59 49 (83.1%) 9 (25.3%) 1 (1.7%) 0.827 
p-Akt low 26 22 (84.6%) 4 (15.4%) 0 (0.0%)  
p-Akt neg 8 8 (100%) 0 (0%) 0 (0%)  
      
NFκB high 87 74 (85.1%) 12 (13.8%) 1 (1.1%) 0.616 
NFκB low 6 5 (83.3%) 1 (16.7%) 0 (0%)  
       
MDM2 high 74 64 (86.5%) 9 (14.1%) 1 (1.4%) 0.425 
MDM2 low 14 10 (71.4%) 4 (28.6%) 0 (0%)  
MDM2 neg 5 5 (100%) 0 (0%) 0 (0%)  
      
BCL2 high 47 40 (85.1%) 7 (14.9%) 0 (0%) 0.666 
BCL2 low 20 18 (90.0%) 2 (0.1%) 0 (0%)  
BCL2 neg 26 21 (80.8%) 4 (15.4%) 1 (3.8%)  
      
p53 high 21 16 (76.2%) 5 (23.8%) 0 (0%) 0.514 
p53 low 21 18 (85.7%) 3 (14.3%) 0 (0%)  
p53 neg 51 45 (88.2%) 5 (9.8%) 1 (2.0%)  
      
ER pos 47 43 (91.5%) 4 (8.5%) 0 (0%) 0.105 
ER neg 46 36 (78.3%) 9 (19.6%) 1 (2.2%)  
      
Her-2 pos* 56 48 (85.7%) 7 (12.5%) 1 (1.8%) 0.730 
Her-2 neg* 37 31 (83.8%) 6 (16.2%) 0 (0%)  
Analysis was done using Fishers exact test and/or Chi square test as appropriate 















Appendix 4:  Correlation of PTEN results with protein expression 
Variable N PTEN high PTEN low PTEN neg p-value 
      
PI3K high 79 47 (67.1%) 22 (27.8%) 10 (12.7%) 0.812 
PI3K low 13 7 (53.8%) 5 (38.5%) 1 (7.7%)  
PI3K neg 1 1 (100%) 0 (0%) 0 (0%)  
      
p-Akt high 59 40 (67.8%) 14 (23.7%) 5 (8.5%) 0.053 
p-Akt low 26 13 (50.0%) 10 (38.5%) 3 (11.5%)  
p-Akt neg 8 2 (25.0%) 3 (37.5%) 3 (37.5%)  
      
NFκB high 87 53 (60.9%) 23 (26.4%) 11 (12.6%) 0.114 
NFκB low 6 2 (33.3%) 4 (66.7%) 0 (0%)  
       
MDM2 high 74 44 (59.5%) 20 (27.0%) 10 (13.5%) 0.213 
MDM2 low 14 6 (42.9%) 7 (50.0%) 1 (7.1%)  
MDM2 neg 5 5 (100%) 0 (0%) 0 (0)%  
      
BCL2 high 47 32 (68.1%) 13 (27.7%) 2 (4.3%) 0.163 
BCL2 low 20 10 (50.0%) 6 (30.0%) 4 (20.0%)  
BCL2 neg 26 13 (50.0%) 8 (30.8%) 5 (19.2%)  
      
p53 high 21 12 (57.1%) 8 (38.1%) 1 (4.8%) 0.236 
p53 low 21 9 (42.9%) 8 (38.1%) 4 (19.0%)  
p53 neg 51 34 (66.7%) 11 (21.6%) 6 (11.8%)  
      
ER pos 47 31 (66.0%) 12 (25.5%) 4 (8.5%) 0.370 
ER neg 46 24 (52.2%) 15 (32.6%) 7 (15.2%)  
      
Her-2 pos* 56 35 (62.5%) 18 (32.1%) 3 (53.6%) 0.065 
Her-2 neg* 37 20 (54.1%) 9 (24.3%) 8 (21.6%)  
Analysis was done using Fishers exact test and/or Chi square test as appropriate 













Appendix 5:  Correlation of p-Akt results with protein expression 
Variable N p-Akt high p-Akt low p-Akt neg p-value 
      
PI3K high 79 49 (62.0%) 22 (27.8%) 8 (10.1%) 0.827 
PI3K low 13 9 (69.2%) 4 (30.8%) 0 (0%)  
PI3K neg 1 1 (100%) 0 (0%) 0 (0%)  
      
PTEN high 55 40 (72.7%) 13 (23.6%) 2 (3.6%) 0.053 
PTEN low 27 14 (51.9%) 10 (37.0%) 3 (11.1%)  
PTEN neg 11 5 (45.4%) 3 (27.3%) 3 (27.3%)  
      
NFκB high 87 58 (66.7%) 23 (26.4%) 6 (6.9%) 0.014 
NFκB low 6 1 (16.7%) 3 (50.0%) 2 (33.3%)  
      
MDM2 high 74 52 (70.3%) 16 (21.6%) 6 (12.2%) 0.040 
MDM2 low 14 5 (35.7%) 7 (50.0%) 2 (14.3%)  
MDM2 neg 5 2 (40.0%) 3 (60.0%) 0 (0%)  
      
BCL2 high 47 33 (70.2%) 11 (23.4%) 3 (6.4%) 0.538 
BCL2 low 20 10 (50.0%) 8 (40.0%) 2 (10.0%)  
BCL2 neg 26 16 (61.5%) 7 (26.9%) 3 (11.5%)  
      
p53 high 21 13 (61.9%) 5 (23.8%) 3 (14.3%) 0.754 
p53 low 21 14 (66.7%) 5 (23.8%) 2 (9.5%)  
p53 neg 51 32 (62.7%) 16 (31.4%) 3 (5.9%)  
      
ER pos 47 31 (66.0%) 12 (25.5%) 4 (8.5%) 0.898 
ER neg 46 28 (60.9%) 14 (30.4%) 4 (8.7%)  
      
Her-2 pos* 56 37 (66.1%) 14 (25.0%) 5 (8.9%) 0.803 
Her-2 neg* 37 22 (59.4%) 12 (32.4%) 3 (8.1%)  
Analysis was done using Fishers exact test and/or Chi square test as appropriate 















Appendix 6:  Correlation of MDM2 results with protein expression 
Variable N MDM2 high MDM2 low MDM2 neg p-value 
      
PI3K high 79 64 (81.0%) 10 (12.7%) 5 (6.3%) 0.425 
PI3K low 13 9 (69.2%) 4 (30.8%) 0 (0.0%)  
PI3K neg 1 1 (100%) 0 (0%) 0 (0%)  
      
PTEN high 55 44 (80.0%) 6 (10.9%) 5 (9.1%) 0.214 
PTEN low 27 20 (74.1%) 7 (25.9%) 0 (0%)  
PTEN neg 11 10 (90.9%) 1 (9.1%) 0 (0%)  
      
p-Akt high 59 52 (88.1%) 5 (8.5%) 2 (3.4%) 0.040 
p-Akt low 26 16 (61.5%) 7 (26.9%) 3 (11.5%)  
p-Akt neg 8 6 (75.0%) 2 (25.0%) 0 (0%)  
      
BCL2 high 47 34 (72.3%) 11 (23.4%) 2 (4.3%) 0.085 
BCL2 low 20 18 (90.0%) 0 (0%) 2 (10.0%)  
BCL2 neg 26 22 (84.6%) 3 (11.5%) 1 (3.8%)  
      
p53 high 21 15 (71.4%) 4 (19.0%) 2 (13.3%) 0.603 
p53 low 21 19 (90.5%) 2 (9.5%) 0 (0%)  
p53 neg 51 40 (78.4%) 8 (15.7%) 3 (5.9%)  
      
ER pos 47 37 (78.7%) 6 (12.8%) 4 (8.5%) 0.384 
ER neg 46 37 (80.4%) 8 (17.4%) 1 (2.2%)  
      
Her-2 pos* 56 46 (82.1%) 9 (16.1%) 1 (1.8%) 0.197 
Her-2 neg* 37 28 (75.7%) 5 (13.5%) 4 (10.8%)  
      
NFκB high 87 69 (79.3%) 13 (14.9%) 5 (5.7%) >0.999 
NFκB low 6 5 (83.3%) 1 (16.7%) 0 (0%)  
Analysis was done using Fishers exact test and/or Chi square test as appropriate 













Appendix 7:  Correlation of NFκB results with protein expression 
Variable N NFκB high NFκB low p-value 
     
PI3K high 79 74 (93.7%) 5 (6.3%) 0.616 
PI3K low 13 12 (92.3%) 1 (7.7%)  
PI3K neg 1 1 (100%) 0 (0%)  
     
PTEN high 55 53 (96.4%) 2 (3.6%) 0.114 
PTEN low 27 23 (85.2%) 4 (14.8%)  
PTEN neg 11 11 (100%) 0 (0%)  
     
MDM2 high 74 69 (93.2%) 5 (6.8%) >0.999 
MDM2 low 14 13 (92.9%) 1 (7.1%)  
MDM2 neg 5 5 (100%) 0 (0%)  
      
p-Akt high 59 58 (98.3%) 1 (1.7%) 0.014 
p-Akt low 26 23 (88.5%) 3 (11.5%)  
p-Akt neg 8 6 (75.0%) 2 (25.0%)  
     
BCL2 high 47 44 (93.6%) 3 (6.4%) 0.74 
BCL2 low 20 18 (90.0%) 2 (10.0%)  
BCL2 neg 26 25 (96.2%) 1 (3.8%)  
     
p53 high 21 21 (100%) 0 (0%) 0.180 
p53 low 21 18 (85.7%) 3 (14.3%)  
p53 neg 51 48 (94.1%) 3 (5.9%)  
      
ER pos 47 45 (95.7%) 2 (4.3%) 0.435 
ER neg 46 42 (91.3%) 4 (8.7%)  
     
Her-2 pos* 56 55 (98.2%) 1 (1.8%) 0.035 
Her-2 neg* 37 32 (86.5%) 5 (13.5%)  
Analysis was done using Fishers exact test and/or Chi square test as appropriate 













Appendix 8:  Correlation of BCL2 results with protein expression 
Variable N BCL2 high BCL2 low BCL2 neg p-value 
      
PI3K high 79 40 (50.6%) 18 (22.8%) 21 (26.6%) 0.666 
PI3K low 13 7 (53.8%) 2 (15.4%) 4 (30.8%)  
PI3K neg 1 0 (0%) 0 (0%) 1 (100%)  
      
PTEN high 55 32 (58.2%) 10 (18.2%) 13 (23.6%) 0.163 
PTEN low 27 13 (48.1%) 6 (22.2%) 8 (29.6%)  
PTEN neg 11 2 (18.2%) 4 (36.4%) 5 (45.4%)  
      
MDM2 high 74 34 (45.9%) 18 (24.3%) 22 (29.7%) 0.085 
MDM2 low 14 11 (78.6%) 0 (0%) 3 (21.4%)  
MDM2 neg 5 2 (40.0%) 2 (40.0%) 1 (20.0%)  
       
p-Akt high 59 33 (55.9%) 10 (16.9%) 16 (27.1%) 0.538 
p-Akt low 26 11 (42.3%) 8 (30.8%) 7 (26.9%)  
p-Akt neg 8 3 (37.5%)  2 (25.0%) 3 (37.5%)  
      
NFκB high 87 44 (50.6%) 18 (20.7%) 25 (28.7%) 0.740 
NFκB low 6 3 (50.0%) 2 (33.3%) 1 (16.7%)  
      
p53 high 21 8 (38.1%) 5 (23.8%) 8 38.1%) 0.387 
p53 low 21 13 (61.9%) 2 (9.5%) 6 (28.6%)  
p53 neg 51 26 (51.0%) 13 (25.5%) 12 (23.5%)  
      
ER pos 47 30 (63.8%) 9 (19.2%) 8 (17.0%) 0.022 
ER neg 46 17 (37.0%) 11 (23.9%) 18 (39.1%)  
      
Her-2 pos* 56 26 (46.4%) 10 (17.9%) 20 (35.7%) 0.109 
Her-2 neg* 37 21 (56.8%) 10 (27.0%) 6 (16.2%)  
Analysis was done using Fishers exact test and/or Chi square test as appropriate 













Appendix 9:  Correlation of p53 results with protein expression 
Variable N p53 high p53 low p53 neg p-value 
      
PI3K high 79 16 (20.2%) 18 (22.8%) 45 (57.0%) 0.514 
PI3K low 13 5 (38.5%) 3 (23.1%)  5 (38.5%)  
PI3K neg 1 0 (0%) 0 (0%) 1 (100%)  
      
PTEN high 55 12 (21.8%) 9 (16.4%) 34 (61.8%) 0.236 
PTEN low 27 8 (29.6%) 8 (29.6%) 11 (40.7%)  
PTEN neg 11 1 (9.1%) 4 (36.4%) 6 (54.5%)  
      
MDM2 high 74 15 (20.3%) 19 (25.7%) 40 (54.1%) 0.603 
MDM2 low 14 4 (28.6%) 2 (14.3%)  8 (57.1%)  
MDM2 neg 5 2 (40.0%) 0 (0%) 3 (60.0%)  
       
p-Akt high 59 13 (2.0%) 14 (23.7%) 32 (54.2%) 0.754 
p-Akt low 26 5 (19.2%) 5 (19.2%) 16 (61.5%)  
p-Akt neg 8 3 (37.5%) 2 (25.0%) 3 (37.5%)  
      
NFκB high 87 21 (24.1%) 18 (20.7%) 48 (55.2%) 0.180 
NFκB low 6 0 (0%) 3 (50.0%) 3 (50.0%)  
      
BCL2 high 47 8 (17.0%) 13 (27.7%) 26 (55.3%) 0.387 
BCL2 low 20 5 (25.0%) 2 (10.0%) 13 (65.0%)  
BCL2 neg 26 8 (30.8%) 6 (23.1%) 12 (46.1%)  
      
ER pos 47 9 (19.1%) 9 (19.1%) 29 (61.7%) 0.367 
ER neg 46 12 (26.1%) 12 (26.1%) 22 (47.8%)  
      
Her-2 pos* 56 17 (30.4%) 13 (23.2%) 26 (46.4%) 0.057 
Her-2 neg* 37 4 (10.8%) 8 (21.6%) 25 (67.6%)  
Analysis was done using Fishers exact test and/or Chi square test as appropriate 













Appendix 10:  Association between age and level of protein expression   
Variable N Mean age SD p-value 
PTEN neg 11 52.1 8.2 0.154 
PTEN low 27 54.7 9.8  
PTEN high 55 53.1 11.7  
     
NFκB low 6 60.2 10.5 0.595 
NFκB high 87 53.1 10.7  
     
MDM2 neg 5 53.8 5.8 0.850 
MDM2 low 14 51.1 13.6  
MDM2 high 74 53.9 10.5  
     
p53 neg 51 54.2 10.3 0.148 
p53 low 21 53.5 9.9  
p53 high 21 51.6 12.8  
     
BCL2 neg 26 55.2 3.7 0.813 
BCL2 low 20 50.6 10.9  
BCL2 high 47 53.7 10.4  
     
p-Akt neg 8 51.4 3.7 0.874 
p-Akt low 26 53.6 10.9  
p-Akt high 59 53.7 10.4  
     
PI3K neg 1 40.0 - 0.392 
PI3K low 13 55.3 11.3  
PI3K high 17 53.3 10.7  
     
ER neg 46 52.8 10.8 0.476 
ER pos 47 54.1 10.8  
     
Her-2  Neg 37 56.2 8.6 0.044 
Her-2 Pos 56 51.6 11.7  
Analysis of variance (ANOVA) was used to analyze level of protein expression and age 













Appendix 11:  Association between tumour type and protein expression 
Variable N Ductal Lobular p-value 
      
PTEN high 55 50 (90.9%) 5 (9.1%) >0.999 
PTEN low 27 25 (92.6%) 2 (7.4%)  
PTEN neg 11 10 (90.9%) 1 (9.1%)  
      
NFκB high 87 81 (93.1%) 6 (6.9%) 0.082 
NFκB low 6 4 (66.7%) 2 (33.3%)  
     
MDM2 high 74 68 (91.9%) 6 (8.1%) 0.051 
MDM2 low 14 14 (100%) 0 (0%)  
MDM2 neg 5 3 (60.0%) 2 (40.0%)  
      
p53 high 21 21 (100%) 0 (0%) 0.172 
p53 low   21 20 (95.2%) 1 (4.8%)  
p53 neg 51 44 (86.3%) 7 (13.7%)  
      
BCL2 high 47 42 (89.4%) 5 (10.6%) 0.135 
BCL2 low 20 17 (85.0%) 3 15.0%)  
BCL2 neg 26 26 (100%) 0 (0%)  
      
p-Akt high 59 54 (91.5%) 5 (8.5%) 0.183 
p-Akt low 26 25 (96.2%) 1 (3.8%)  
p-Akt neg 8 6 (75.0%) 2 (25.0%)  
      
PI3k high 79 72 (91.1%) 7 (8.9%) 0.630 
PI3k low 13 12 (92.3%) 1 (7.7%)  
PI3k neg 1 1 (100%)  0 (0%)  
      
ER pos 47 40 (85.1%) 7 (6.7%) 0.059  
ER neg 46 45 (97.8%) 1 (2.2%)  
      
Her-2 pos* 56 55 (98.2%) 1 (1.8%) 0.006  
Her-2 neg* 37 30 (81.1%) 7 (18.9%)  
Analysis was done using Fishers exact test and/or Chi square test as appropriate 











Appendix 12:  Association between tumour grade and protein expression 
Variable N grade1 grade2 grade3 p-value 
PTEN high 55 8 (14.5%) 24 (43.6%) 23 (41.8%) 0.592 
PTEN low 27 5 (18.5%) 7 (25.9%) 15 (55.6%) 
 
PTEN neg 11 1 (9.1%) 5 (45.5%) 5 (45.5%) 
 
      
NFκB high 87 11 (12.6%) 34 (39.1%) 42 (48.3%) 0.051 
NFκB low 6 3 (50.0%) 2 (33.3%) 1 (16.7%) 
 
      
MDM2 high 74 10 (13.5%) 31 (41.9%) 33 (44.6%) 0.590 
MDM2 low 14 3 (21.4%) 3 (21.4%) 8 (57.1%) 
 
MDM2 neg 5 1 (20.0%) 2 (40.0%) 2 (40.0%) 
 
      
p53 high 21 0 (0.0%) 5 (23.8%) 16 (76.2%) 0.013 
p53 low 21 4 (19.0%) 11 (52.4%) 6 (28.6%) 
 
p53 neg 51 10 (19.6%) 20 (39.2%) 21 (41.2%) 
 
      
BCL2 high 47 11 (23.4%) 17 (36.2%) 19 (40.4%) 0.215 
BCL2 low 20 2 (10.0%) 9 (45.0%) 9 (45.0%) 
 
BCL2 neg 26 1 (3.8%) 10 (38.5%) 15 (57.7%) 
 
      
p-Akt high 59 8 (13.6%) 23 (39.0%) 28 (47.4%) 0.928 
p-Akt low 26 5 (19.2%) 9 (34.6%) 12 (46.2%) 
 
p-Akt neg 8 1 (12.5%) 4 (50.0%) 3 (37.5%) 
 
      
PI3k high 79 10 (12.7%) 33 (41.8%) 36 (45.6%) 0.275 
PI3k low 13 4 (30.8%) 3 (23.1%) 6 (46.2%) 
 
PI3k neg 1 0 (0.00%) 0 (0.00%) 1 (100%) 
 
      
ER pos 47 6 (12.8%) 23 (48.9%) 18 (38.3%) 0.123 
ER neg 46 8 (17.4%) 13 (28.3%) 25 (54.3%) 
 
      
Her-2 pos* 56 3 (5.4%) 22 (39.3%) 31 (55.4%) 0.004 
Her-2 neg* 37 11 (29.7%) 14 (37.8%) 12 (32.4%) 
 
Analysis was done using Fishers exact test and/or Chi square test as appropriate 
















Appendix 13:  Association between lymphovascular invasion and level of 
protein expression  
 
Variable N No Invasion Invasion p- value 
      
PTEN high 55 13 (23.6%) 42 (76.4%) 0.777 
PTEN low 27 8 (29.6%) 19 (70.4%)  
PTEN neg 11 2 (18.2%) 9 (81.8%)  
     
NFκB high 87 22 (25.3%) 65 (74.7%) >0.999 
NFκB low 6 1 (16.7%) 5 (83.3%)  
     
MDM2 high 74 17 (23.0%) 57 (77.0%) 0.656 
MDM2 low 14 5 (35.7%) 9 (64.3%)  
MDM2 neg 5 1 (20.0%) 4 (80.0%)  
     
p53 high 21 6 (28.6%) 15 (71.4%) 0.403 
p53 low 21 7 (33.3%) 14 (66.6%)  
p53 neg 51 10 (19.6%) 41 (80.4%)  
     
BCL2 high 47 13 (27.7%) 34 (72.3%) 0.858 
BCL2 low 20 4 (20.0%) 16 (80.0%)  
BCL2 neg 26 6 (23.1%) 20 (76.9%)  
     
p-Akt2 high 59 12 (20.3%) 47 (79.7%) 0.175 
p-Akt2 low 26 10 (38.5%) 16 (61.5%)  
p-Akt2 neg 8 1 (12.5%) 7 (87.5%)  
     
PI3K high 79 16 (20.3%) 63 (79.7%) 0.010 
PI3K low 13 7 (53.8%) 6 (46.1%)  
PI3K neg 1 0 (0.0%) 1 (100%)  
     
ER pos 47 2 (4.3%) 45 (95.7%) <0.001 
ER neg 46 21 (45.7%) 25 (54.3%)  
     
Her-2 pos* 56 16 (28.6%) 40 (71.4%) 0.337 
Her-2 neg* 37 7 (18.9%) 30 (81.1%)  
Analysis was done using Fishers exact test and/or Chi square test as appropriate 









Appendix 14:  Association between lymph node metastasis and protein 
expression 
 
Variable N Yes No p-value 
     
PI3K high 79 53 (67.1%) 26 (32.9%) 0.062 
PI3K low 13 5 (38.5%) 8 (61.5%)  
PI3K neg 1 1 (100%) 0 (0%)  
     
PTEN high 55 37 (67.3%) 18 (32.7%) 0.574 
PTEN low 27 15 (55.6%) 12 (44.4%)  
PTEN neg 11 7 (63.6%) 4 (36.4%)  
     
p-Akt high 59 40 (67.8%) 19 (32.2%) 0.444 
p-Akt low 26 15 (57.7%) 11(42.3%)  
p-Akt neg 8 4 (50.0%) 4 (50.0%)  
     
NFκB high 87 55 (63.2%) 32 (36.8%) 0.999 
NFκB low 6 4 (66.7%) 2 (33.3%)  
     
MDM2 high 74 47 (63.5%) 27 (36.5%) 0.999 
MDM2 low 14 9 (64.3%) 5 (35.7%)  
MDM2 neg 5 3 (60.0%) 2 (40.0%)  
     
BCL2 high 47 27 (57.4%) 20 (42.6%) 0.558 
BCL2 low 20 14 (70.0%) 6 (30.0%)  
BCL2 neg 26 18 (69.2%) 8 (30.1%)  
     
P53 high 21 14 (66.6%) 7 (33.3%) 0.228 
P53 low 21 10 (47.6%) 11 (52.4%)  
P53 neg 51 35 (68.6%) 16 (31.4%)  
     
ER pos 47 37 (78.7%) 10 (21.3%) 0.002 
ER neg 46 22 (47.8%) 24 (52.2%)  
     
Her-2 pos 56 34 (60.7%) 22 (39.3) 0.502 
Her-2 neg 37 25 (67.6%) 12 (32.4%)  








Appendix 15:   Association between distant metastasis (other than regional 
lymph nodes) and level of protein expression        
  
Variable N No Yes p-value 
     
PTEN high 52 39 (75.0%) 16 (25.0%) 0.165 
PTEN low 27 16 (59.3%) 11 (40.7%)  
PTEN neg 11 10 (90.9%) 1 (9.1%)  
     
NFκB high 87 62 (71.3%) 25 (28.7%) 0.361 
NFκB low 6 3 (50.0%) 3 (50.0%)  
     
MDM2 high     74 56 (75.7%) 18 (24.3%) 0.017 
MDM2 low    14 8 (57.1%) 6 (42.9%)  
MDM2 neg     5 1 (20.0%) 4 (80.0%)  
     
p53 high 21 12 (57.1%) 9 (42.9%) 0.122 
p53 low 21 18 (85.7%) 3 (14.3%)  
p53 neg 51 35 (68.6%) 16 (31.4%)  
     
BCL2 high 47 33 (70.2%) 14 (29.8%) 0.837 
BCL2 low 20 13 (65.0%) 7 (35.0%)  
BCL2 neg 26 19 (73.1%) 7 (26.9%)  
     
p-Akt high 59 42 (71.2%) 17 (28.8%) 0.882 
p-Akt low  26 18 (69.2%) 8 (30.8%)  
p-Akt neg 8 5 (62.5%) 3 (37.5%)  
     
PI3K high 79 53 (67.1%) 26 (32.9%) 0.532 
PI3K low 13 11 (84.6%) 2 (15.4%)  
PI3K neg 1 1 (100%) 0 (0%)  
     
ER pos 47 30 (63.8%) 17 (36.2%) 0.198 
ER neg 46 35 (76.1%) 11 (23.9%)  
     
Her-2 pos 56 39 (69.6%) 17 (30.4%) >0.999 
Her-2 neg 37 26 (70.3%) 11 (29.7%)  










Appendix 16:  Association between apoptotic index and protein expression 
Variable N < 3 3 <5 5 <7 ≥7 p- value 
       
PTEN high 55 19 (34.5%) 16 (29.1%) 12 (21.8%) 7 (12.7%) 0.479 
PTEN low 27 4 (14.8%) 9 (33.3%) 8 (29.6%) 6 (22.2%)  
PTEN neg 11 2 (18.2%) 3 (27.3%) 3 (27.3%) 3 (27.3%)  
       
NFκB high 87 23 (26.4%) 26 (29.9%) 21 (24.1%) 18 (20.7%) 0.798 
NFκB low 6 2 (33.3%) 2 (33.3%) 2 (33.3%) 0 (0.0%)  
       
MDM2 high     74 21 (28.4%) 22 (29.7%) 18 (24.3%) 12 (16.2%) 0.439 
MDM2 low    14 4 (28.6%) 4 (28.6%) 2 (14.3%) 4 (28.6%)  
MDM2 neg     5 0 (0.0%) 2 (40.0%) 3 (60.0%) 0 (0.0%)  
       
p53 high 21 4 (19.0%) 8 (38.0%) 3 (14.3%) 6 (28.6%) 0.490 
p53 low 21 5 (23.8%) 7 (33.3%) 7 (33.3%) 2 (9.5%)  
p53 neg 51 16 (31.4%) 13 (25.5%) 13 (25.5%) 8 (15.7%)  
       
BCL2 high 47 11 (23.4%) 13 (27.7%) 14 (29.8%) 8 (17.0%) 0.887 
BCL2 low 20 7 (35.0%) 6 (30.0%) 3 (15.0%) 4 (20.0%)  
BCL2 neg 26 7 (26.9%) 9 (34.6%) 6 (23.1%) 4 (15.4%)  
       
p-Akt high 59 16 (27.1%) 16 (27.1%) 15 (25.4%) 11 (18.6%) 0.643 
p-Akt low  26 8 (30.8%) 10 (38.5%) 4 (15.4%) 4 (15.4%)  
p-Akt neg 8 1 (12.5%) 2 (25.0%) 4 (50.0%) 1 (12.5%)  
       
PI3K high 79 17 (21.5%) 26 (32.9%) 21 (26.6%) 13 (16.5%) 0.014 
PI3K low 13 8 (61.5%) 1 (7.7%) 1 (7.7%) 3 (23.1%)  
PI3K neg 1 0 (0.0%) 1 (100%) 0 (0.0%) 0 (0.0%)  
       
ER pos 47 12 (25.5%) 15 (31.9%) 13 (27.7%) 7 (14.9%) 0.854 
ER neg 46 13 (28.3%) 13 (28.3%) 10 (21.7%) 9 (19.6%)  
       
Her-2 pos 56 15 (26.8%) 19 (33.9%) 13 (23.2%) 9 (16.1%) 0.838 
Her-2 neg 37 10 (27.0%) 9 (24.3%) 10 (27.0%) 7 (18.9%)  










Appendix 17:  Median and 5 year OS and DFS for the total population of 93 
subjects according to the Kaplan-Meier graph 
 
Variable Category N Median OS 5 yr OS Median DFS 5 year DFS 
Trastuzumab No 67 80 months 90% - 80% 
 Yes 26 - 75% - 70% 
Stage 1 (T1) 14 - 86% - 80% 
 2 (T2) 48 80 months 85% - 75% 
 3 (T3) 30 - 62% - 61% 
 4 (T4) 1 - 0% - 0% 
Grade 1 14 - 94% - 74% 
 2 36 - 78% - 82% 
 3 43 80 months 72% - 64% 
Age 1(<45) 20 - 65% - 80% 
 2 (45-65) 59 80 months 76% - 65% 
 3 (>65) 14 - 100% - 85% 
PTEN High  55 80 months 80% - 70% 
 Low 27 - 73% - 64% 
 Neg 11 - 91% - 90% 
NFκB High 87 80 months 80% - 73% 
 Low 6 48 months 50% - 60% 
MDM2 High 74 80 months 80% - 75% 
 Low 14 - 65% - 80% 
 Neg 5 - 60% 34 months 0% 
Akt High 59 80 months 83% - 71% 
 Low 26 - 73% - 68% 
 Neg 8 46 months 46% - 80% 
PI3K High 79 80 months 75% - 68% 
 Low 13 - 92% - 85% 
 Neg 1 - 100% - 100% 
P53 High 21 - 57% - 0% 
 Low 21 - 89% - 79% 
 Neg 51 80 months 81% - 75% 
BCL2 High 47 80 months 80% - 68% 
 Low 20 - 75% - 76% 
 Neg 26 - 75% - 79% 
Her2 Pos 33 80 months 79% - 77% 
 Neg 46 - 76% - 65% 
ER MH (pos) 47 80 months 82% - 70% 
 NL (neg) 46 - 73% - 75% 
Apop index < 3 25 - 77% - 85% 
 3 <5 28 - 72% - 67% 
 5 <7 23 80 months 85% - 63% 













Appendix 18:  Median and 5 year OS and DFS for the cohort of 67 patients 
that did not receive trastuzumab treatment according to the Kaplan-Meier 
graph 
 
Variable Category N Median OS 5 yr OS Median DFS 5 year DFS 
Stage 1 (T1) 8 - 80% - 86% 
 2 (T2) 37 - 84% - 73% 
 3 (T3) 21 - 56% - 56% 
 4 (T4) 1 - 0% - 0% 
Grade 1 12 - 92% - 71% 
 2 27 - 79% - 78% 
 3 28 - 63% - 60% 
Age 1(<45) 12 - 57% - 75% 
 2 (45-65) 47 - 74% - 65% 
 3 (>65) 8 - 100% - 88% 
PTEN High 38 - 76% - 68% 
 Low 19 - 62% - 56% 
 Neg 10 - 100% - 100% 
NFκB High 61 - 77% - 70% 
 Low 6 47 months 50% - 60% 
MDM2 High 50 - 79% - 74% 
 Low 12 - 58% - 78% 
 Neg 5 - 60% 36 months 0% 
Akt High 34 - 81% - 67% 
 Low 25 - 72% - 68% 
 Neg 8 47 months 47% - 80% 
PI3K High 57 - 72% - 67% 
 Low 10 - 90% - 80% 
 Neg 0 - - - - 
P53 High 14 42 months 40% 45 months 41% 
 Low 16 - 85% - 75% 
 Neg 37 - 83% - 77% 
BCL2 High 35 - 77% - 76% 
 Low 15 - 77% - 76% 
 Neg 17 - 70% - 70% 
Her2 Pos 36 - 70% - 74% 
 Neg 31  78%  65% 
ER MH (pos) 32 - 76% - 69% 
 NL (neg) 35 - 72% - 70% 
Apop index < 3 18 - 75% - 80% 
 3 <5 18 - 65% - 64% 
 5 <7 19 - 80% - 66% 






Appendix 19:  Median and 5 year OS and DFS for the cohort of 26 patients 
that did receive trastuzumab treatment according to the Kaplan-Meier graph 
 
Variable Category N Median OS 5 yr OS Median DFS 5 year DFS 
Grade 1 (T1) 2 - 100% 80 months 94% 
 2 (T2) 9 80 months 91% - - 
 3 (T3) 15 - 78% - 78% 
 4 (T4) 0 - - - - 
Stage 1 6 - 100% - 100% 
 2 11 - 78% - - 
 3 9 80 months 94% 80 months 94% 
Age 1 (<45) 8 - 75% - 85% 
 2 (45-65) 12 80 months 92% - 0% 
 3 (>65) 6 - 100% - 0% 
PTEN High 17 80 months 89% - 80% 
 Low 8 - 100% - 100% 
 Neg 1 18 months 0% 18 months 0% 
NFκB High 26 80 months 88% - 80% 
 Low 0 - - - - 
MDM2 High 24 80 months 87% - 87% 
 Low 2 - 100% - 100% 
 Neg 0 - - - - 
Akt High 25 80 months 87% - 80% 
 Low 1 - 100% - - 
 Neg 0 - - - - 
PI3K High 22 80 months 86% - 71% 
 Low 3 - - - - 
 Neg 1 - - - - 
P53 High 7 - 100% - 100% 
 Low 5 - 100% - 100% 
 Neg 14 80 months 78% - 63% 
BCL2 High 12 - 92% - 68% 
 Low 5 - 0% - 100% 
 Neg 9 80 months 0% - 87% 
Her2 Pos 26 80 months 92% - 80% 
ER MH (pos) 15 80 months 94% - 66% 
 NL (neg) 11 - 0% - 89% 
Apop index < 3 25 - 85% - - 
 3 <5 28 - 90% - 75% 
 5 <7 23 80 
months100 
100% 41 months 0% 











Appendix 20:  Analysis of overall survival (OS) of complete sample of 93 
cases, using Cox regression analysis adjusted for age 
 
Variable Category N Person time Deaths Death rate 95% CI HR 95%CI 
Trastuzumab No 67 3177 16 5.0 (3.1 – 8.2) 1.0 (ref) 
 Yes 26 1237 4 3.2 (1.2 - 8.6) 0.4 (0.1 – 1.5) 
Stage 1 (T1) 14 747 1 1.3 (0.2 - 9.5) 1.0 (ref) 
 2 (T2) 48 2338 8 3.4 (1.7 – 6.8) 2.1 (0.2 – 17.1) 
 3 (T3) 30 1287 11 8.5 (4.7 – 15.4) 5.0 (0.6 – 42.4) 
 4 (T4) 1 42 0 0.0 - - - 
Grade 1 14 731 1 1.4 (0.2 – 9.7) 1.0 (ref) 
 2 36 1758 7 4.0 (1.9 – 8.4) 3.1 (0.4 – 25.6) 
 3 43 1925 12 6.2 (3.5 – 11.0) 3.8 (0.5 – 29.6) 
Age 1(<45) 20 796 7 8.8 (4.2 – 18.4) 1.0 (ref) 
 2 (45-65) 59 2873 13 4.5 (2.6 – 7.8) 0.5 (0.2 – 1.3) 
 3 (>65) 14 745 0 0.0 - - - 
PTEN High 55 2606 12 4.6 (2.6 – 8.1) 1.0 (ref) 
 Low 27 1273 7 5.5 (2.6 – 11.5) 1.6 (0.6 – 4.3) 
 Neg 11 535 1 1.9 (0.3 – 13.3) 0.4 (0.1 – 3.5) 
NFκB High 87 4110 17 4.1 (2.6 – 6.7) 1.0 (ref) 
 Low 6 304 3 9.9 (3.2 – 30.6 ) 3.6 (1.0 – 13.1) 
MDM2 High 74 3614 13 3.6 (2.1 – 6.2) 1.0 (ref) 
 Low 14 550 5 9.1 (3.8 – 21.8) 2.4 (0.8 – 6.9) 
 Neg 5 250 2 8.0 (2.0 – 32.0) 2.8 (0.6 – 13.0) 
Akt High 59 2836 9 3.2 (1.7 – 6.1) 1.0 (ref) 
 Low 26 1261 7 5.6 (2.6 – 11.6) 2.1 (0.8 – 5.9) 
 Neg 8 317 4 12.6 (4.7 – 33.6) 5.1 (1.5 – 17.3) 
PI3K High 79 3738 19 5.1 (3.2 – 8.0) 1.0 (ref) 
 Low 13 625 1 1.6 (0.2 – 11.4) 0.3 0.0 – 2.3) 
 Neg 1 51 0 0.0 - - - 
P53 High 21 839 8 9.5 (4.8 – 19.1) 1.0 (ref) 
 Low 21 1073 2 1.9 (0.5 – 7.4) 0.18 (0.0 – 0.9) 
 Neg 51 2502 10 4.0 (2.1 – 7.4) 0.4 (0.2 – 1.0) 
BCL2 High 47 2338 10 4.3 (2.3 – 7.9) 1.0 (ref) 
 Low 20 976 4 4.1 (1.5 – 11.0) 0.9 (0.3 – 2.8) 
 Neg 26 1100 6 5.5 (2.5 – 12.1) 1.6 (0.5 – 4.4) 
Her2 Neg 33 1780 8 4.5 (2.2 – 9.0) 1.0 (ref) 
 Pos 46 2634 12 4.6 (2.6 – 8.0) 0.7 (0.2 -1.7) 
ER MH (pos) 47 2303 9 3.9 (2.0 – 7.5) 1.0 (ref) 
 NL (neg) 46 2111 11 5.2 (2.9 – 9.4) 1.2 (0.5 – 3.1) 
Apop index < 3 25 1079 5 4.6 (1.9 – 11.1) 1.0 (ref) 
 3 <5 28 1335 7 5.2 (2.5 – 11.0) 1.1 (0.4 – 4.6) 
 5 <7 23 1202 4 3.3 (1.2 – 8.9) 0.7 (0.2 – 3.4) 






Appendix 21:  Analysis of overall survival for the cohort of 67 cases that has 
not received trastuzumab treatment, using Cox regression analysis adjusted 
for age 
 
Variable Category N Person time Deaths Death rate 95% CI HR 95% CI 
Stage 1 (T1) 14 425 1 2.4 (0.3 – 16.7) - (ref) 
 2 (T2) 48 1850 6 3.2 (1.5 – 7.2) 1.4 (0.2 – 11.5) 
 3 (T3) 30 860 9 10.5 (5.4 – 20.1) 4.3 (0.5 – 34.3) 
 4 (T4) 1 42 0 0.0 - - - 
Grade 1 14 644 1 1.6 (0.22 – 11.0) - (ref) 
 2 36 1346 50 3.7 (1.5 – 8.9) 2.5 (0.3 – 21.2) 
 3 43 1187 10 8.4 (4.5 – 15.7) 4.5 (0.6 – 36.0) 
Age 1(<45) 12 448 5 11.2 (4.65 – 26.8) 1.0 (ref) 
 2 (45-65) 47 2299 11 4.8 (2.6 –  8.6) 0.4 (0.1 – 1.2) 
 3 (>65) 8 430 0 - - - - 
PTEN High 38 1825 9 4.0 (2.6 – 9.5) 1.0 (ref) 
 Low 19 835 7 8.4 (4.0 – 17.6) 1.9 (0.7 - 5.2) 
 Neg 10 517 0 - - - - 
NFκB High 61 2873 13 4.5 (2.6 – 7.8) 1.0 (ref) 
 Low 6 304 3 9.9 (3.2 – 30.6) 2.8 (0.8 – 10.2) 
MDM2 High 50 2495 9 3.6 (1.9 – 6.9) 1.0 (ref) 
 Low 12 432 5 4.8 (4.8 – 27.8) 3.2 (1.1 – 9.7) 
 Neg 5 250 2 2.0 (2.0 – 32.0) 2.6 (0.6 – 12.2) 
Akt High 34 1670 5 3.0 (1.2 – 7.2) 1.0 (ref) 
 Low 25 1190 7 5.9 (2.8 – 12.3) 2.0 (0.6 – 6.3) 
 Neg 8 317 4 12.6 (4.7 – 33.6) 4.4 (1.2 – 16.7) 
PI3K High 57 2689 15 5.6 (3.3 – 9.3) 1.0 (ref) 
 Low 10 488 1 2.1 (0.3 – 14.5) 0.4 (0.1 – 2.9) 
 Neg 0 - - - - - - 
P53 High 14 518 8 15.4 (7.7 – 30.9) 1.0 (ref) 
 Low 16 796 2 2.5 (0.6 – 10.0) 0.2 (0.0 – 0.9) 
 Neg 37 1863 6 3.2 (1.4 – 7.2) 0.2 (0.1 – 0.7) 
BCL2 High 35 1678 8 4.8 (2.4 – 9.5) 1.0 (ref) 
 Low 15 758 3 4.0 (1.3 – 12.3) 0.6 (0.2 – 2.3) 
 Neg 17 741 5 6.7 (2.8 – 16.2) 1.8 (0.6 – 5.9) 
Her2 Neg 36 1762 7 4.0 (1.9 – 8.3) 1.0 (ref) 
 Pos 31 1415 9 6.4 (3.3 – 12.2) 1.2 (0.4 – 3.4) 
ER MH (pos) 32 1504 7 4.7 (2.2 – 9.8) 1.0 (ref) 
 NL (neg) 35 1673 9 5.4 (2.8 – 10.3) 1.1 (0.4 – 2.9) 
Apop index  < 3 25 804 4 5.0 (1.9 – 13.3) 1.0 (ref) 
 3 <5 28 816 6 7.4 (3.3 – 16.4) 1.8 (0.5 – 6.5) 
 5 <7 23 983 3 3.1 (1.0 – 9.5) 0.7 (0.2 – 3.1) 







Appendix 22:  Analysis for disease free survival (DFS) of complete sample, 
using Cox regression analysis adjusted for age (N=79) 
 
Variable Category N Person time Regressions Regr. rate 95% CI HR 95%CI 
Trastuzumab No 19 2775 17 6.1 (3.8 – 9.9) 1.0 (ref) 
 Yes 60 818 3 3.7 (1.2 – 11.4) 0.6 (0.2 – 2.1) 
Stage 1 (T1) 14 577 2 3.5 (0.9 – 14.0) 1.0 (ref) 
 2 (T2) 29 2063 10 4.8 (2.6 – 9.0) 1.5 (0.3 – 7.1) 
 3 (T3) 36 911 8 8.8 (4.4 – 17.6) 2.9 (0.6 – 14.9) 
 4 (T4) 1 42 0 - - - - 
Grade 1 14 689 3 4.3 (1.4 – 13.5) 1.0 (ref) 
 2 29 1356 5 3.7 (1.5 – 8.9) 0.8 (0.2 – 3.5) 
 3 36 1548 12 7.8 (4.4 – 13.6) 1.9 (0.5 – 6.9) 
Age 1(<45) 15 665 3 4.5 (1.5 – 14.0) 1.0 (ref) 
 2 (45-65) 51 2298 15 6.5 (3.9 – 10.8) 1.5 (0.4 – 5.2) 
 3 (>65) 13 630 2 3.2 (0.8 – 12.7) 0.7 (0.1 – 4.2) 
PTEN High 48 2181 12 5.5 (3.1 – 9.7) 1.0 (ref) 
 Low 21 940 7 7.4 (3.6 – 15.6) 1.4 (0.6 – 3.7) 
 Neg 10 472 1 2.1 (0.3 – 15.0) 0.4 (0.05 – 2.8) 
NFκB High 74 3351 18 5.4 (3.4 – 8.5) 1.0 (ref) 
 Low 5 242 2 8.3 (2.1 – 33.0) 1.6 (0.4 – 7.3) 
MDM2 High 65 2964 15 5.1 (3.1 – 8.4) 1.0 (ref) 
 Low 10 465 2 4.3 (1.1 – 17.2) 0.8 (0.2 – 3.5) 
 Neg 4 164 3 18.3 (5.9 – 56.7) 3.5 (1.01 – 12.1) 
Akt High 52 2297 12 5.2 (3.0 – 9.2) 1.0 (ref) 
 Low 22 1062 7 6.6 (3.1 – 13.8) 1.3 (0.5 – 3.3) 
 Neg 5 234 1 4.3 (0.6 – 30.3) 0.8 (0.1 – 6.0) 
PI3K High 65 2948 18 6.1 (3.8 – 9.7) 1.0 (ref) 
 Low 13 594 2 3.4 (0.8 – 13.5) 0.5 (0.1 – 2.2) 
 Neg 1 51 0 - - - - 
P53 High 16 631 6 9.8 (4.4 – 21.8) 1.0 (ref) 
 Low 20 977 4 4.1 (1.5 – 11.0) 0.4 (0.1 – 1.4) 
 Neg 43 2003 10 5.0 (5.0 – 2.7) 0.5 (0.2 – 1.3) 
BCL2 High 38 1836 11 6.0 (3.3 – 10.8) 1.0 (ref) 
 Low 17 749 4 5.3 (2.0 – 14.2) 0.9 (0.3 – 2.9) 
 Neg 24 1008 5 5.0 (2.1 – 11.9) 0.9 (0.3 – 2.5) 
Her2 Neg 33 1780 8 4.5 (2.2 – 9.0) 1.0 (ref) 
 Pos 46 2634 12 4.6 2.6 – 8.0) 0.7 (0.3 – 1.8) 
ER MH (pos) 39 1765 10 5.7 (3.0 – 10.5) 1.0 (ref) 
 NL (neg) 40 1828 10 5.5 (2.9 – 10.2) 1.0 (0.4 – 2.3) 
Apop index  < 3 23 1041 3 2.9 (0.9 – 8.9) 1.0 (ref) 
 3 <5 25 1114 8 7.1 (3.6 – 14.4) 2.7 (0.7 – 10.4) 
 5 <7 19 866 6 6.9 (3.1 – 15.4) 2.5 (0.6 – 10.0) 







Appendix 23:  Analysis of DFS of cohort of cases that has not trastuzumab 
treatment, using Cox regression analysis adjusted for age (N=60) 
 
Variable Category N Person time Regressions Regr. rate 95% CI HR 95%CI 
Stage 1 (T1) 7 370 1 2.7 (0.4 – 19.2) 1.0 (ref) 
 2 (T2) 36 1679 9 5.4 (2.8 – 10.3) 2.0 (0.2 – 15.5) 
 3 (T3) 16 684 7 10.2 (10.2 - 21.5) 3.9 (0.5 – 13.8) 
 4 (T4) 1 42 0 - - - - 
Grade 1 12 602 3 5.0 (1.6 – 15.5) 1.0 (ref) 
 2 25 1184 5 4.2 (1.8 – 10.1) 0.8 (0.2 – 3.5) 
 3 23 989 9 9.1 (4.7 – 17.5) 2.0 (0.5 – 7.3) 
Age 1(<45) 8 334 2 6.0 (1.5 – 24.0) 1.0 (ref) 
 2 (45-65) 44 2012 14 6.9 (4.1 – 11.7) 1.2 (0.3 – 5.1) 
 3 (>65) 8 422 1 2.4 (0.3 – 16.8) 0.4 (0.03 – 4.2) 
PTEN High 35 1614 10 6.2 (3.3 – 11.5) 1.0 (ref) 
 Low 16 708 7 9.9 (4.7 – 20.7) 1.6 (0.6 – 4.2) 
 Neg 9 453 0 - - - - 
NFκB High 55 2533 15 5.9 (3.6 – 9.8) 1.0 (ref) 
 Low 5 242 2 8.3 (2.1 – 33.0) 1.5 (0.3 – 6.8) 
MDM2 High 47 2193 12 5.5 (3.1 – 9.6) 1.0 (ref) 
 Low 9 418 2 4.8 (1.2 – 19.1) 0.8 (0.2 – 3.8) 
 Neg 4 164 3 18.3 (5.9 – 56.7) 3.2 (0.9 – 11.3) 
Akt High 33 1479 9 6.1 (3.2 – 11.7) 1.0 (ref) 
 Low 22 1062 7 6.6 (3.1 – 13.8) 1.1 (0.4 – 3.1) 
 Neg 5 234 1 4.3 (0.6 – 30.3) 0.7 (0.1 – 5.4) 
PI3K High 50 2318 15 6.5 (3.9 – 10.7) 1.0 (ref) 
 Low 10 457 2 4.4 (1.1 – 17.5) 0.7 (0.1 – 2.9) 
 Neg 0 - 0 - - - - 
P53 High 11 406 6 14.8 (6.6 – 32.9) 1.0 (ref) 
 Low 16 771 4 5.2 (1.9 – 13.8) 0.3 (0.1 – 1.1) 
 Neg 33 1598 7 4.4 (2.1 – 9.2) 0.3 (0.1 – 0.8) 
BCL2 High 31 1498 9 6.0 (3.1 – 11.5) 1.0 (ref) 
 Low 13 580 4 6.9 (2.6 – 18.4) 1.2 (0.3 – 4.1) 
 Neg 16 697 4 5.7 (2.2 – 15.3) 1.0 (0.3 – 3.1) 
Her2 Neg 33 1509 10 6.6 (3.6 – 12.3) 1.0 (ref) 
 Pos 27 1266 7 5.5 (2.6 – 11.6) 0.8 (0.3 – 2.2) 
ER MH (pos) 29 1319 8 6.1 (3.0 – 12.1) 1.0 (ref) 
 NL (neg) 31 1456 9 6.2 (3.2 – 11.9) 1.0 (0.4 – 2.7) 
Apop index  < 3 17 784 4 3.8 (1.2 – 11.9) 1.0 (ref) 
 3 <5 17 757 6 7.9 (3.6 – 17.6) 2.2 (0.5 – 8.8) 
 5 <7 17 788 3 6.3 (2.6 – 15.2) 1.6 (0.4 – 6.9) 
 ≥ 7 8 407 3 7.4 (2.4 – 22.9) 2.1 (0.4 – 10.2) 
 
   
 
 
